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Abstract 
Neuronal death due to excitotoxicity and oxidative stress is a critical part of 
several major disease processes, including ischaemic brain damage and 
Alzheimer’s disease. This study used cultures of cerebellar granule neurones as a 
model for investigation of these processes, considering both their 
pharmacological and molecular aspects. Another important part of the study was 
the development and investigation of a mode of neuroprotection which was 
effective in protecting against these factors. Additionally, the optimal culturing 
conditions for neurone survival were determined and the efficacy of two cell 
viability assays established.  
Examination of excitotoxicity and oxidative stress considered the effects of 
glutamate, N-methyl-D-aspartate, 3-nitropropionic acid and oxygen-glucose 
deprivation. Additionally, extensive study was carried out of the actions of 
increased glucose concentration and a range of metabolites of the essential 
amino acid tryptophan. It was demonstrated that several tryptophan metabolites 
induced neurotoxic effects, including 5-hydroxyanthranilic acid, which caused 
neuronal death via oxidative damage mediated by generation of reactive oxygen 
species and prevented by catalase but not superoxide dismutase. 5-
Hydroxyanthranilic acid treatment also led to activation of the p38 signalling 
pathway, although the cell death caused was independent of caspase-3 
activation.  
Investigation of neuroprotection was concerned with establishing an effective 
method of protection, with a range of stimuli used to precondition neurones, 
such as N-methyl-D-aspartate, 3-nitropropionic acid, hydrogen peroxide, 
bicuculline and 4-aminopyridine. Preconditioning with 100µM N-methyl-D-
aspartate at 8 DIV was effective in protecting against the neurotoxic effects of 
glutamate or 3-nitropropionic acid applied 24 hours after the commencement of 
preconditioning, but was not effective against oxygen-glucose deprivation of 4 
hours duration. Preconditioning with 2.5mM 4-aminopyridine was effective in 
providing protection against a range of insults (glutamate, N-methyl-D-aspartate, 
3-nitropropionic acid). This protection was independent of N-methyl-D-aspartate 
receptor activation, reduced by blockade of depolarisation and was effective in 
protecting against caspase-3-independent cell death.  
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1 Introduction 
1.1   Background pathology 
1.1.1 Ischaemia and stroke 
Ischaemia is a major cause of morbidity and mortality in the Western world, 
primarily due to damage and destruction of cardiac and brain tissue, in the form 
of myocardial infarctions and strokes respectively. Stroke has an annual 
incidence throughout Europe of 200-500 per 100,000 in the general population, 
and thus, even in areas with relatively low prevalence, it causes a significant 
impact on public health, with an additional notable economic cost associated 
with this (Taylor et al., 1996, Bejot et al., 2007).  
In the context of cerebral ischaemia, an interruption of the blood supply 
sufficient to cause permanent damage is termed a cerebro-vascular accident 
(CVA), with the majority of cases (~80%) being due to blockage of the arterial 
lumen, and the remainder caused by a bleed from a supplying artery or arteriole 
(Bejot et al., 2007, Ribo and Grotta, 2006). The most common cause of vessel 
occlusion is thrombus (blood clot) forming over a ruptured arteriosclerotic 
plaque in the vessel wall (the cause of ~75% of occlusive strokes), or due to 
thrombo-embolism (lumen blockade with thrombus formed in a distant location, 
commonly in the heart due to irregular flow) (Bejot et al., 2007). This sudden 
interruption of blood supply causes tissue death due to a variety of mechanisms, 
with the area of cell death due to ischaemia referred to as an infarct.  
Due to the high demand of brain tissue for glucose for oxidative phosphorylation, 
the loss of oxygen and glucose is felt very rapidly, with cell death proceeding 
more rapidly than in the case of other tissues subjected to ischaemia (Dirnagl et 
al., 1999). The cause of neuronal death is not only due to loss of substrates for 
neuronal energy requirements, but the effects of ischaemia on excitatory 
neurotransmitter release and the resultant depolarisation of neurones.  
Due to loss of energy, maintenance of the ionic gradients that sustain the 
membrane potential is lost, causing depolarisation and influx of sodium and 
chloride initially. These effects of depolarisation lead to influx of water due to 
the osmotic pressure from increased intracellular sodium and chloride, and of 
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calcium due to activation of voltage-sensitive calcium channels. The effect of 
this influx of water is to cause neuronal swelling at a cellular level and oedema 
at a tissue level, which can further restrict perfusion and worsen ischaemia due 
to direct pressure of patent vessels.  
The influx of calcium leads in turn to pre-synaptic release of excitatory amino 
acids (EAAs), causing a rise in extracellular glutamate concentrations within 
minutes of the onset of ischaemia. This release of glutamate causes activation of 
N-methyl-D-aspartate (NMDA) and metabotropic glutamate receptors, which 
causes further calcium influx in post-synaptic neurones. Furthermore, activation 
of α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) and kainate 
receptors causes additional sodium influx and depolarisation in post-synaptic 
neurones. Another cause of increased glutamate release is the stimulation of 
volume-regulated anion channels, an effect predominantly found in the outer 
areas of an infarct (Feustel et al., 2004). This is consistent with the dependency 
on adenosine triphosphate (ATP) of these channels, as the ATP levels available 
during an ischaemic event depend on the cell’s location within the infarct, Cells 
at the centre of the infarction (the infarct ‘core’) have little or no ATP available 
to them, whereas cells on the periphery (the infarct ‘penumbra’) have more ATP 
available (Hou and MacManus, 2002).  
The process of cell death due to over-stimulation by excitatory 
neurotransmitters is known as excitotoxicity (Olney and de Gubareff, 1978) and 
is a major component of the damage caused by ischaemia in neurones, acting 
early in the sequence of damaging events (Dirnagl et al., 1999).  
The loss of ATP production causes failure of the sodium-potassium pump on the 
plasma membrane, triggering depolarisation (due both to loss of sodium and 
failure to preserve a polarised state by potassium gradient maintenance). Also, 
potassium released from lysed cells following an ischaemic insult will cause 
further depolarisation, with attendant excitotoxicity in glutamatergic neurones 
due to this causing release of intracellular glutamate. An association between 
this process of additional depolarisation and increased infarct size has been 
demonstrated in animal models, with blockade of NMDA receptors causing a 
reduction in current shift and infarct size (Iijima et al., 1992, Mies et al., 1993).  
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Ischaemia causes increased production of reactive oxygen species (ROS), highly 
reactive molecules that are capable of damaging cellular structures extensively. 
Cellular damage due to these molecules is termed oxidative stress, a major 
component of ischaemia-induced damage.  
Inflammation is another significant aspect of damage following an ischaemic 
event, occurring due to nuclear factor kappa B (NF-κB) and hypoxia inducible 
factor 1 (HIF1), in response to hypoxia and generation of ROS (O’Neill and 
Kaltschmidt, 1997, Ruscher et al., 1998). This leads to increased expression of 
inflammatory mediators (tumour necrosis factor α (TNFα) and interleukin 1β), 
which due to increased adhesion molecule expression cause neutrophils, 
monocytes and macrophages to infiltrate the infarct (Iadecola, 1997), in addition 
to the activation of microglia in the affected area. These processes lead to 
increased activity of nitric oxide synthase (NOS) and cyclo-oxygenase 2, causing 
increases in nitric oxide (NO) and superoxide respectively. Nitric oxide is capable 
of reacting with superoxide to produce peroxynitrite, a highly reactive molecule 
that causes extensive damage. Peroxynitrite is particularly damaging in 
neurones, which are highly sensitive to damage from ROS (see section 1.3.4).  
Ischaemia-induced neuronal cell death cannot be described as either completely 
necrotic or completely apoptotic in character, as neurones that suffer an 
ischaemic insult display biochemical signs of apoptotic cell death, although 
cytological examination reveals the appearance of necrotic cell death (Martin, 
2001, Hou and MacManus, 2002).  
The pathway of cell death followed depends partly on the level of energy, in the 
form of ATP available to the cell. When higher levels of ATP are available, then 
the cell activates the pathway of ordered DNA fragmentation and cell death via 
apoptosis. If available ATP levels are lower or non-existent then the cell, unable 
to activate the apoptotic pathway, dies due to necrosis. As cells at the infarct 
core have little or no ATP available, they die due to necrosis. Conversely, cells 
in the penumbra (where more ATP is available) follow the apoptotic pathway of 
ordered cell destruction (Hou and MacManus, 2002).  
In the intermediate area of the infarct the means of cell death may involve 
stages of both the necrotic and apoptotic pathways. This can be explained by a 
fall in the ATP level causing cells that had initially activated an apoptotic 
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pathway to change to a necrotic type of cell death, as the fall in ATP prevents 
completion of the apoptotic process (Roy and Sapolsky, 1999, Hou and 
MacManus, 2002).  
Apoptosis is a process of energy-dependent controlled cell death, which occurs 
both during disease and as a physiological control of cell numbers during 
development (in the latter case the process is referred to as ‘programmed cell 
death’). The process involves breakdown of cells into components that are then 
packaged into and contained in vesicles, genetically controlled by the bcl-2 
(beta-cell lymphoma 2) family of genes and the gene p53 (Kam and Ferch, 2000). 
The pathways followed by apoptosis depend on the activation of cell death 
signalling proteins such as the members of the extracellular-regulated kinase 
(ERK) family, c-Jun-N-terminal kinase (JNK) and p38. Activation of caspases such 
as caspases 8, 9 and 12, then occurs due to: release of cytochrome c from the 
mitochondria, which forms a pro-apoptotic complex (termed an apoptosome) 
with pro-caspase 9; Fas receptor activation leads to caspase-8 activation; 
release of calcium from the endoplasmic reticulum causes activation of caspase-
12 (Sima, 2003). This subsequently leads to activation of caspases 1 and 3, 
caspases which act directly to cleave cellular structures.  
The process of apoptosis in the penumbra take some time to be completed, with 
the possibility that interruption of its activation by blockade of one or more of 
the executioner caspases will prevent cell death several hours after an 
ischaemic episode (Cheng et al., 1998, Fink et al., 1998). This indicates that the 
window of opportunity for effective damage-limiting treatment may be notably 
longer in CVA patients than was previously believed. However, the need to 
develop an effective preventative therapy which allows improved neuronal 
survival in the infarct core during an ischaemic event remains.  
1.1.2 Neurodegeneration 
In addition to brain damage due to ischaemia, there are several progressive 
neurodegenerative disorders which have a substantial impact in terms of both 
long-term morbidity and associated mortality from complications. These 
disorders can occur in any part of the brain: cerebral cortex and hippocampus 
(Alzheimer’s disease), the striatum (Huntingdon’s disease), deep nuclei 
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(Parkinson’s disease) or with a more generalised distribution (AIDS dementia 
complex).  
Alzheimer’s disease is a neurodegenerative disorder characterised clinically by 
progressive loss of higher mental functions, particularly cognitive and emotional 
tasks, and pathologically by ‘neurofibrillary tangles’ and amyloid plaques, with 
generalised cerebral atrophy seen in long-standing, extensive disease. 
Neurofibrillary tangles are in fact composed of collections of the microtubule-
associated protein tau, associated with oxidative stress; the plaques are 
accumulations of amyloid-β peptide (Cummings et al., 1998), which is capable of 
inducing apoptosis directly in cultured cortical neurones (Loo et al., 1993).  
Amyloid-β can induce lipid peroxidation in neuronal plasma membranes, which 
leads to reduced trans-membrane transport of ions and glucose, with resultant 
depolarisation and ATP depletion and associated calcium influx and impaired 
mitochondrial function (Mattson, 1998). There is evidence that Alzheimer’s 
disease involves DNA fragmentation (Su et al., 1994) and activation of caspases 
3, 8 and 9 (Stadelmann et al., 1999, Rohn et al., 2001, Rohn et al., 2002), with 
protection against amyloid-β-induced damage provided by antioxidants or by 
anti-apoptotic neurotrophins (Mattson, 1998). The specific actions of amyloid-β 
include stimulation of nicotinic acetylcholine receptors (particularly the alpha-7 
subunit), leading to increased calcium influx; amyloid-β also causes reduction of 
glutamate re-uptake (Liu and Wu, 2006). Furthermore, JNK signalling-dependent 
down-regulation of the anti-apoptotic protein bcl-w due to amyloid-β has also 
been identified (Yao et al., 2005), and amyloid- β can induce mitochondrial 
permeability transition (MPT) pore formation in isolated mitochondria (Rodrigues 
et al., 2000).  
Huntington’s disease is inherited in an autosomal dominant fashion and is 
characterised clinically by a progressive increase in choreaform movements and 
dementia, due to loss of neurones in the striatum and cerebral cortex. Clinical 
appearances of the disease typically manifest from the fourth or fifth decade of 
life, by which time the disease has usually been passed to the next generation. 
The pathological cause is due to a gene mutation which due to an expanded 
trinucleotide sequence (CAG) codes for the production of an abnormal protein 
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named huntingtin, containing an excessive series of repeats of glutamine (Brandt 
et al., 1996).  
The expression of the mutated huntingtin protein causes caspase-8-dependent 
apoptosis, and Huntington’s disease has been associated with abnormalities of 
mitochondrial function (Sanchez et al., 1999, Sawa et al., 1999) and activation 
of caspases 1 and 3 (Ona et al., 1999). A further finding related to the 
pathogenesis of Huntington’s disease is that remarkably similar lesions can be 
induced by direct injection of the specific NMDA receptor agonist quinolinic acid 
(QA). Quinolinic acid is a product of tryptophan catabolism, which is capable of 
inducing neuronal death due to excitotoxicity and has been found to be present 
in higher concentration in cerebral cortical and striatal tissue in Huntington’s 
disease patients (Guidetti and Schwarcz, 1999, Guidetti et al., 2004).  
The clinical manifestations of Parkinson’s disease are termed Parkinsonism, as 
the condition can be reproduced by causes other than Parkinson’s disease, such 
as exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This 
compound is metabolised to 1-methyl-4-phenyl-2,3-dihydropyridinium (MPP+), 
which inhibits mitochondrial electron transport, an effect prevented by 
glutathione (Annepu and Ravindranath, 2000). The clinical syndrome is 
comprised of bradykinesia (slowness and difficulty in initiating movements), fine 
resting tremor and rigidity of muscle tone. The pathological basis for these 
symptoms is degeneration of dopaminergic neurones in the substantia nigra, 
either idiopathically in the case of Parkinson’s disease or due to an identified 
neurotoxic action in the case of MPTP, with oxidative stress and associated 
apoptosis integral to progression of the disease (Jenner and Olanow, 1998).  
The AIDS dementia complex is a process of cognitive decline which can 
supervene in long-standing HIV infection complicated by AIDS, with the 
pathology as yet unclear although with several indications that the involvement 
of oxidative damage is a key component in pathogenesis. The severity of clinical 
neurological decline has been correlated with higher concentrations of QA in 
both early and late-stage infection (Heyes et al., 1991). Additionally, QA applied 
at nanomolar concentrations for 24 hours has been demonstrated to induce 
apoptosis in human astrocytes (Guillemin et al., 2005).  
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There are indications that the increased concentration of QA may be due to 
production by microglia and macrophages, as astrocytes produce no QA and in 
fact produce the neuroprotective metabolite kynurenic acid (Guillemin et al., 
2001). This suggests that increased QA production is a manifestation of extensive 
inflammation and associated macrophage and microglial activation (Espey et al., 
1997), consistent with the association between extent of infection and increased 
QA levels.  
This brief review of the pathology of these conditions emphasises the 
importance of excitotoxicity and oxidative stress as causes of neuronal damage, 
with a variety of routes of inducing this damage, such as: direct induction of 
oxidative stress by toxic agents, enhanced vulnerability to excitotoxicity and 
oxidative damage and damage from excitotoxic by-products of inflammation. 
Therefore, the scope of use for treatments aimed at alleviating the damage 
done by excitotoxic and oxidative stressors is broad, with study of these 
processes offering the potential for important interventions in disease 
progression.  
1.2 Excitotoxicity 
1.2.1 Neurotransmission 
1.2.1.1 Excitatory amino acids 
Excitatory amino acids are a group of neurotransmitters including glutamate and 
aspartate, which transmit excitatory signals in the CNS. The most important 
neurotransmitter of this group is glutamate, which is synthesised primarily from 
intermediate metabolites in the Krebs cycle and also from glutamine. Storage of 
glutamate in neurones is in synaptic vesicles, with the compound released during 
neurotransmission by exocytosis, a calcium-dependent process (Rang et al., 
1995). Cerebellar granule neurones are capable of generating glutamate through 
carboxylation of pyruvate, indicating no dependence on glutamate synthesised 
from glutamine by glial cells (Hassel and Bråthe, 2000).  
Glutamate mediates its actions via four classes of receptor: the ionotropic 
NMDA, AMPA and kainate receptors, and the metabotropic glutamate receptors. 
The AMPA and kainate receptors are involved in fast excitatory post-synaptic 
responses, the NMDA receptors in slow post-synaptic potential generation and 
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the metabotropic rectors (reflecting their less rapidly-acting mode of action) in 
delayed neuromodulatory responses (Rang et al., 1995).  
1.2.1.2 Gamma-amino-butyric acid 
Gamma-amino-butyric acid (GABA) is found extensively in the brain and acts as 
an inhibitory neurotransmitter on the receptor subtypes GABAA, GABAB and 
GABAC. Synthesis of GABA is via the action of glutamic acid decarboxylase, which 
uses glutamate as its substrate (Rang et al., 1995). Inhibition of excitatory 
neurotransmission by GABAA receptors is mostly post synaptic, due to increased 
influx of chloride ions causing hyperpolarisation of the membrane.  In contrast, 
GABAB receptors act mainly presynaptically to reduce calcium influx and 
increase potassium efflux, these actions respectively reducing excitatory 
transmitter release and inducing hyperpolarisation (Rang et al., 1995). GABAC 
receptors are ligand-gated ion channels that are predominantly located in the 
retina, but have been speculated to elsewhere be involved in memory formation 
(Chebib, 2004). It has already been established that GABAA receptors are 
involved with memory formation, and that transgenic mice deficient in the α5 
subunit of the GABAA receptor show enhanced learning and memory in water 
maze testing (Collinson et al., 2002). Earlier in neuronal development, GABA 
receptors can have an excitatory function: this is because intracellular 
concentrations of chloride are higher, so opening chloride channels can cause 
efflux of chloride, sodium influx and activation of voltage-gated calcium 
channels (Ben-Ari et al., 2007). As GABA excitatory transmission is established 
earlier than glutamatergic neurotransmission, it can have a significant impact on 
synaptic plasticity, and thus on neuronal survival and development (Ben-Ari et 
al., 2007).  
1.2.2 Glutamate (NMDA, AMPA, kainate, metabotropic receptors) 
1.2.2.1 N-methyl-D-aspartate receptors 
Stimulation of NMDA receptors causes activation of cation channels, inducing 
influx of calcium and sodium ions. There are a variety of NMDA receptor 
subunits, grouped into three subtype categories: NR1, NR2 and NR3 (each 
category encompassing several varieties of subunit), with a set of four subunits 
(two NR1 and two NR2 or occasionally NR3 subunits) believed to be grouped 
together to construct a complete receptor (Paoletti and Neyton, 2007).  
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Activation of NMDA receptors requires the stimulation of two sites on the 
receptor, namely the glutamate recognition site (on the NR2 subunit) and the 
glycine binding site (on the NR1 subunit) and also the removal of a voltage-
dependent magnesium block of the associated ion channel: once the receptor is 
activated, the ion channel allows entry of calcium and sodium (Lynch and 
Guttmann, 2002).  
Receptor subunit composition changes with neuronal development: NMDA 
receptors in immature rat hippocampal cultures are predominantly NR1/2B 
receptors at developing synapses (Waxman and Lynch, 2005). By 14 days in vitro 
(DIV), NR2A expression increases and the dominant synaptic receptor 
configuration is NR1/2A/2B, with NR1/2B levels higher at extra-synaptic 
locations: p38 phosphorylation requires NR1/2A/2B activation, which indicates 
that synaptic NMDA receptor activity induces p38 activation and extra-synaptic 
activity induces p38 de-phosphorylation (Waxman and Lynch, 2005).  
Neuronal NMDA receptors are situated in both synaptic and extra-synaptic 
locations, with different outcomes resulting from receptor stimulation in these 
different locations. It has been reported that calcium influx induced by extra-
synaptic NMDA receptor stimulation induces neuronal death, whereas calcium 
influx from synaptic NMDA receptors does not (Hardingham et al., 2002b). This 
may be due to differences in the responses of mitochondria at these locations to 
influxes of calcium (Young et al., 2008). It appears that both the intensity and 
duration of the calcium influx mediated by NMDA receptor stimulation 
(irrespective of location) are critical to the response that is induced, with pro-
survival signalling more likely to be induced by a moderate calcium signal and 
pro-death signalling more likely in response to an intense or prolonged calcium 
influx (Soriano and Hardingham, 2007, Hou et al., 2008).  
The pro-survival signals activated by NMDA receptor-mediated calcium influx 
include: Akt, ERK 1/2 and phosphorylation of cyclic-AMP response element 
binding protein (CREB), whereas the pro-death signals include activation of p38, 
JNK and calpains (Papadia and Hardingham, 2007).  
Receptor activation can be blocked by co-application of D-(-)-2-amino-5-
phosphonovalerate (APV, a competitive NMDA antagonist), (+)-5-Methyl-10,11-
dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine hydrogen maleate (MK-801 or 
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dizocilpine, non-competitive NMDA antagonist, which directly blocks the 
receptor-associated pore) or by the endogenously-generated glycine co-site 
antagonist kynurenic acid (Foster et al., 1984, Paoletti and Neyton, 2007).  
1.2.2.2 AMPA receptors 
Activation of α-amino-3-hydroxy-5-methylisoxazole-4-propionate receptors 
causes influx of sodium, which can lead to depolarisation and depending on 
subunit composition, may allow influx of calcium when stimulated, a process 
integral to development of long-term potentiation (Stone and Addae, 2002, Liu 
and Zukin, 2007). A major component of AMPA-mediated excitotoxicity is AMPA-
induced depolarisation, which removes the voltage-dependent magnesium gate 
on the NMDA receptor and thus allows influx of calcium through this receptor 
(review: Hou and Macmanus, 2002).  
α-Amino-3-hydroxy-5-methylisoxazole-4-propionate induced neurotoxicity but 
was not toxic to glia in cultured neonatal rat cerebral cortical tissue (Rzeski et 
al., 2005). Activation of AMPA receptors was prolonged and associated with 
enhanced current flow following exposure to a modelled traumatic injury in rat 
neonatal cortical neurones, a process which was induced by repression of AMPA 
receptor desensitisation and represents a potential mechanism for post-
traumatic neuronal injury (Goforth et al., 1999).  
The development of long-term potentiation (LTP), although mediated initially by 
NMDA receptor stimulation, involves alterations to AMPA receptors. Long-term 
potentiation is long-lasting enhanced signalling between two neurones resulting 
from simultaneous stimulation, which is believed to be a major component of 
learning and memory. Early LTP involves NMDA receptor activation and calcium 
influx leading to AMPA receptor insertion and increased AMPA receptor 
conductance (although it should be noted that while NMDA receptor activation is 
required for LTP in the hippocampus, it is not required for LTP in mossy fibres). 
Late LTP involves excitation of NMDA, AMPA and metabotropic glutamate 
receptors (mGluRs), which causes ERK activation: this leads to gene 
transcription, protein synthesis and morphology changes and ultimately to LTP 
expression (Izquierdo, 1994). Long-term potentiation is a process believed to be 
of importance during neuronal development.  
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The AMPA receptors develop relatively late, with glutamatergic transmission 
therefore ‘silent’ initially, as NMDA receptors cannot be stimulated due to the 
voltage-gated magnesium block. The role of AMPA receptors in providing a rapid 
excitatory response (which allows removal of the magnesium block) is taken by 
GABA receptors initially, as mentioned previously (Ben-Ari et al., 1997).  
1.2.2.3 Kainate receptors 
Activation of kainate receptors is also capable of inducing neuronal death: in 
parallel with AMPA receptor stimulation, a significant component of kainate 
receptor-mediated neurotoxicity in vivo is depolarisation-induced NMDA receptor 
activity (Behan and Stone, 2000). This finding was not reproduced in either rat 
or mouse cerebellar granule neurones (CGNs) in vitro however, as blockade with 
the kainate receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione disodium 
protected against kainate toxicity, but NMDA blockade with MK-801 did not 
(Simonian et al., 1996, Smith et al., 2003). An additional effect of kainate 
receptor stimulation is the stimulation of GABA release, acting to induce a 
negative feedback loop and prevent over-excitation (review: Pinheiro and Mulle, 
2006).  
Kainate toxicity induces DNA fragmentation and apoptotic appearances but does 
not involve caspase-3 activation and is not dependent on new protein or RNA 
synthesis (Simonian et al., 1996, Smith et al., 2003). In neonatal rat CGNs, the 
neurotoxic effect of kainate, which appeared to involve a necrotic death 
mechanism, was potentiated by nifedipine or exhaustion of intracellular calcium 
stores (Leski et al., 1999).  
1.2.2.4 Metabotropic glutamate receptors 
Metabotropic glutamate receptors mediate their effects via second messenger 
systems, particularly phospholipase C and adenylate cyclase: due to this 
mechanism of action, mGluRs act less rapidly than the ionophoric channels. 
There are eight subtypes of these receptors (mGluR1-8), which are divided into 
three groups. Group I receptors (mGluRs 1 and 5) are located postsynaptically 
and act via phospholipase C, increasing the activity of NMDA receptors, with 
mGluR1 receptors increasing glutamate release via increased calcium influx 
(Stone and Addae, 2002). However, Group I receptors can also induce inhibitory 
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post-synaptic potentials and modulate the action of voltage-gated calcium 
channels. Nontheless, blockade of mGluR1 receptors protects against both 
oxygen-glucose deprivation (OGD) in vitro and ischaemia in vivo (Pellegrini-
Giampietro et al., 1999).  
Group II (mGluRs 2 and 3) and Group II receptors (mGluRs 4, 6, 7 and 8) both act 
to reduce adenylate cyclase activity, which reduces cyclic AMP levels and NMDA 
receptor activity. Group II and III mGluRs are mainly presynaptic, although they 
have been identified at both pre- and postsynaptic locations. Stimulation of 
mGluR2 and mGluR3 subtypes has been demonstrated as being neuroprotective 
against the neurotoxic effects of NMDA and traumatic brain damage, with 
protection also seen with stimulation of mGLuR4 and mGluR7 subtypes (Stone 
and Addae, 2002).  
1.2.3 Mechanisms of damage post-receptor 
Excess glutamate damages neurones via the process of excitotoxicity, which 
involves over-stimulation of neurones with excitatory amino acids (Olney and de 
Gubareff, 1978). In the case of glutamate, this is primarily mediated via an 
influx of calcium due to NMDA receptor activation (Manev et al., 1989), which 
causes calcium, sodium, chloride and zinc influx, and efflux of potassium. This 
results in depolarisation and increased calcium and water content, which in turn 
disturbs metabolic function and produces neuronal swelling, damaging the cell 
membrane (Sapolsky, 2001, Hou and MacManus, 2002). A further effect of 
glutamate excitotoxicity is the development of dendritic beading, an effect 
induced by a collapse in mitochondrial ATP production associated with ion 
(sodium or calcium) influx, which leads to influx of extracellular water and 
resultant formation of beading on dendrites (Greenwood et al., 2007).  
Glutamate-induced excitotoxicity depends on the presence of extracellular 
calcium (Choi and Rothman, 1990), with cell death due to excitotoxicity 
proportional to neuronal calcium uptake and attenuated by removal of 
extracellular calcium up to 30 minutes after glutamate application in CGNs 
(Manev et al., 1989). Activation of NMDA receptors causes calcium influx, which 
initially accumulates in mitochondria prior to a subsequent efflux of calcium into 
the cytoplasm (Budd and Nicholls, 1996). It does not appear however, that this 
calcium is emitted from the mitochondria (Ward et al., 2005).  
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Glutamate-induced excitotoxicity leads to MPT pore opening, leading to leakage 
of calcium, ROS and cytochrome c from the mitochondria (Chalmers and 
Nicholls, 2003). Further damage to the cell membrane results from glutamate-
induced ROS production, which damages cell membrane lipids (Sapolsky, 2001, 
Hou and MacManus, 2002).  
Destruction of the plasma membrane calcium pump by calcium-activated 
calpains is another feature of excitotoxicity (Bano et al., 2005). This may 
explain the link between excitotoxicity and necrosis, as plasma membrane 
calcium pump cleavage leads to excessive intracellular calcium, despite initial 
activation of apoptosis mechanisms (Schwab et al., 2002). Exposure to 
glutamate for a short period (30 minutes) has been shown to induce breakdown 
of the structural proteins laminin and β-tubulin in neonatal rat CGNs (Ankarcrona 
et al., 1996).  
The possibilities remain that glutamate toxicity induces cell death via both 
necrotic and apoptotic mechanisms or that cells follow the necrotic pathway of 
cell death as a ‘second choice’ when the apoptotic pathway becomes 
unavailable, analogous to the switch from apoptosis to necrosis due to falling 
levels of ATP in the penumbra of an infarct (Dessi et al., 1993).  
There are several mechanisms by which cells act to reduce or avert glutamate-
induced damage, most triggered by glutamate’s immediate effects on the 
neuronal intracellular environment. The potential for depolarisation is affected 
by small-conductance potassium channels and ATP-dependant potassium 
channels as follows. The small-conductance channels are calcium-dependant; 
hence rising intracellular calcium levels due to glutamate stimulation open the 
channels and produce neuronal hyper-polarisation. Falling levels of ATP, a 
consequence of ATP consumption due to over-excitation, cause ATP-dependant 
potassium channel to open. Calcium influx due to NMDA receptor stimulation 
also increases Na+/K+/ATPase activity, which also maintains membrane 
polarisation, although this effect will be reduced due to falling levels of ATP 
(Sapolsky, 2001). Glutamate also triggers release of GABA, adenosine and 
taurine, inhibiting subsequent glutamate release, with adenosine having the 
additional beneficial effect of being an ATP precursor (Sapolsky, 2001).  
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The results of glutamate excitotoxicity can themselves limit the damage 
produced, specifically the increases in calcium and ROS: NMDA receptors can be 
damaged by the action of calpain, and calcium currents inhibited by the 
calcium-dependant activation of calcineurin and calmodulin, which are all 
activated by increasing levels of intracellular calcium (Sapolsky, 2001).  
Activation of protein kinase C (PKC) attenuates NMDA-mediated calcium 
increases, perhaps by feedback inhibition of the NMDA receptor itself by PKC 
(Snell et al., 1994). Furthermore, damage to intracellular proteins initiates 
production of 'heat shock proteins', which protect against calcium and ROS-
induced protein damage, and also antioxidant enzymes production rises to 
compensate for increased ROS levels (Sapolsky, 2001).  
1.3 Oxidative stress 
1.3.1 Energy metabolism 
Glycolysis occurs in the cytoplasm, converting glucose initially to glucose-6-
phosphate, then through a series of other intermediates to pyruvate. When 
there is sufficient oxygen to reoxidise the NAD+ (nicotinamide adenine 
dinucleotide) reduced during this process, aerobic glycolysis occurs, with the 
pyruvate becoming the substrate for the first stage of the citric acid cycle and 
the reduced nicotinamide adenine dinucleotide (NADH) being utilised in 
oxidative phosphorylation. Alternatively, in the presence of an inadequate 
oxygen supply, the pyruvate is converted into lactate by anaerobic glycolysis, 
with the reduced form NADH oxidised back to NAD+ during lactate production 
(Champe and Harvey, 1994).  
The citric acid cycle occurs in the mitochondrial matrix and is a major source of 
the reduced cofactors which power oxidative phosphorylation. Pyruvate is 
converted to acetyl CoA, which then enters the cycle by combining with 
oxaloacetate to form citrate. Citrate is metabolised over several stages to 
oxaloacetate, which then re-enters the cycle on combination with a new 
molecule of acetyl CoA.  
Oxidative phosphorylation occurs on the inner mitochondrial membrane, using a 
series of four inter-linked complexes collectively known as the electron 
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transport chain. This leads on to a fifth complex which utilises free protons 
generated by the previous four complexes to synthesise ATP and water from ADP 
(adenosine diphosphate), free phosphate and oxygen. Cytochromes a+a3, b and c 
are integral components of the electron transport chain, each containing an iron 
atom which alternates between the ferrous and ferric states during different 
stages of electron transport (Champe and Harvey, 1994).  
1.3.2 Causes of oxidative stress 
The main sources of ROS in the cell are the mitochondria, so abnormalities of 
mitochondrial function due to inherent defects or abnormal stresses are likely to 
lead to production of excessive quantities of ROS. When these levels overwhelm 
the cell’s normal antioxidant defences, such as the free radical scavengers found 
in the inner mitochondrial membrane and antioxidant enzymes such as catalase 
and superoxide dismutase (SOD), DNA and cellular structures are damaged, a 
process referred to as oxidative stress. Another route by which oxidative stress 
can occur is due to antioxidant defences being abnormally impaired, as occurs in 
amyotrophic lateral sclerosis, an inherited neurodegenerative disorder 
commonly due to an inherited mutation in Cu,Zn-SOD (Ryu et al., 2005).  
Formation of superoxide in the mitochondria can lead to production of hydrogen 
peroxide (H2O2) by the action of Mn-SOD in the mitochondria, or can react with 
nitric oxide to produce peroxynitrite, a highly reactive ROS with significant 
potential for oxidative damage. Should superoxide be converted to H2O2, it may 
then either be removed by the action of catalase or glutathione peroxidase, 
however any remaining H2O2 is free to be converted to the highly toxic hydroxyl 
radical following reaction with free ferrous (Fe2+) ions (Trushina and McMurray, 
2007).  
1.3.3 Mechanisms of damage 
The route by which oxidative stress induces damage in neurones is by direct 
molecular reactions of the ROS with DNA molecules (both mitochondrial and 
nuclear) and with structural molecules in the cell, particularly lipids. The main 
sites of reaction in lipid molecules are the double bonds found in unsaturated 
fats, with polyunsaturated molecules thus being especially vulnerable (see 
section 1.3.4, Weisbrot-Lefkowitz et al., 1998).  
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Damage to cell membranes by lipid peroxidation is due both to direct action on 
membrane lipids, affecting the viscosity and function of the membrane itself and 
by damage to membrane proteins (acting as ion channels and transporters) by 
aldehydes that are produced by this lipid peroxidation (Mattson, 1998, Mattson, 
2004). These effects on membrane functions reduce ion transport, hence 
increasing vulnerability to calcium influx and providing a secondary mechanism 
by which damage can be multiplied (Mattson, 1998). Furthermore reduced 
glucose transport secondary to glucose transporter damage causes a rapid 
decrease in ATP formation which further enhances vulnerability to excitotoxic 
damage by glutamate (Novelli et al., 1987, Mark et al., 1997).  
The damage to mitochondrial function, particularly to the mitochondrial 
membrane, is a critical step in the cascade leading to apoptosis, as the cycles of 
further loss of ion balance and ATP production which are established by 
oxidative damage lead to worsening mitochondrial disruption. This could lead to 
loss of mitochondrial membrane potential, MPT pore opening and consequent 
release of calcium and cytochrome c from the mitochondrial matrix, causing 
activation of caspase-9 and resultant apoptosis. However, triggering of this 
sequence of events is not dependent on apoptotic mechanisms, as it can also 
lead to neuronal death by necrosis (Chinopolous and Adam-Vizi, 2006).  
1.3.4 Vulnerability of neurones 
Cerebral metabolism is notably out of proportion to the volume of tissue 
concerned: although comprising only 2% of body weight, the brain is responsible 
for 20% of the body’s oxygen use. The substrate used for cerebral energy 
metabolism is exclusively glucose, although ketone bodies are used in prolonged 
(three weeks or more) starvation (Champe and Harvey, 1994).  
Cell damage due to ischaemia is extensively mediated via ROS, to which the 
brain is especially vulnerable for several reasons. These include the fact that the 
brain’s high rate of respiration causes the production of a higher quantity of ROS 
than in other tissues.  
Additionally, the brain is especially vulnerable to the oxidative action of ROS 
due to the extensive amount of polyunsaturated fatty acids present within its 
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tissues and the lower levels of antioxidant enzymes compared with those 
available in other tissues (Weisbrot-Lefkowitz et al., 1998).  
There is a higher concentration of lipids containing polyunsaturated acyl 
molecules, which are especially vulnerable to the actions of ROS (Bolanos et al., 
1997). This is a potential explanation for the heightened vulnerability; as such 
damage could rapidly translate into reduced ATP formation and ability to cope 
with calcium influx due to ongoing neurotransmission, hence the damage to 
neurones could be rapidly compounded.  
1.3.5 Involvement of tryptophan metabolites 
The metabolism of tryptophan in the body is unavoidable, as its status as an 
essential amino acid necessitates its inclusion in the diet (Champe and Harvey, 
1994). The kynurenine pathway constitutes the primary route for the catabolism 
of tryptophan and hence exposure to the compounds found on this pathway will 
be similarly unavoidable. Therefore it is unfortunate that several of these 
compounds have neurotoxic properties, with effects noted in neuronal cultures, 
brain slices and from in vivo studies. The reasons that the metabolism of 
tryptophan, rather than that of other essential amino acids such as 
phenylalanine, is of interest are that one of its metabolites (QA) is the only 
known endogenous agonist of the NMDA receptor and another (kynurenic acid) is 
an endogenous glutamate receptor antagonist (Foster et al., 1984). The pathway 
therefore provides a unique opportunity to examine endogenous sources of 
excitotoxic damage.  
Tryptophan can be metabolised into melatonin, although the main route for the 
catabolism of tryptophan in the body is via the kynurenine pathway, which 
ultimately leads to the production of nicotinamide (Figure 1.1). The first step is 
the conversion of tryptophan into formylkynurenine by indolamine dioxygenase, 
which is then converted (by kynurenine formylase) to kynurenine (Stone, 2000).  
Kynurenine can then be metabolised in a number of different ways, one of which 
leads to the production of kynurenic acid, although the main pathway of 
kynurenine catabolism leads to the production of a number of neurotoxic 
compounds, capable of effecting damage through both excitotoxic and oxidative 
mechanisms. There are two sub-pathways through which kynurenine catabolism 
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may take place, although the common end-point of both, immediately prior to 
the formation of nicotinamide, is the formation of QA. It is not possible to 
completely avert metabolism away from this route, as it leads to the synthesis of 
nicotinamide, which is essential for normal metabolic function in the cell.  
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Figure 1.1 – Simplified diagram of kynurenine pathway (adapted from Stone, 2000), showing 
route of metabolism from tryptophan to nicotinamide and main pathway branches; 
compounds with previously identified neurotoxic properties marked by underlining.  
 
Quinolinic acid has both excitatory (via NMDA receptors) and neurotoxic 
properties, with injection of QA in rat striatum in vivo producing an axon-sparing 
neurodegenerative lesion, proportional in volume to the QA dose applied 
(Perkins and Stone, 1983, Schwarcz et al., 1983, Guidetti and Schwarcz, 1999). 
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Further study of QA toxicity in vivo found that injection of a nanomolar 
concentration of QA increased expression of JNK and p38 in the lesion core, 
which although no longer evident at 24 hours correlated with areas of 
subsequent cell death (Ferrer et al., 2001).  
Quinolinic acid neurotoxicity is closely related to its ability to act as an NMDA 
receptor agonist, as it can be attenuated by co-application of kynurenic acid or 
MK-801 (Rios and Santamaria, 1991, Chiarugi et al., 2001). It is also clear that 
QA neurotoxicity involves generation of oxidative stress, as application of QA to 
rat brain homogenates caused a significant increase in lipid peroxidation and QA-
induced damage was reduced in a dose-dependant manner by co-administration 
of the antioxidant melatonin (Rios and Santamaria, 1991, Behan et al., 1999). 
Furthermore, the co-application of the free radical generator xanthine oxidase 
significantly potentiated QA neurotoxicity in rat hippocampus in vivo, whereas 
each compound applied alone caused only minor neuronal loss (Behan and Stone, 
2002).  
Co-application of the NOS inhibitor, nitroindazole, or the poly (ADP-ribose) 
polymerase (PARP) inhibitor, 3,4-dihydro-5-[4-1(piperidinyl) buthoxy]-1(2H)-
isoquinolone (DPQ), significantly reduced damage due to QA application, 
although toxicity was not reduced by cyclosporine or the pan-caspase inhibitor, 
carbonbenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fuoromethylketone (Z-VAD-fmk), 
indicating that QA neurotoxicity is more likely to induce neuronal death via 
necrosis rather than apoptosis (Chiarugi et al., 2001). Injection of QA into the 
somatosensory cortex caused cell death with necrotic features in the core of the 
injection-induced lesion, with no activation of caspase-3 seen in any neurones, 
although there was transient positive staining of p38 and JNK in the core, which 
was absent by 24 hours (Ferrer et al., 2001).  
As previously described, there is strong evidence linking QA to the AIDS dementia 
complex, particularly with regard to increased QA levels, produced by microglia 
due to neuroinflammatory processes and leading to increased QA levels both in 
CSF and brain parenchyma. There is also evidence suggesting a link between QA 
and cerebral malaria, possibly due to the utilisation of the kynurenine pathway 
in the inflammatory responses mediated by microglia. In a retrospective study, 
the CSF of children diagnosed with malaria was compared with a control group 
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of samples taken from healthy adults, with a significant association found 
between higher QA concentrations in the CSF and an increased risk of mortality 
in patients with cerebral malaria (Medana et al., 2003).  
Although QA is long-established as a neurotoxic product of tryptophan 
metabolism, two other compounds on the main pathway leading to the 
formation of QA have also been identified as potent neurotoxins, namely 3-
hydroxykynurenine (3-HK) and 3-hydroxyanthranilic acid (3-HAA). As these 
compounds show similar (although not identical) characteristics, the evidence 
for the neurotoxic effects of each will be considered together.  
Application of 3-HAA for 48 hours induced a significant degree of apoptosis in 
monocyte-derived cell lines (U937 and THP-1), an effect enhanced by ferrous or 
manganese ions (Morita et al., 2001). Although the use of the antioxidant 
enzymes catalase or SOD did not significantly attenuate toxicity, a significant 
reduction in apoptosis was induced by Trolox, α-tocopherol or allopurinol (Morita 
et al., 2001). Although these experiments involved exogenous application of the 
compounds, which if generated in neurones will be cytoplasmic, the generation 
by cells throughout the body ensure that they will be distributed throughout the 
body via the bloodstream, and in the case of 3-HK at least, will be taken up by 
neurones both in situ and in the experimental setting.  
These effects were reproduced in striatal neurones, with 3-HK causing 
significant neuronal death, an effect prevented by the co-application of catalase 
or allopurinol, which indicated that the neurotoxic effect was due to oxidative 
damage (Okuda et al., 1996). Further evidence reinforcing this was that N-
acetylcysteine, an antioxidant particularly effective at scavenging the hydroxyl 
radical, provided protection against 3-HK-induced neurotoxicity (Okuda et al., 
1998).  
Treatment of striatal neurones with 3-HAA produced a comparable level of 
neuronal death to that seen with 3-HK (Okuda et al., 1998). Both 3-HK and 3-
HAA are capable of generating ROS, specifically H2O2 and superoxide, when 
added to phosphate buffer solution, with both compounds causing reduction of 
cupric (Cu2+) to cuprous (Cu+), and of ferric (Fe3+) to Fe2+, at physiological pH 
(Goldstein et al., 2000). Although superoxide was produced by both 3-HK and 3-
HAA in phosphate-buffered saline (PBS) alone, the compounds were unable to 
38 
generate H2O2 in PBS alone, although both produced significant amounts of H2O2 
in the presence of Cu2+, with copper ions cycling between oxidised and reduced 
status during cycles of H2O2 generation (Goldstein et al., 2000). The increased 
H2O2 production was completely abolished by catalase and notably inhibited by a 
reduction in molecular oxygen concentration (Goldstein et al., 2000).  
The importance of oxygen in the oxidation of 3-HAA was emphasised by a study 
which reported 3-HAA auto-oxidation in aerobic reaction solution but not 
anaerobic, with oxidation of 3-HAA increased dramatically by addition of Cu,Zn-
SOD (but not Mn-SOD) to anaerobic solution or by re-admittance of air in 
anaerobic conditions (Liochev and Fridovich, 2001). It seems likely that the 
enhancement of oxidation by Cu,Zn-SOD was due to copper ions acting as redox 
reagents, rather than enzymatic activity (Liochev and Fridovich, 2001).  
Although 3-HK and 3-HAA are capable of oxidising, they are in fact redox 
reagents and the antioxidant activity of 3-HK and 3-HAA has been successfully 
demonstrated in rat cerebral cortex homogenate, with incubation of 
homogenates with either 3-HK or 3-HAA for 1 hour reducing levels of ROS present 
(Leipnitz et al., 2006). This effect was achieved with higher (100µM) 
concentrations of 3-HK and 3-HAA (although not 1 or 10µM), and reproduced in 
homogenate solutions containing either Fe2+ or Fe3+ ions (Leipnitz et al., 2006). 
It should be noted however, that this experiment used predominantly glial cell 
types (these being the most numerous cell type in adult cerebral cortex 
homogenate), with similar results achieved using cells of glial tumour origin 
(Leipnitz et al., 2006).  
To further investigate the actions of 3-HAA on Fe2+ and Fe3+ ions, the effect of 3-
HAA on methaemoglobin production (a form of haemoglobin in which the Fe2+ 
ions have become Fe3+ ions, and hence cannot function as oxygen transporters) 
from haemoglobin was studied: 3-HAA caused a concentration-related increase 
in the percentage of methaemoglobin and also the percentage of damaged ‘non-
intact’ haemoglobin (Dykens et al., 1989). Methaemoglobin formation was 
exacerbated by the presence of SOD, although not by catalase, with application 
of both SOD and catalase together giving very similar results to SOD alone 
(Dykens et al., 1989).  
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The evidence linking 3-HK or 3-HAA with pathological conditions is less extensive 
than that implicating QA, although a study of pneumococcal meningitis in infant 
Wistar rats showed significant increases in 3-HK levels in cortex and 
hippocampus between 16 and 44 hours post-infection, with no rises found in 
plasma samples (Bellac et al., 2006). Although 3-HAA levels increased at 44 
hours in the hippocampus, the levels in either hippocampus or cortex were lower 
than those in plasma. There was correlation between 3-HK concentrations and 
increased apoptosis in the hippocampus; with 3-HK levels of 190nM or higher 
corresponding to higher levels of apoptosis (Bellac et al., 2006).  
Additionally, alterations in the activity levels of the enzymes which catalyze the 
reaction of the kynurenine pathway were seen, with significant rises in the 
activities of kynurenine-3-hydroxylase (which converts kynurenine to 3-HK) and 
kynureninase (converting 3-HK to 3-HAA) in both cortex and hippocampus (Bellac 
et al., 2006).  
1.3.6 Effects of hyperglycaemia 
Given that oxidative phosphorylation, fuelled by glucose uptake, leads to ROS 
production and that an increase in the ratio of ROS: antioxidant defences leads 
to oxidative stress, it would be expected that hyperglycaemia or raised 
exogenous glucose would cause such damage. It has been shown that 
hyperglycaemia in vivo and raised glucose concentrations in vitro both cause a 
variety of effects, with increased neurotoxic effects seen due to 
hyperglycaemia/raised glucose directly and also manifested as heightened 
vulnerability to oxidative damage from other sources.  
Streptozotocin-induced diabetes caused a significant increase in the lipid 
peroxidation product 4-hydroxy-2-nonenal (HNE) in hippocampal CA1 and CA3 
regions and in Cu,Zn-SOD levels in rats subjected to restraint-induced stress, 
both indicating an increase in oxidative stress (Grillo et al., 2003).  
Hyperglycaemia in vivo enhances vulnerability to ischaemia, with ischaemia 
inducing significant increases in release of mitochondrial cytochrome c into the 
cytosol between 0.5 and 3 hours reperfusion, positive caspase-3 staining after 1 
and 3 hours and positive terminal dUTP nick-end labelling (TUNEL) staining after 
3 hours (Li et al., 2001, Muranyi et al., 2003). Cytochrome c release was 
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correlated with increased TUNEL staining compared to normoglycaemic animals 
subjected to ischaemia (Li et al., 2001, Muranyi et al., 2003).  
Transient (30 minutes) middle cerebral artery (MCA) occlusion in diabetic rats 
caused more extensive ischaemia-related damage 3 and 6 hours post-occlusion in 
diabetic than non-diabetic rats (Muranyi et al., 2003). Examination 7 days post-
occlusion showed continued development of damage beyond 6 hours’ reperfusion 
in non-diabetic but not in diabetic animals, although infarct volume in diabetic 
animals was significantly larger, demonstrating that ischaemic damage in 
diabetic animals was both more extensive and of more rapid onset (Muranyi et 
al., 2003).  
Comparable effects exist in vitro: exposing embryonic rat dorsal root ganglion 
(DRG) neurones cultured in medium with 25mM glucose to ‘hyperglycaemia’ 
(induced by raising the concentration to 45mM), demonstrated that this increase 
in glucose caused a range of effects. These included: increased NADH oxidase 
activity, increased ROS generation, mitochondrial swelling and disruption of 
inner cristae, caspase-3 cleavage and TUNEL staining, and greater responses 
from antioxidant defences, with expression of SOD and catalase increased 
(Vincent et al., 2005).  
Although hyperglycaemia can increase apoptosis due to osmotic effects, glucose 
has an effect beyond hyperosmolarity and DRG neurones of diabetic rats suffered 
from a progressive increase in intracellular calcium (Sima, 2003). Additionally, 
increased glucose levels induce alterations in redox status, dysregulation of 
glutathione synthesis and glucose autoxidation, generating ROS (Sima, 2003).  
N-methyl-D-aspartate receptor activation in neonatal rat CGNs caused a 
concentration-dependent increase in glucose uptake which was seen from 2 DIV, 
reaching its maximum by 8 DIV, with increases also seen following kainate and 
AMPA receptor stimulation (Minervini et al., 1997).  
It appears however, that the concentration-dependent effect of increasing 
exogenous glucose concentrations can be limited: the rate of glucose oxidation 
in cultured mouse cortical neurones became saturated when the extracellular 
concentration of glucose reached 1.4mM, with no further rise when this 
concentration was increased up to 16.7mM (Gorus et al., 1984). Use of radio-
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labelled 2-deoxyglucose in neonatal rat CGNs showed that saturation occurred at 
4mM (Minervini et al., 1997). 2-Deoxyglucose is an effective tool for studying 
this effect, as it is phosphorylated (phosphorylation being the rate-limiting step 
of glucose utilisation), although it should be noted that phosphorylation uses ATP 
rather than generates it (Whitesell et al., 1995).  
However, as with the in vivo studies, the possibility remains of a more subtle 
increase in underlying vulnerability to subsequent damage from a neurotoxic 
stimulus, despite the absence of any obvious increase in cell death. It should be 
noted that such strikingly raised glucose levels as decribed above will be rare in 
diabetic patients, with diagnosis and subsequent treatment acting to avert such 
increases. However, notable increases will still occur, which although less 
extensive in size will be for much more prolonged periods than in the studies 
described above.  
1.4 Preconditioning 
1.4.1 Background overview 
Extensive study has been carried out concerning the protective mechanism 
termed ‘preconditioning’ following work by Murry et al. (1986). This term 
referred to the protection conferred on tissue by brief periods of ischaemia 
against a subsequent, more severe ischaemic episode. This protective effect was 
initially demonstrated in canine myocardium, using a protocol of four 5-minute 
circumflex artery occlusions, after which an infarction was caused by a sustained 
40-minute occlusion of the circumflex. The resultant average infarct in 
preconditioned animals was reduced in size by 75% relative to the average 
infarct seen in control animals.  
It has been recognised that preconditioning can occur in two ways: early and 
delayed preconditioning, which take place over approximate periods of up to 2 
hours and from 24 hours to 3 days respectively (review: Halestrap et al., 2007). 
Early preconditioning has received the greatest attention in studies concerned 
with cardiac preconditioning.  
There is evidence that the generation of ROS during cardiac preconditioning 
causes activation of protein kinase C, specifically the epsilon subtype. This 
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protein appears to play an integral part in mediating protection, as ischaemic 
preconditioning cannot be induced in mice with the protein kinase C gene 
knocked out (Saurin et al., 2002). Activation of protein kinase C by ROS is a 
critical step, with scavengers of free radicals preventing protein kinase C 
activation and preconditioning (Baines et al., 1997).  
Inhibition of the opening of the MPT pore is a major component of the 
mechanism of cardiac preconditioning: this opening is triggered by calcium influx 
combined with oxidative stress, hence reduction of these by preconditioning acts 
to inhibit MPT pore opening (Halestrap et al., 2007). A possible mechanism for 
this is that preconditioning causes opening of mitochondrial ATP-sensitive 
potassium (KATP) channels, resulting in a reduction in mitochondrial polarisation 
which reduced ROS formation due to decreased calcium uptake, but not 
sufficient to impair ATP formation.  
Another phenomenon identified following the discovery of preconditioning was 
postconditioning, which refers to intermittent interruptions in blood flow which 
occur after an ischaemic insult. This method is effective in inducing a degree of 
protection similar to early preconditioning, although there does not appear to be 
an additive effect on protection from the use of both in rat (Zhao and Vinten-
Johanson, 2006), however combined treatments did give synergistic protection 
in rabbit (Yang et al., 2004).  
It is not clear whether protection due to postconditioning is induced by the 
recurrence of brief episodes of ischaemia or of reperfusion, but to be effective 
postconditioning must occur immediately after the commencement of 
reperfusion (Zhao and Vinten-Johanson, 2006). There are several mechanisms 
common to both pre- and postconditioning, including increased mitochondrial 
ROS generation, protein kinase C signalling, activation of KATP channels and 
inhibition of MPT pore opening (Zhao and Vinten-Johanson, 2006).  
However, a notable finding regarding the clinical potential of preconditioning is 
that ischaemia severe enough to cause pain (pre-infarction angina) was not 
associated with a reduction in infarct size or improvement in clinical outcome 
following acute myocardial infarction (Psychari et al., 2004). This suggests that 
the degree of stress to which cells are subjected must be of considerable 
severity for cardiac early preconditioning to effectively occur. A possible 
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candidate for a ‘common link’ of convergence of pathways triggered by 
preconditioning is inhibition of glycogen synthase kinase 3β (GSK-3β), preventing 
MPT pore formation (Juhaszora et al., 2004).  
A link between the mechanisms of preconditioning thus far identified and 
protection against oxidative damage in the brain is that a hippocampal neuronal 
cell line (HT22) which expresses elevated levels of GSK-3β shows increased 
resistance to neurotoxicity induced by glutamate or H2O2 (Schäfer et al., 2004).  
Both early and delayed preconditioning have been studied in brain tissue, with 
the first finding concerning ischaemic preconditioning in vivo by Kitagawa et al. 
(1990). A wide range of studies of this phenomenon have been performed, in a 
large number of laboratories using different neuronal types (Damschroder-
Williams et al., 1995, Blondeau et al., 2001, Tauskela et al., 2001, Meller et al., 
2005). Studies concerning the investigation of early preconditioning involved 
mechanisms similar to those described in cardiac preconditioning, whereas 
delayed preconditioning in neurones involves different mechanisms, with 
particular focus on NMDA receptor activation.  
The preconditioning protocol used in the first demonstration was of two 2-
minute ischaemic episodes, followed after a two-day interval by a 5-minute 
ischaemic event (caused by occlusion of both common carotids), which yielded a 
significant protective effect (Kitagawa et al., 1990). Similar benefits were 
achieved using ischaemia to precondition the cerebral cortex of adult male 
Sprague-Dawley rats (Zhang et al., 2003). This work used a preconditioning 
protocol of two 20-minute carotid artery occlusions 20 minutes prior to occlusion 
of the ipsilateral middle cerebral artery for six hours, which reduced the average 
infarct volume by 60% in preconditioned animals relative to non-preconditioned 
subjects.  
The discovery of ischaemic preconditioning in the brain in vivo was 
complemented by findings of Schurr et al. (1986) that exposure of adult rat 
hippocampal slices to a brief period of anoxia allowed them to regain electrical 
activity after exposure to a subsequent longer episode of hypoxia.  
The protective effect of ischaemia in vivo can be reproduced with OGD in vitro: 
preconditioning by OGD for 5-30 minutes protected cultured murine cortical 
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neurones against a subsequent 45-55 minute insult, with the protective effect 
present between 7 and 72 hours (Grabb and Choi, 1999). Preconditioning with 
OGD in rat cortical neurones gave protection against a subsequent severe OGD 
insult, which was effective against both necrotic and apoptotic cell death 
(Arthur et al., 2004).  
There are interactions between NMDA and adenosine receptors, with stimulation 
of presynaptic adenosine A1 receptors reducing calcium influx and glutamate 
release, and stimulation of postsynaptic A1 receptors increasing potassium 
efflux, with resultant hyper-polarisation of cell membranes (review: de 
Mendonça et al., 2000). Both of these effects reduce NMDA receptor stimulation 
and therefore decrease calcium influx. However, A2a receptors act to stimulate 
glutamate release (Popoli et al., 1995). In the context of ischaemia, application 
of an A1 receptor agonist reduced ischaemia-related increase in extracellular 
glutamate and other excitatory amino acids (Goda et al., 1998).  
The role of adenosine receptors in preconditioning is complex, with some 
receptor subtypes mediating a protective effect and other subtypes harmful 
effects. Antagonism of adenosine A2a receptors reduces damage in cerebral 
infarction, whereas antagonism of A1 receptors enhances ischaemic damage 
(Phillis et al., 1995, Melani et al., 2003). However, it should be noted that not 
all models required A1 receptor activation (Tauskela et al., 2003).  
Early preconditioning-induced protection in rat hippocampal slices with 
sublethal OGD against subsequent otherwise lethal OGD completely prevented by 
A1 receptor antagonists, whereas A3 receptor antagonists enhanced the 
protection of preconditioning (Pugliese et al., 2003). The use of A2a antagonists 
in this study was not found to have any identifiable effect on preconditioning 
(Pugliese et al., 2003).  
Although A1 receptor stimulation is generally accepted to be beneficial and A3 
receptor stimulation harmful, the role of the A2a receptor is rather less clear-
cut, with a study of the effect of A2a agonists and antagonists on kainate-induced 
excitotoxicity finding protective effects from both groups (Jones et al., 1998).  
Another interesting aspect of the role of adenosine receptors is the difference in 
effect seen when comparing acute and chronic use of A1 receptor agonists and 
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antagonists. Agonists were protective when applied acutely, but detrimental 
when applied chronically, with the detrimental effect of A1 antagonists’ acute 
application reversed when applied chronically (review: de Mendonça et al., 
2000).  
An important question is whether the preconditioning phenomenon actually 
exists in humans; otherwise the clinical benefit of understanding the 
mechanisms of preconditioning may be minor or even non-existent. There is 
however evidence which suggests that a protective preconditioning effect may 
indeed be inducible in humans suffering sub-lethal ischaemia.  
A study of patients presenting with their first CVA (cerebro-vascular accident, 
i.e. a stroke) involved MRI imaging of the patients’ brains within twelve hours of 
the onset of their CVA symptoms (Wegener et al., 2004). It was found that 
patients who had experienced a transient ischaemic attack (TIA, in which 
symptoms and signs consistent with a CVA resolve fully within 24 hours) within 
the four week period prior to the CVA had smaller final infarct sizes than those 
patients with no history of a previous TIA (Wegener et al., 2004).  
A larger study concerning clinical evaluation of the severity of patients’ 
presenting symptoms, and the extent of final recovery, identified that a previous 
TIA was associated with both reduced severity in presenting symptoms of a first-
presentation CVA, and with a more favourable outcome, with a prolonged 
interval between TIA and CVA reducing protection (Moncayo et al., 2000, Sitzer 
et al., 2004). The protective effect was such that despite compensating for the 
reduced severity of presenting symptoms, previous TIA was still associated with 
a greater likelihood of a more complete recovery (Sitzer et al., 2004).  
1.4.2 NMDA receptor involvement and associated mechanisms 
Preconditioning neurones with a subtoxic concentration of NMDA prior to a toxic 
application of glutamate or OGD will greatly improve rates of neuronal survival 
against the toxic insult (Marini and Paul, 1993, Tauskela et al., 2001). However, 
this protection was significantly reduced by inhibition of protein or RNA 
synthesis at the time of NMDA preconditioning (Marini and Paul, 1993, 
Damschroder-Williams et al., 1995). The period over which the application of 
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sub-toxic NMDA provided protection against a toxic application of glutamate was 
over a range of 12-48 hours (Damschroder-Williams et al., 1995).  
Stimulation of NMDA receptors in CGNs caused release of brain-derived 
neurotrophic factor (BDNF), with subsequent increase in neurotrophin receptor 
TrkB tyrosine phosphorylation, due to BDNF binding with and activating TrkB. 
Blockade of either the NMDA receptor site or of TrkB receptor prevented 
preconditioning (Marini et al., 1998).  
The transcription factor nuclear factor kappa B (NF-κB) was also involved in the 
mediation of NMDA receptor-induced protection, with preconditioning 
completely lost if cells were pre-treated with NF-κB target DNA acting as a 
‘decoy’ for the transcription factor and blocking any protein synthesis that 
would have been mediated by it (Marini et al., 1998, Ravati et al., 2001). 
Nuclear factor kappa B is a family of transcription factors that regulate genes 
involved in several processes, including growth factor regulation, cell 
proliferation and apoptosis. Normally found in the cytosol, in an inactive 
complex with the inhibitory protein IκBα, NF-κB is phosphorylated and degraded 
upon complex activation, with active NF-κB subsequently released (Ravati et al., 
2001).  
Preconditioning rat cortical cell cultures with either sub-lethal OGD or NMDA 
provides protection against subsequent otherwise lethal exposure to either 
glutamate or OGD, i.e. cross-tolerance between the two toxic insults was 
demonstrated (Tauskela et al., 2001).  
There are complicated interactions between delayed preconditioning and 
adenosine, with findings from different studies frequently at variance. The use 
of adenosine or a range of adenosine A1 receptor antagonists before, during and 
after OGD preconditioning did not affect protection against lethal OGD (Tauskela 
et al., 2003). In contrast, Boeck et al. (2005) found that co-application of the A1 
receptor antagonist 8-cyclopentyl-1,3-dimethylxanthine (8-CPT) prevented NMDA 
preconditioning.  
A study of the involvement of adenosine receptors investigated the effect on 
NMDA preconditioning against a subsequent glutamate insult of the co-
application of A1 and A2a receptor antagonists, showing that the adenosine A1 
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antagonist 8-CPT prevented NMDA preconditioning, whereas the A2a receptor 
antagonist 4-(2-[7-amino-2-(2-furyl{1,2,4}-triazolo{2,3-a{1,3,5}triazian-5-yl-
aminoethyl)phenol (ZM 241385) did not affect the protection (Boeck et al., 
2005). It was suggested that NMDA preconditioning reduces the amount of 
adenosine formed by AMP hydrolysis, this adenosine having preferentially 
activated A2a receptors (Boeck et al., 2005).  
Pre-treatment of neonatal rat CGNs with kainate or glutamate and glycine, 
followed by exposure to an otherwise lethal glutamate and glycine insult, 
significantly reduced the neurotoxic calcium influx induced by glutamate and 
glycine (Ward et al., 2005). However, this contrasted with the findings of 
Chuang et al. (1992), who successfully preconditioned CGNs with NMDA, but not 
kainate, and with another study which found no protection by kainate 
preconditioning in murine neuronal cultures (Grabb and Choi 1999).  
Pre-treatment of rat CGNs with the QA for 6 hours prior to application of a 
neurotoxic glutamate treatment caused a 68% reduction in apoptosis in QA-
treated cultures compared with controls (Sei et al., 1998). Protection was lost in 
the absence of glucose and magnesium, or in the presence of an NMDA receptor 
antagonist. However QA was incapable of protecting against necrosis induced by 
glutamate and this protective effect was not evident against apoptosis induced 
by exposing neurones to 5mM potassium chloride (KCl) (Sei et al., 1998).  
1.4.3 Alternative methods 
An alternative approach to inducing protection by preconditioning has recently 
been examined, using lower-intensity stimulation of NMDA receptors for a more 
prolonged period, prior to subjecting the neurones thus treated to a neurotoxic 
stimulus. This has been investigated in cultures of hippocampal and also of 
cerebral cortical neurones, with a significant degree of protection provided in 
each case to a variety of neurotoxic insults (Papadia et al., 2005, Soriano et al., 
2006, Tauskela et al., 2008).  
The stimulation of rat hippocampal neurones in culture with the GABAA receptor 
inhibitor bicuculline is effective in causing an increase in neuronal firing, due to 
stimulation with glutamate released because of the loss of GABA-mediated 
inhibition. This caused NMDA receptor stimulation and a resultant increase in 
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action potential (AP) firing, with receptor stimulation restricted to synaptic 
NMDA receptors only. This treatment was effective in conferring resistance to 
apoptosis induced by trophin deprivation or a variety of toxic agents: 
staurosporine, C-2 ceramide, retinoic acid or okadaic acid (Papadia et al., 2005).  
These actions were potentiated by co-application of the potassium channel 
inhibitor 4-aminopyridine (4-AP), which was effective in amplifying both the AP-
generating and neuroprotective effects of bicuculline treatment. The 
importance of AP generation in inducing protection was confirmed by use of the 
sodium channel blocker tetrodotoxin (TTX), co-application of which abolished 
protection (Papadia et al., 2005).  
This method of stimulation significantly increased CREB (cyclic-AMP response 
element binding protein) phosphorylation, an NMDA receptor-dependent effect. 
Although blockade of CREB gene expression with inducible cAMP early repressor 
(ICER), an inhibitor of CREB, significantly reduced CREB gene expression in 
bicuculline-stimulated cultures, it did not prevent the bicuculline-mediated 
protective effect when stimulation was continued until the toxic stimulus.  
Although the CREB pathway is not involved in protection in the short term, when 
bicuculline treatment was followed by a pause preceding a toxic insult, CREB 
pathway activation was important, as protection induced by the bicuculline and 
4-AP increased neuronal survival was blocked by ICER. Nuclear calcium and 
calmodulin signalling were necessary for the delayed form of neuroprotection, 
but not for short-term protection (Papadia et al., 2005).  
Another method for providing stimulation of NMDA receptors in rat hippocampal 
neurones was the use of very low concentrations of NMDA itself, applied for 12-
24 hours to stimulate both synaptic and extra-synaptic receptors prior to a 
neurotoxic insult (although the majority of the resultant calcium influx occurs 
via synaptic NMDA receptors). Neuroprotection was demonstrated against both 
excitotoxic and apoptotic stimuli (glutamate, staurosporine or neurotrophin 
deprivation), with effective protection generated in both acute and long-lasting 
forms (Soriano et al., 2006). Protection was again dependent on AP production, 
and was still evident 48 hours after termination of the NMDA stimulus (Soriano et 
al., 2006).  
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This method of preconditioning did not affect mitochondrial membrane potential 
(although higher concentrations of NMDA caused a progressive decrease in 
mitochondrial membrane potential and an associated increase in toxicity). 
Intracellular Rhodamine red dye showed that levels of NMDA that induced 
effective preconditioning caused transient increases in mitochondrial calcium, 
whereas toxic levels of NMDA caused sustained rises in mitochondrial calcium 
(Soriano et al., 2006). There were further differences in calcium influx patterns, 
with preconditioning stimuli causing cytoplasmic calcium levels to ‘spike’ briefly 
and then oscillate at a lower level, whereas cytoplasmic calcium rises in 
response to higher concentrations of NMDA were sustained and non-oscillatory 
(Soriano et al., 2006).  
As with bicuculline-induced neuroprotection, NMDA treatment induced AP 
generation-dependent CREB activation and was also associated with an increase 
in BDNF mRNA expression (which could be blocked by TTX). A similar AP-
dependent effect was seen with phosphorylation of TrkB, the BDNF receptor 
(Soriano et al., 2006).  
A further demonstration of the effectiveness of lower-intensity NMDA receptor 
stimulation as a neuroprotective stimulus was identified by the use of bicuculline 
and 4-AP to effectively protect rat cerebral cortical neurones against OGD 
(Tauskela et al., 2008). This protection was induced by treatment for 48 hours 
prior to OGD exposure for 65-80 minutes and was effective over an interval of 24 
to 72 hours between preconditioning and OGD, although if the intervening period 
was extended to 96 hours then protection was lost.  
Calcium influx, as with the studies using hippocampal neurones, was seen in 
response to bicuculline and 4-AP treatment, and was abolished by TTX or by 
NMDA receptor blockade, with the associated protection prevented by TTX 
treatment and reduced by NMDA antagonism (Tauskela et al., 2008).  
Activation of CREB was also identified in this work, with phosphorylation 
abolished by TTX. Blockade of NMDA receptors reduced CREB phosphorylation 
due to stimulation with lower doses of 4-AP, but CREB phosphorylation induced 
by higher concentrations of 4-AP was not prevented by NMDA antagonism 
(Tauskela et al., 2008).  
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Taken together, these results demonstrate that an effective, AP-driven 
mechanism of preconditioning exists, which utilises the activation of CREB to 
provide protection against neurotoxic damage from a wide range of agents. This 
represents a potential method for the development of preconditioning-based 
protection, but without the necessity for a moderate-to-severe stimulus which 
puts neurones in jeopardy of suffering excitotoxic or oxidative damage.  
1.5 Cerebellar granule neurones 
1.5.1 CGN anatomy and physiology 
The cerebellum is part of the hindbrain, with connections to each part of the 
brainstem: the inferior peduncle connects with the medulla oblongata, the 
middle peduncle with the pons, and the superior peduncle with the junction of 
the pons and midbrain. The prime function of the cerebellum is to coordinate 
motor activity through connections with brainstem motor centres.  
Like the cerebral hemispheres, each of the cerebellar hemispheres has a layer of 
grey matter on its surface, comprised of three cell layers. The most superficial 
layer is the molecular layer; the middle layer consists of a single layer of 
Purkinje cells, with dendrites extending to reach the molecular layer and axons 
projecting in the opposite direction (i.e. away from the cerebellar cortical 
surface). The innermost layer of the cortex consists primarily of CGNs, the 
dendrites of which receive afferent input from the cortex, whereas axons of 
these cells extend to the superficial layer, where they branch at an angle 
parallel to the cerebellar hemisphere’s surface, forming interconnections 
between neurones (Bowsher, 1988, Trenkner, 1998).  
Cerebellar granular neurones are small, with a large nucleus, and are by far the 
commonest neuronal subtype in mammals, with more than 70 billion found in 
the adult human cerebellum (Lange, 1975). After birth, the CGNs migrate from 
the external to the internal granule cell layers, where they receive excitatory 
input from mossy fibre neurones. If they do not migrate to the correct location, 
the granule neurones die from apoptosis, probably due to loss of depolarising 
input from mossy fibres (Wood et al., 1993). A similar process has been 
recognised in cultured CGNs, specifically that calcium flux due to depolarisation 
is essential for survival in neonatal rat CGNs (Gallo et al., 1987).  
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When CGNs are depolarised, calcium influx via voltage-dependent calcium 
channels increases, activating calcium-calmodulin dependent kinases and 
calcineurin phosphatase (Nakanishi and Okazawa, 2006). Calcineurin 
phosphatase activation is associated with genes involved in CGN differentiation 
and neurite growth in the external granule layer, whereas inactivation of 
calcinueurin is associated with genes coding for GABAA receptor and NR2C 
subunits, both integral to synaptic transmission involved in CGN maturation in 
the internal granule layer (Nakanishi and Okazawa, 2006).  
The developing cerebellar cortex of Sprague-Dawley rats is affected by the 
mothers (prior to the birth of the test subjects) being fed a diet deficient in 
tryptophan, when compared to both rats fed a generally protein deficient diet, 
and those fed a normal diet. This tryptophan-deficient diet was associated with 
retarded maturation of Bergmann glial cells (manifested by the persistence of 
basal filopedia, which normally disappear at 15-19 days) and abnormal migration 
of CGNs, with granule cells staying in the upper molecular layer of the 
cerebellar cortex for longer than in control animals before migrating to the 
granular layer (Del Angel-Meza et al., 2001).  
Cerebellar granule neurones in rat neonates actively transport glucose via the 
GLUT3 transporter, a neurone-specific and high-affinity glucose transporter 
identified in pre- and post-synaptic areas of neurones and with mitochondria 
(Maher et al., 1996, Leino et al., 1997).  
1.5.2 Reason for use of CGNs in present study 
As the cerebellum contains only a small number of neuronal subtypes, with CGNs 
massively outnumbering Purkinje cells by a ratio of 897 to 1 in rat (or by 2991 to 
1 in humans), cerebellar material provides a model with a highly purified and 
homogenous population of neurones (Lange, 1975). Cerebellar granule neurones 
are known to release glutamate as their principal neurotransmitter and can 
produce glutamate independently of glial cells (Hassel and Bråthe, 2000). 
Cultures of this type of neurone have been used in studies concerning cell 
viability, excitotoxicity, oxidative stress and preconditioning (White et al., 1996, 
Atlante et al., 1997, Marini et al., 1998, Ward et al., 2005); with CGN cultures 
well-recognised as an effective tool for investigation in these areas.  
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Another reason that use of CGN cultures was suitable was that this cell type is 
known to produce BDNF, rather than the alternative neurotrophins nerve growth 
factor, neurotrophin-3 or neurotrophins-4/5, as BDNF has been demonstrated to 
be involved in the establishment of preconditioning (Marini et al., 1998).  
An additional benefit of using this neuronal type was that the cells were 
prepared from neonatal rather than embryonic animals, as CGNs continue to 
develop post-natally, and can therefore be harvested later than cerebral cortical 
neurones for example (Trenkner, 1998). Therefore the actual number of 
cerebella available was known in advance, allowing experimental design to be 
tailored to best utilise the available material.  
1.5.3 Advantages of cell culture technique 
The use of cell culture allows the effects of neurotoxic insults on neurones 
themselves to be identified and studied in isolation, as glial cells can be 
eliminated, thereby preventing any protective or potentiating actions of that 
cell population occurring. When using cell cultures, there is the option of using 
cell lines, with immortalised cells which reproduce and form monolayer cultures 
consisting entirely of clones of one cell. This allows complete homogeneity of 
cultures, but the very nature of these cells means that they are substantially 
altered; raising questions over how relevant any findings made would be to 
normal tissue (Smith and Jiang, 1994). For this reason, primary cultured 
neuronal cells are preferable for use in studies in vitro.  
The effect of alteration in cell environment, such as the concentration of 
glucose and ions in the culture medium, can be studied with great accuracy, as 
it is possible to control medium conditions precisely.  
Similarly, an experimental protocol involving exposure of cultured neurones to 
(for example) OGD for a set period can be achieved with a high degree of 
consistency across all repetitions of the experiment. Furthermore, the use of 
one isolated cell type reduces a number of potential sources of variation, 
allowing results with a higher degree of consistency to be produced.  
It should be noted that although this reductive approach has these advantages, 
there are also limitations: for instance, the absence of glial cells causes 
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alterations to the formation of synapses, as there are no glial cells to sheath 
these connections as would normally be the case. Additionally, the cell 
preparation process itself must unavoidably involve a short period of stress for 
the neurones, although as cultures were maintained for at least 8 days prior to 
treatments, the effect of this on the CGNs during experiments was minimised.  
1.6 Rationale of study 
1.6.1 Reasons for study 
As the processes of excitotoxicity and oxidative stress are integral to the 
generation of neuronal death during ischaemia and neurodegenerative disease, 
the current study set out to investigate these processes and means of protecting 
against them. Elevated glucose and tryptophan metabolites are two sources of 
potential oxidative damage which are both widespread and unavoidable, and 
therefore were selected for detailed study.  
The use of preconditioning to protect against neuronal death provides a 
potential endogenously-generated source of effective neuroprotection, with 
great potential benefit.  
1.6.2 Aims of study 
The initial aims of the study were to establish reliable neuronal cell culture 
methods, optimise the conditions for neuronal growth and development and 
ascertain the effectiveness of available viability assays, in order to select the 
most appropriate.  
A major part of this study was to determine the optimal methods of inducing 
excitotoxic and oxidative damage in neuronal cultures, and to establish the most 
suitable method for subjecting CGN cultures to OGD. Particular focus was given 
to the study of selected tryptophan metabolites, including investigation of the 
mechanisms of damage in both a pharmacological and molecular context.  
The investigation of preconditioning protection was another key area of this 
study and development of two different methods of generating this protection 
was carried out. The mechanisms involved in the most effective method were 
explored, again with regard to both pharmacological and molecular aspects.  
54 
2 Materials and Methods 
2.1 CGN culture procedures 
The following reagents and consumables were used routinely in preparing 
primary cultures of cerebellar granule neurones.  
2.1.1 Culture preparation materials 
Minimum Essential Medium (Gibco, 32360-026) 
 
Fetal Calf Serum –heat inactivated (Sigma, F9665) 
 
L-Glutamine 200mM solution (Gibco, 25030-024) 
 
Potassium chloride (BDH Laboratory Supplies, 101984L) 
 
Gentamicin 50mg/ml (Gibco, 17570-037) 
 
Phosphate Buffered Saline 1x, (Gibco, 14200-067) 
 
Magnesium sulphate powder (FSA Laboratory Supplies, M/1050) 
 
Bovine Serum Albumin (Sigma, A2153) 
 
D (+)-Glucose powder (Fisher Scientific, G/0500/53) 
 
Trypsin [porcine pancreas] powder (Sigma, T4799) 
 
Soy Bean Trypsin Inhibitor liquid (Sigma, T6414) 
 
Deoxyribonuclease I powder (Sigma, D5025) 
 
96-well plate (Corning Costar 3596) 
 
24-well plate (Corning Costar 3524) 
 
13mm Borosilicate Glass coverslips (BDH, 406/0189/12) 
 
100-mm Petri dish (Nunc Delta 150350) 
 
Poly-D-lysine (Sigma, P7280) 
 
DEPC-Treated water (Invitrogen, 750024) 
 
Trypan Blue dye (Sigma, T8154) 
 
Cytosine arabinoside (Sigma, C1768) 
 
Millipore filter (Minisart, 0.2µm pore size) 
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2.1.2 CGN medium, buffer and enzyme solutions 
Eagle’s minimum essential medium, supplemented with 10% fetal calf serum, 
2mM glutamine, 50µg/ml gentamicin and KCl to a final concentration of 25mM 
was used. In some studies potassium supplementation was omitted, in which 
case a potassium concentration of approximately 5.4mM present from the serum 
and buffer alone was used for routine culture. Medium was prepared the day 
before plating and used within 5 days or discarded, to minimise the risk of L-
glutamine degradation. In experiments requiring high-glucose medium, glucose 
powder was added to a concentration of 25mM in total (the medium’s basal 
glucose concentration without supplement was 5.5mM). Medium was filter-
sterilised before use and stored at 4°C.  
The buffer solution was made of single-strength PBS, supplemented with 1ml of 
magnesium sulphate from 3.82% stock solution, 250mg of D-glucose and 300mg of 
BSA (bovine serum albumin) dissolved in a total volume of 100ml. If required, pH 
was adjusted to 7.4 with titrated 1M sodium hydroxide. Buffer was filter-
sterilised before use and stored at 4°C.  
This buffer was used as the diluent for the trypsin solution and both the ‘weak’ 
and ‘concentrated’ solutions of soy bean trypsin inhibitor (SBTI) and 
deoxyribonuclease (DNase). A stock solution of trypsin (5mg/ml) was prepared 
by dissolving trypsin powder in sterile water. 1ml of this stock was added to 
19ml of buffer (i.e. a final concentration of 0.25mg/ml trypsin solution or 
0.25%). SBTI stock was aliquotted directly from the supplier’s stock solution, and 
DNase stock was produced from DNase I powder dissolved in sterile water at a 
concentration of 10,000 U/ml. The SBTI and DNase were added to the buffer to 
give respective concentrations of 5% and 500U/ml in the ‘concentrated’ solution 
and 0.75% and 80U/ml in the ‘weak’ solution.  
2.1.3 Culture plate and dish preparation 
96-well plates were used routinely for viability studies, with 24-well plates used 
in some preliminary work. For immunocytochemical (ICC) studies, cultures were 
plated in both 24-well (containing glass coverslips) and 96-well plates. Cultures 
for producing protein samples for Western blots were maintained in 100mm 
diameter Petri dishes to yield the required quantity of cell material.  
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In all cases, plates or coverslips were coated with poly-D-lysine (PDL) prior to the 
application of cells to enhance adhesion to the substratum. This involved 
dissolving PDL in DEPC (diethyl pyrocarbonate)-treated water to a final 
concentration of 15µg/ml for viability or Western blot studies and 50µg/ml for 
ICC work, the solution being applied to the growth surface for at least 24 hours. 
Plates were rinsed in sterile water for one hour, drained, and allowed to dry for 
a further 24 hours before plating neurones.  
For 96-well plates, 50µl of PDL solution was applied to each well; for 24-well 
plates, 100µl was applied per well; for 100mm dishes, 5ml was applied per dish. 
An increased concentration of PDL was applied to ICC experiment plates to 
minimise cell detachment due to repeated aspirations and rinses during the ICC 
procedure.  
Poly-D-lysine is widely used in cell culture work as a plating substrate. However, 
it is recommended that sterile water be used to wash away any free poly-D-
lysine before cell plating, since otherwise the free poly-D-lysine may have a 
cytotoxic effect (Banker and Goslin, 1998).  
2.1.4 Glass pipette preparation 
Three nine inch disposable glass Pasteur pipettes were sterilised by autoclaving 
and prepared for trituration of cell suspension during culture preparation. Each 
Pasteur pipette had a different size of opening, the largest being of normal 
diameter, the smallest similar to the diameter of a P200 pipette tip and the 
third approximately half-way between the two. This was achieved by flaming the 
tips with a small Bunsen burner for varying periods, the pipettes rotated in the 
flame: this narrowed the tip apertures to the required degree. Following 
flaming, pipette tips were cooled in sterile water before use with cell material.  
2.1.5 Animals for neuronal culture preparation 
Sprague-Dawley rats aged 7-8 days are most commonly used by others using 
CGNs in studies of oxidative stress, excitotoxicity and preconditioning (Castilho 
et al., 1998, Chuang et al., 1992, Damschroder-Williams et al., 1995, Marini et 
al., 1998, Valencia and Morán, 2001). They were therefore used in our method in 
the present study for comparative purposes.  
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In 7-8 day old rat neonates, CGNs are still developing, but have begun to express 
NMDA receptors (Trenkner, 1998), whilst adenosine receptors of all four 
subtypes have also been identified as being present (Vacas et al., 2003).  
Litter sizes ranged from 6 to 16, with an average litter size of 11 (n=70). 
Neonates of either sex were kept in groups with the mother in cages at 21+/-2 
°C, under a 12-hour light/12-hour dark cycle, the mother having access to food 
and water ad libitum.  
2.1.6 Euthanasia  
In order to minimise suffering, rats were given a lethal intraperitoneal dose of 
**mg of pentobarbital sodium, also known as ‘Euthanal’, (which does not 
interfere with experiments via unwanted effects on either NMDA or adenosine 
receptors) prior to brain tissue harvesting, thereby following the Home Office 
regulations for use of animals in scientific research, permitted under schedule 1 
of the Animals (Scientific Procedures) Act of 1986.  
Given that the harvesting procedure by necessity involves an ischaemic insult to 
the brain tissue, additional interference from the anaesthetic must be avoided, 
as this could increase uncertainty in the final results achieved. Of the 
anaesthetic agents that were easily available for use, pentobarbitone was found 
to have an acceptably low potential for side effects.  Also, pentobarbitone has 
been demonstrated to have no neuroprotective effect against ischaemia-induced 
neuronal injury in vivo in gerbil hippocampal CA1 region, parietal cortex, 
caudate putamen and lateral thalamus (Ito et al., 1999).  
Pentobarbitone acts mainly on GABA receptors and sodium channels (Wartenberg 
et al., 1999), and although NMDA receptor activity has been proposed, when 
tolerance to sedative actions of the NMDA antagonists CGP39551 and CGP37849 
was achieved, no cross-tolerance to pentobarbitone was seen, suggesting that 
tolerance is not due to action at NMDA receptors (Rabbani et al., 1995).  
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2.1.7 Dissection 
The actual harvesting process itself involved the following stages: 
 Decapitation (as already indicated, this was done post-mortem) 
 Recovery of cerebella from cranium 
 Separation of cerebella from remaining brain tissue and meninges 
 
All equipment used was sterile, and procedures were carried out using aseptic 
technique. Decapitation was performed using large scissors, the cut being made 
through the mid-cervical region of the spine. The undamaged cerebellum was 
recovered from the cranium using fine dissection scissors to make two incisions 
from the foramen magnum, advancing anteriorly and laterally to a point 
approximately halfway between the foramen magnum and the orbit. It was then 
possible to retract the dorsal section of the skull, now a flap, without risking 
trauma to the cerebellum from either the incisions or skull retraction.  
As the skull at this stage is still relatively soft and cartilaginous, reflecting the 
flap anteriorly causes the skull at the point of flexure to bend. This puts gentle 
pressure onto the area of the posterior cerebral hemispheres and midbrain, 
resulting in the cerebellum being pushed posteriorly and hence was considerably 
easier to dissect from the remainder of the brain.  
The immediate removal of the cerebellum from the cranial cavity was achieved 
using fine forceps. The forceps blades were advanced anteriorly through the 
brainstem, held apart to allow the blades to pass immediately above and below 
the cerebellum. Once in a position anterior to the cerebellum, the blades were 
closed. This allowed removal of the cerebellum (usually with some adjoined 
brainstem tissue) from the cranium, after which it was placed in ice-chilled PBS 
and transferred to a 50mm Petri dish for fine dissection.  
To remove unwanted brain tissue and meninges, the cerebellum was held in 
place using a 23-gauge needle, and fine-tipped forceps used to strip meninges 
from the surface of the cerebellum. A scalpel blade was used to sever the 
cerebellary peduncles attaching the cerebellum to any remaining pons and the 
isolated cerebellum was placed in a fresh container of chilled buffer solution. 
Isolated cerebella were transferred to a 35mm Petri dish and chopped to a fine 
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paste using the free scalpel blade to cut two series of twenty vertical strokes 
through the tissue, the second series oriented perpendicular to the first, and the 
resulting cell material used to prepare cell cultures.  
2.1.8 Culture preparation 
The culture plating protocol used for our culture work was based on one used 
successfully by Sam Greenwood in Dr. C. N. Connolly’s group at Dundee 
University (Ward et al., 2005) with some adaptations added to increase culture 
uniformity. This was selected as the most effective culture preparation method 
following attempts with three alternative protocols of culture preparation.  
First, cerebellar cell material was transferred into 20ml of 0.25% trypsin solution 
at room temperature. The tube containing cell material and trypsin was 
incubated at 37°C for 20 minutes, with gentle swirling of the tube at 5-minute 
intervals, to allow trypsin to permeate the cell material as fully as possible. 
After incubation was complete, 20ml of ‘weak’ SBTI and DNase solution 
(concentrations of 0.75% and 80U/ml respectively) was added to the tube at 
room temperature, prior to 2 minutes’ centrifugation at 1200 rpm in a Sanyo 
Harrier 18/80 centrifuge. The supernatant was aspirated and discarded.  
Following this, 2ml of ice-chilled ‘concentrated’ SBTI and DNase solution 
(concentrations of 5% and 500U/ml respectively) was added to the cell material 
pellet, which was resuspended with a P1000 pipette tip, then further triturated 
through the three flame-polished Pasteur pipettes (ten strokes up and down 
through each pipette). Phosphate buffer solution was added to a final volume of 
20ml and the suspension centrifuged at 1200 rpm for 2 minutes, and supernatant 
aspirated and discarded.  
Two ml of culture medium, warmed to 37°C, was added to the cell pellet, and 
the trituration stage repeated. A 10µl sample of cell suspension was added to 
each side of an Improved Neubauer haemocytometer counting chamber, in order 
to calculate the cell suspension density, and consequently the volume of 
additional medium necessary to adjust the final cell density to the level required 
for plating.  
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A viability count was carried out to ensure that a sufficient percentage of cells 
were viable at the time of plating. This was achieved by adding 100µl of cell 
suspension to 100µl of Trypan Blue dye: after vortexing and 2 minutes’ 
incubation, another 10µl sample of the resultant suspension was added to each 
side of a second haemocytometer counting chamber, and a viability count taken, 
using an inverted binocular microscope and hand-held counter.  
Cell viability at plating was consistently found to be at least 95%, with an 
average viability of 99.4% (n=68). Trypan blue stain was used for a viability count 
at plating as it provided a rapid cell viability assessment, but was not used for 
final viability assays as it can be inaccurate when used with older cultures, 
causing over-estimation of cell viability (Altman et al., 1993).  
Cells were plated out on 24- or 96-well culture plates, at a concentration of 
1x106 cells per ml. When using 96-well plates, the outer rows of wells were 
excluded to avoid the risk of interference with results due to excessive 
evaporation (hence, only the inner 6x10 group of wells of the total plate’s 8x12 
wells was used). When using 100mm dishes in Western blot studies, a plating 
density of 1.5x106 cells per ml was used, with additional medium added 24 hours 
post-plating. Cultures were then transferred to a Flow Laboratories 220 CO2 
incubator, which maintained an interior environmental temperature of 37°C and 
an atmosphere of 95% air and 5% CO2.  
2.1.9 Elimination of non-neuronal cells from cultures 
The cytotoxic agent cytosine arabinoside has been used in many studies to rid 
cultures of non-neuronal cells (glial cells, residual meningeal cells, etc.) 
(Castilho et al., 1998, Chuang et al., 1992, Damschroder-Williams et al., 1995, 
Marini et al., 1998, Orr and Smith, 1988). This was applied 24 hours post-plating 
at a final concentration of 10µM.  
Cytosine arabinoside is a nucleotide analogue, which interferes with DNA 
replication and repair, and is therefore toxic to dividing cells. As 7-8 day old 
cerebellar neurones are no longer replicating, the cytotoxic effect selectively 
destroys replicating non-neuronal cells. This was used in all experiments (except 
negative controls in ICC studies studying the efficacy of cytosine arabinoside).  
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2.2 Alamar blue and fluorescein diacetate viability assays 
2.2.1 Alamar blue assay 
This viability assay involves use of the dye Alamar Blue (Biosource International, 
DAL1100), an indicator of reduction and oxidation which changes colour (from 
blue to pink) in response to the chemical reduction of cell culture medium due 
to metabolic products of cell growth (Fatokun et al., 2007, White et al., 1996). 
Twenty-four hours after treatments were applied, culture medium was aspirated 
and fresh medium added at a volume of 100µl per well, containing the dye at a 
concentration of 10% (v/v) (Abe et al., 2002).  
Alamar Blue can be altered in colour by reduction reactions involving 
nicotinamide adenine dinucleotide phosphate (NADP), NAD, flavin adenine 
dinucleotide (FAD), flavin mononucleotide (FMN) and cytochromes and it is 
believed that it only successfully reacts when taken up into the intracellular 
space. The assay dye was applied to each well, with two control wells, one 
containing medium only and the other containing medium with 10% Alamar blue 
dye only. The cultures were incubated at 37°C, with readings of the level of dye 
oxidation taken at 4 and 6 hours, using an Opsys MR plate-reader (Dynex 
industries), at wavelengths of 540 and 595nm. The two readings were then 
combined to determine the fraction of dye that had been reduced in a negative 
control well (containing no cells) and in each of the wells of treated and control 
neurones. These values were used to quantify cell viability levels for each 
treatment group as a percentage, calculated relative to the negative control.  
The dual time points were used with the Alamar blue assay as 4 hours is the 
standard time for this assay, but it had been suggested that a more accurate 
assessment can be made in CGN cultures using the 6 hour time point (White et 
al., 1996). Readings were therefore taken at both time points on all occasions 
that this assay was used, in order to be certain that optimal assay results had 
been achieved.  
2.2.2 Fluorescein diacetate assay 
This assay involves application of an esterified form of fluorescein (fluorescein 
diacetate, Sigma F7378) to cell cultures, which is taken up by living cells and the 
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acetate groups cleaved from the molecule by intracellular esterases, producing 
fluorescein. The level of fluorescein in each culture well is quantified by a 
fluorometer, and cell viability is thus determined, as uptake of fluorescein 
diacetate (FDA) and subsequent conversion to fluorescein only take place in 
living cells (Favaron et al., 1988, Rotman and Papermaster, 1966).  
Fluorescein diacetate powder was first dissolved in absolute alcohol (5mg in 
10ml) and added to 90ml of PBS, producing a solution of 10% ethanol and 
50µg/ml FDA. This solution was added to minimum essential medium (MEM), 
producing another ten-fold dilution, to reach a final FDA concentration of 
5µg/ml, and 1% ethanol. This FDA concentration was consistent with that used in 
previous studies (Novelli et al., 1988, Valencia and Morán, 2001).  
The medium in the wells was aspirated and replaced with the solution of MEM 
containing FDA, after which the plate was incubated at 37°C for ten minutes, to 
allow the intracellular de-esterification reaction to take place. Then the plate 
was transferred to the fluorometer for analysis, with the excitation at a 
wavelength of 485nm and the emission read at a wavelength of 538nm (Valencia 
and Morán, 2001). The resultant data (including that of the 'calibration' well 
containing MEM only and the 'blank' well containing 5µg/ml FDA in MEM solution, 
without either well having any cells present) was collected and analysed.  
The incubation time chosen was based on several studies using the assay for 
neuronal cultures (Dargent et al., 1996, Didier et al., 1990, Favaron et al., 1988, 
Novelli et al., 1988, Valencia and Morán, 2001). The application times used 
ranged from one to twenty minutes, so ten minutes was chosen as an 
approximate median average. It was also sufficiently long to allow some time for 
incubation at 37°C (as the application process in a 96-well plate takes some time 
in itself), but brief enough to minimise the risk of the produced fluorescein 
leaking from the cells.  
Co-staining with propidium iodide (PI, Sigma P4170) was achieved by adding to 
FDA-containing MEM solution to a final concentration of 4.5µM PI (Tauskela et 
al., 2003), before applying to cultured CGNs for 10 minutes in the normal 
fashion, with images recorded using an Olympus IX50 phase-contrast microscope 
and Olympus DP50 digital camera.  
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2.3 Immunocytochemistry procedure 
2.3.1 ICC materials 
4% or 8% paraformaldehyde solution (in 0.1M phosphate buffer) 
 
0.1M phosphate buffer solution 
 
0.3% triton solution (in 0.1M PBS) 
 
0.2M PBS 
 
1.5% blocking serum solution in PBS and 0.3% triton  
 
Heidolph Polymax 1040 plate-shaking platform 
 
Six inch glass Pasteur pipette 
 
Olympus IX50 Phase-contrast microscope 
 
Olympus DP50 Digital camera 
 
Olympus TH3 Light source 
 
Olympus U-RFL-T Fluorescent light source 
 
Mouse anti-betaIII tubulin antibody (Chemicon MAB1637)  
 
Rabbit anti-glial fibrillary acid protein antibody (Sigma G9269)  
 
FITC-conjugated donkey anti-rabbit antibody (Jackson 711-095-152)  
 
Rhodamine red X-conjugated goat anti-mouse antibody (Jackson 115-295-146) 
 
 
2.3.2 Immunocytochemistry procedure 
A 4% paraformaldehyde solution was applied to cultures immediately following 
treatment and aspiration of all culture medium. In later experiments, a more 
consistent result with less subsequent loss of cells was achieved by adding 8% 
paraformaldehyde solution (at 4°C) at an equivalent volume to the medium in 
the wells (final concentration of 4%). This solution was left in place for thirty 
minutes prior to aspiration and rinse in three washes in 0.1M phosphate buffer 
solution for five minutes to remove fixative. Fixed cultures were flooded with 
0.1M phosphate buffer and stored at 4°C prior to ICC staining.  
The first stage of ICC staining involves applying 1.5% blocking serum (raised in 
the same species as the secondary antibody to be used: usually either goat or 
64 
donkey serum) for 1 hour at 50µl per well, to prevent interference from non-
specific protein binding sites in the subsequent labelling with secondary 
antibody. Incubations were at room temperature for one hour on a plate-shaking 
platform to ensure complete coverage of the fixed cultures.  
Following this, the blocking serum was aspirated and 50µl per well or 30µl per 
coverslip of primary antibody added (diluted in PBS and 0.3% triton), following 
which the plate was placed on the plate-shaker for 5 minutes, before an 
overnight incubation at 4°C. A set of wells were incubated as negative controls 
with 50µl of PBS and triton solution added without primary antibody to 
demonstrate staining specificity.  
Following overnight incubation, the fixed cultures were rinsed three times in 
50µl of 0.2M PBS for 5 minutes. Once completed, 50µl of secondary antibody 
(diluted in PBS with 3% triton) was added to each well. As fluorescent 
conjugated secondary antibodies were routinely used, aliquots were wrapped in 
tinfoil, as was the plate, to prevent bleaching. To minimise the risk of light-
related interference, room lights were switched off during these stages.  
The cultures were rinsed twice in phosphate buffer solution, viewed under the 
microscope with fluorescent light at a wavelength relevant to the fluorochrome 
of the secondary antibody used and the images were recorded using a digital 
camera.  
2.3.3 Microscopic photography 
The software used to obtain the images and to adjust or overlay images if 
necessary was Cell^D, produced by Soft Imaging System GmbH. This software 
provides the necessary tools for image capture, labelling (e.g. scale-bars) and 
subsequent adjustment for consistency of image intensity or contrast. An 
additional capability is that the software can allow separately captured images 
to be overlaid and amalgamated into one image; an example of this being the 
collection of images of the same field using fluorescence at different 
wavelengths (such as when collecting images of immunocytochemically-stained 
cultures labelled with more than one fluorochrome).  
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2.4 Protein sample preparation and protein assay 
2.4.1 Protein sample preparation and assay materials 
Tris powder (Boehringer Mannheim, 708976) 
 
Sodium chloride powder (BDH, 102415K) 
 
Sodium dodecyl sulphate powder (BDH, 442444H) 
 
Triton X-100 (Sigma, T8787) 
 
IGEPAL (Sigma, I7771) 
 
Protease Inhibitor cocktail tablets (Roche, 11 836 170 001) 
 
PBS (Gibco, 14200-067) 
 
BSA (Sigma, A2153) 
 
BIORAD protein assay dye (BIORAD, 500-0006) 
 
Costar disposable cell scraper (Corning, 3010) 
 
 
2.4.2 Protein sample preparation procedure 
The radio-immuno precipitation assay (RIPA) buffer was prepared as follows: 
60mg Tris, 87.6mg NaCl, 10mg sodium dodecyl sulphate (SDS), 50µl Triton X-100, 
100µl IGEPAL and 9.85ml sterile distilled water (this came to 50mM Tris, 150mM 
NaCl, 0.5% Triton, 0.1% SDS, 1% IGEPAL). One protease inhibitor cocktail mini-
tablet was added to each 10ml of RIPA buffer.  
The culture medium was drained, with residual medium aspirated by pipette. 
Cultures were washed once with ice-cold PBS, which was drained and aspirated 
as before.  
Next, ice-cold RIPA buffer was added (1ml if 9cm dish; 0.5ml if 5cm dish) if 
nuclear or cytosolic lysate was sought. After 1 minute, cells were scraped off the 
plating surface with a Corning Costar cell scraper, and the buffer/cell suspension 
was transferred to a 1.5ml Eppendorf tube. Finally, cell suspension was 
centrifuged at 13,000 rpm for 5 minutes at 4°C in an Eppendorf 5417R 
centrifuge.  
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2.4.3 Protein assay 
The BSA stock solution (20mg/100ml) was diluted 1 in 10 with distilled water and 
BSA standard solutions (0, 0.25, 0.5, 1.0, 1.5, and 2.0mg/ml) prepared to 
produce a protein concentration curve. Experimental samples were made into 
dilutions of 1/100 (thus expressing results in mg/ml) by addition of 4µl sample to 
396µl distilled water. The Biorad reagent was diluted by half –sufficient to add 
200µl to each standard and sample (a total of 2ml was usually ample). The 
Biorad reagent was effective with samples containing SDS at or below 0.1%.  
200µl of diluted Biorad reagent was added to each standard and sample, then 
vortexed to ensure thorough mixing of the protein standard or sample and 
reagent. Each standard and sample was pipetted out in duplicate onto a 96-well 
plate. Results were read at 595nm on the Opsys MR plate-reader and the total 
protein concentration in each sample was determined. Samples could then be 
diluted if necessary to allow a consistent concentration across all protein 
samples.  
 
2.5 Western blotting procedure 
2.5.1 Western blotting materials 
12% SDS-Page gel (Invitrogen, NP0341) 
 
Sample buffer (Invitrogen, NP0007) 
 
Sample reducing agent (Invitrogen, NP0004) 
 
SeeBlue protein marker (Invitrogen, LC5925) 
 
MOPS running buffer (Invitrogen, NP0001) 
 
Antioxidant (Invitrogen, NP0005) 
 
Gel running tank: Novex Mini-cell (Invitrogen) 
 
Gel running chamber (Invitrogen) 
 
Protein transfer chamber (Invitrogen, E19051) 
 
Gel knife (Invitrogen) 
 
Nitrocellulose membrane (Invitrogen, LC2001) 
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PVDF membrane (Invitrogen, LC2005) 
 
‘PowerEase 500’ powerpack (Invitrogen) 
 
Transfer buffer (Invitrogen, NP0006) 
 
Methanol (Fisher, M/4056/17) 
 
Ponceau stain (Sigma, P7170) 
 
Milk powder (Upstate, 20-200) 
 
IgG-free BSA (Sigma, A2058) 
 
Tween-20 (Sigma, 27,434-8) 
 
ECL kit (Amersham, RPN2132) 
 
Photosensitive films (Amersham, RPN3103K) 
 
‘Hypercassette’ film cassette (Amersham RPN12642) 
 
‘Restore’ stripping buffer (Pierce, 21059) 
 
Eppendorf 5417R centrifuge 
 
Anti-GAPDH antibody (Santa Cruz sc-25778, rabbit) 
 
Anti-actin antibody (Santa Cruz sc-1615, goat) 
 
Anti-GAPDH antibody (Santa Cruz sc-20356, goat) 
 
Anti-bcl-2 antibody (Santa Cruz sc-492, rabbit) 
 
Anti-CREB antibody (Santa Cruz sc-186, rabbit) 
 
Anti-phosphorylated CREB antibody (Cell Signaling 9198, rabbit)  
 
Anti-caspase-3 antibody (Santa Cruz sc-7148, rabbit) 
 
Anti-cleaved caspase-3 antibody (Cell Signaling 9664, rabbit) 
 
Anti-p38 antibody (Cell Signaling 9212, rabbit) 
 
Anti-phosphorylated p38 antibody (Cell Signaling 9211, rabbit)  
 
Goat anti-rabbit horseradish peroxidase antibody (Upstate 12-348) 
 
Donkey anti-goat horseradish peroxidase antibody (Santa Cruz sc-2020) 
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2.5.2 Gel running procedure 
Protein samples were added to loading buffer and reducing agent, at the 
following proportions: 65% sample, 25% sample buffer, 10% reducing agent. They 
were mixed thoroughly prior to being heated at 70°C for 10 minutes and 
centrifuged at 2000rpm (425 rcf) at 4°C for 1 minute using an Eppendorf 5417R 
centrifuge.  
The gel tank was filled with MOPS running buffer (from 50ml MOPS buffer 
concentrate and 950ml distilled water), with 200ml of buffer supplemented with 
0.5ml antioxidant set aside for the inner section of the tank containing the gel 
itself. The gel cassette was rinsed with distilled water and the white paper 
stripe and gel comb were removed prior to the gel lanes being rinsed with 
running buffer.  
10µl of rainbow protein marker was added to a marker lane at the side of the gel 
and 20-25µl of each protein sample to the required number of lanes, volume 
chosen according to concentration to ensure 20-30µg of protein loaded per lane. 
The tank was closed and run at 150V for 90 minutes, this voltage and time 
chosen to provide the best placing of the proteins studied in these experiments. 
The level of current used was 120mAmp for one gel or 240mAmp for two gels.  
2.5.3 Protein transfer procedure 
The transfer buffer was prepared as the running procedure was taking place, 
using 50ml of NuPage transfer buffer, 1ml sample antioxidant, 100ml methanol 
and 850ml distilled water (in experiments using two gels, 200ml methanol and 
750ml distilled water were used). 200ml of the resultant solution was set aside 
in a conical flask for the central compartment. For transfers using a 
polyvinylidene difluoride (PVDF) membrane, the membrane was soaked in 
methanol for one minute, prior to soaking in transfer buffer alongside the other 
equipment for gel transfer. Also one corner of the membrane was cut obliquely, 
to allow easy identification of the lanes’ orientation on the membrane.  
The running buffer was emptied from the gel tank and the tank rinsed 
thoroughly. The gel knife was used to crack open the gel cassette, remove half 
of the cassette and cut off the gel strands forming the lanes and the thickened 
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portion at the base of the gel, which prepared the gel for the transfer 
procedure.  
Next the gel was applied to the PVDF membrane: the membrane was applied to 
the gel surface and suspended over filter paper. The gel knife was then used to 
gently release a corner of gel, allowing the gel to slowly peel off the cassette 
onto the filter paper beneath. Finally the second filter paper was placed on the 
other surface of the gel.  
The membrane ‘sandwich’ was placed on top of two soaked sponges in the tray 
(cathode core) of the transfer assembly, with the gel beneath the membrane. 
Two further soaked sponges were placed on top of the ‘sandwich’, the lid (anode 
core) of the transfer assembly was placed on top and the entire assembly placed 
in the tank.  
The 200ml of fresh transfer buffer in the conical flask was added to the central 
compartment to a level 1cm above the ‘sandwich’, and the remainder of the 
transfer buffer was added to the outer compartment of the tank until 
approximately 3/4 full. The power pack was attached, and run at 30V for 1 hour, 
at a current of 400mAmp.  
2.5.4 Ponceau staining 
Ponceau stain was used in order to confirm constant protein concentrations 
across the sample lanes. This simple and rapid procedure allowed confirmation 
of sample concentration uniformity without an excessive delay in the blotting 
procedure. The membrane was rinsed twice with distilled water, and immersed 
in Ponceau solution for 5 minutes. The protein bands were viewed to ensure an 
equal density in all sample lanes and an image of the bands recorded. Following 
this, the membrane was rinsed with distilled water and immersed in an aqueous 
solution of 0.1M sodium hydroxide for approximately 30 seconds, until the 
stained bands had disappeared. Finally, the membrane was rinsed with running 
distilled water for 2-3 minutes to ensure all of the Ponceau stain and sodium 
hydroxide had been thoroughly rinsed out.  
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2.5.5 Antibody incubation 
The membrane was blocked from non-specific binding by immersion with 
agitation in TBS solution containing 5% milk and 0.05% Tween-20 for 60 minutes. 
If blotting for phosphorylated proteins, the membrane was washed for 15 
minutes in 200ml TBS/0.05% Tween-20 three times to remove any unbound milk 
proteins. An appropriate dilution of primary antibody solution (in 5% milk and 
0.05% Tween-20 TBS solution) was prepared and applied to the membrane for an 
overnight incubation at 4°C (with agitation). When blotting for phosphorylated 
proteins, 5% IgG-free BSA solution was used in place of milk solution.  
The next day, the membrane was washed in TBS for 15 minutes (with agitation) 
three times to remove all remaining unbound primary antibody. An appropriate 
dilution of secondary antibody solution was made in TBS solution with 5% milk 
and 0.05% Tween-20 and applied to the membrane for incubation at room 
temperature for 60 minutes (with agitation). Following this, the membrane was 
again rinsed in TBS for 15 minutes (with agitation) five times to remove all 
unbound secondary antibody from the membrane.  
2.5.6 Enzymatic Chemiluminescence 
The final stage of the Western blotting process was to apply the enzymatic 
chemiluminescence (ECL) solution to the membrane for 5 minutes, apply 
photosensitive film to the membrane in a darkroom for the required period, and 
develop the film.  
The ECL kit was removed from refrigeration prior to use; for each membrane, 
6ml of the large ECL solution bottle was added to 150µl of small ECL bottle 
solution immediately prior to use (this was done within a container shielded 
against light, e.g. a centrifuge tube wrapped in foil). The ECL reagent mixture 
was applied to the membrane for 5 minutes and agitated while shielded from 
light.  
When incubation was complete, excess developing solution was blotted off onto 
filter paper and the membrane placed in a developing cassette, with a saran 
wrap cover smoothed over the membrane to eliminate air bubbles. The cassette 
was transferred to a red-light room, where films were cut to the correct size and 
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placed over the membrane for the required time to achieve a reproduction of 
the blotting. The length of time for which the film was applied was adjusted 
according to how strong a reaction to the ECL solution was occurring. When 
exposure was complete, the films were fed into the developing machine and the 
results viewed.  
Quantification of the blotting intensity was achieved using the program ImageJ 
(freeware from NIH, Bethesda), with corrections made according to the densities 
of the ‘housekeeping’ proteins (actin or glyceraldehyde phosphate 
dehydrogenase [GAPDH]).  
 
2.6 Compounds used in experiments 
L-Glutamic acid powder (Sigma, G1626) 
 
N-methyl-D-aspartate powder (Sigma, M3262) 
 
3-Nitropropionic acid powder (Sigma, N5636) 
 
Hydrogen peroxide 30% solution (Sigma, H1009) 
 
D (+)-Glucose powder (Fisher Scientific, G/0500/53) 
 
3-O-methyl-D-glucopyranose powder (Sigma, M4879) 
 
L-Tryptophan powder (Sigma, T0254) 
 
L-Kynurenine powder (Sigma, K8625) 
 
Kynurenic acid powder (Sigma, K3375) 
 
3-Hydroxykynurenine powder (Sigma, H1771) 
 
3-Hydroxyanthranilic acid powder (Sigma, H9391) 
 
Anthranilic acid powder (Aldrich, A8985-5) 
 
5-Hydroxyanthranilic acid powder (Fluorochem, 011772) 
 
2-Picolinic acid powder (P5503) 
 
Quinolinic acid powder (Aldrich, P6320-4) 
 
Superoxide dismutase powder, bovine erythrocyte (Sigma, S5395) 
 
Catalase powder, bovine liver (Sigma, C1345) 
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Desferrioxamine mesylate (Sigma, D9533) 
 
Cycloheximide (Sigma, C7698) 
 
Sodium chloride powder (BDH, 102415K) 
 
Potassium chloride (BDH, 101984L) 
 
Calcium chloride (BDH, 190464K) 
 
HEPES (BDH, 442854V) 
 
Glycine (Fisher, G/0800/60) 
 
Magnesium chloride (BDH, 10149) 
 
4-Aminopyridine (Sigma, A0152) 
 
Bicuculline methobromide (550-040-M050, Alexis biochemicals) 
 
Tetrodotoxin (Sigma, T5651) 
 
Nifedipine (Bayer Leverkusen, BAY-a-1040) 
 
MK-801 maleate (Tocris, 0924) 
 
Staurosporine (Tocris, 1285) 
 
2.7 Treatments 
The majority of compounds used in these experiments were dissolved into stock 
solutions using sterile distilled water. The exceptions to this were 3-
hydroxyanthranilic acid, which was only soluble when first dissolved in 
hydrochloric acid, with this solution diluted using distilled water, and kynurenic 
acid, which required sodium hydroxide solution to dissolve, this solution diluted 
using distilled water. Denaturing of the enzymes catalase and SOD was achieved 
by boiling an aliquot of each enzyme for 10 minutes at 100°C.  
Preconditioning stimuli (such as N-methyl-D-aspartate or 4-aminopyridine) were 
added to in situ culture medium as concentrated solutions to reach the desired 
final concentration (this minimised the number of evacuations of medium 
needed and hence reduced unnecessary stresses and sources of variability to the 
cultures). At the end of the treatment periods the medium was aspirated and 
replaced with fresh medium.  
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Toxic treatments (glutamate or QA for example) were applied in culture medium 
for the indicated durations, then removed and replaced with fresh medium. In 
the case of 24 or 48-hour insults, the viability assay was performed immediately 
following treatment, so the medium was replaced by the FDA-containing MEM 
solution.  
Treatments applied to 10cm dishes (to provide protein sample for subsequent 
Western blotting) were achieved using the same protocols (preconditioning 
stimuli were added without subjecting the cultures to additional aspiration; 
toxic treatments were added in medium). In these cases, the cell material was 
collected at the end of the treatment period (as described under ‘protein 
sample preparation’), so no additional medium change was required.  
All treatments were heated to 37°C using a water bath (Grant Instruments, 
Cambridge) prior to being applied to cultures and culture plates or dishes were 
placed in an incubator during all treatments.  
 
2.8 Neuronal morphology 
Cerebellar granule neurones from neonatal rats appear after dissociation as 
small neurones with spherical cell bodies, which establish extensive neurite 
interconnections after approximately 24-48 hours in culture, the extent of the 
interconnections increasing with the time in vitro. Additionally, the neuron cell 
bodies form small clusters, the size of which increase with increasing plating 
density (Trenkner, 1998).  
When CGNs are subjected to neurotoxic stimuli, the impact can be observed in 
the appearances of both the neuronal somata and the neurite networks. The 
somata shrink, and the neurite interconnections initially become beaded, then 
disintegrate completely, leaving only traces of cellular debris between neurones 
(Ciotti et al., 1996).  
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2.9 Hypoxia and OGD procedure 
The culture plates were transferred to a previously warmed (37oC) portable 
anaerobic cylinder (Rodwell) with two valves (allowing simultaneous removal 
and input of gas) and the cylinder lid sealed. A water pump was attached to the 
cylinder, and the air inside withdrawn for 5 minutes, then for 5 minutes the 
cylinder gas was drained while a 95% nitrogen and 5% carbon dioxide mixture 
was pumped into the chamber, and finally the gas mixture was pumped into the 
chamber for a further 5 minutes in the absence of gas removal.  
In the case of OGD, the cultures had medium aspirated and replaced with a 
buffer solution (140mM NaCl, 5mM KCl, 2mM CaCl2, 20mM HEPES, 30µM glycine, 
800µM MgCl2) without glucose. This buffer was bubbled with the nitrogen-carbon 
dioxide gas mixture for 10 minutes to lower the level of dissolved oxygen, before 
being filter-sterilised and warmed to 37°C prior to application.  
The relative levels of oxygen and carbon dioxide in the gas mixture were 
determined using a Servomex 570A oxygen analyser for oxygen and Servomex 
analyser series 1400 for carbon dioxide, and found to be accurately composed, 
with carbon dioxide present at an average of 5.04%, with 0.025% oxygen present 
in the mixture (n=4).  
Assay of oxygen saturation levels in the buffer following the culture gassing 
procedure was performed, using a Strathkelvin Instruments Oxygen Meter model 
781. The oxygen probe electrode was placed in a solution of sodium sulphite 
(which absorbs any dissolved oxygen in the water) and calibrated to 0%, then 
placed in water fully saturated with oxygen to calibrate for 100% saturation. The 
electrode was then fitted into a sample chamber and rinsed with distilled water, 
a buffer sample that had been gassed was run into the chamber and the degree 
of oxygen saturation recorded. This procedure was carried out for a number of 
independent repetitions of the gassing procedure, and demonstrated an average 
pO2 of 94.45mmHg (60.19% saturation) (n=3).  
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2.10 High performance liquid chromatography 
The experiments using high performance liquid chromatography (HPLC) in this 
study were carried out by Dr. Gillian Mackay, using samples of medium from 
experiments performed on neuronal cultures in 24-well plates treated with 
100µM tryptophan, 100µM kynurenine, 100µM anthranilic acid, 100µM 3-HK or 
100µM 3-HAA. Two methods of HPLC analysis were used, one assaying 
tryptophan, kynurenine, anthranilic acid and kynurenic acid (based on the 
method of Hervé et al., 1996); the other assaying 3-HK, 3-HAA and 5-
hydroxyanthranilic acid (5-HAA) (adapted from Cannazza et al., 2003).  
HPLC involves the injection of 100µl of an extracted sample containing a 
compound of interest into a stream of liquid solvent (the ‘mobile phase’), which 
is then pumped (at a flow rate of 1ml/min in these experiments) through a steel 
column packed with solid spherical particles of the ‘stationary phase’. The 
solvent leaving the column is stimulated using fluorescent or ultraviolet light and 
the responses to this stimulation recorded.  
The peak height of the detected response on the resultant chromatogram can 
then be identified, and this is then quantified against a linear calibration curve 
calculated from a series of standard solutions of the compound of interest 
assayed during the same HPLC analysis series. This allows the concentration in 
the sample to be determined. The standard solutions and samples also contain 
an internal standard (24µM 3-nitrotyrosine) used to identify any variations during 
the extraction of the standards and samples, and thus to allow compensatory 
corrections to be made during the final data analysis.  
In ‘reversed-phase’ HPLC (approximately 80% of HPLC work), the mobile and 
stationary phases are polar and non-polar respectively (Krstulovic and Brown, 
1982). The identification of individual chemical compounds is achieved as 
compounds have different retention times (passage time of the compound 
through the column), and hence peak responses to fluorescent or ultraviolet 
stimulation will occur at predictable times. Retention times may be prolonged 
due to interactions with the stationary phase: this delay increases in proportion 
to the extent of non-polar surface area on the compound’s molecular structure, 
as interactions between the non-polar stationary phase particles and the 
compound hinder passage of the dissolved compound.  
76 
Medium samples were treated with perchloric acid and filtered by centrifugation 
to precipitate and remove any protein prior to HPLC analysis (to prevent protein 
particles blocking HPLC equipment). Analysis of tryptophan, kynurenine, 
anthranilic acid and kynurenic acid was carried out at 37°C, using a mobile 
phase solution of 50mM acetic acid, 100mM zinc acetate and 1.5% acetonitrile 
(pH 7.4); the stationary phase was Synergi Hydro C18 column (containing packed 
4µm silica particles coated with straight hydrocarbon chains). For analysis of 3-
HK, 3-HAA and 5-HAA (performed at 30°C) the mobile phase used was 25mM 
sodium acetate (pH 5) solution and the stationary phase was also a Synergi Hydro 
C18 column.  
Detection of tryptophan was achieved by quantifying absorbance of ultraviolet 
light at a wavelength of 250nm; kynurenine, 3-HK and 3-nitroyrosine were 
detected by absorbance at 365nm; kynurenic acid was detected by fluorescence 
(using an excitation wavelength of 344nm and emission wavelength of 390nm); 
anthranilic acid, 3-HAA and 5-HAA were detected by fluorescence (using an 
excitation wavelength of 320nm and emission wavelength of 420nm).  
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3 Optimising Culture Conditions and Confirming 
Accuracy of Viability Studies  
3.1 Introduction 
In order to ascertain that culture conditions were optimal for neuronal survival 
and development, and that both viability assays used were reliable, 
confirmatory studies were undertaken. Experiments were carried out in 96-well 
plates at a plating density of 1x106 cells/ml, in medium containing 5.5mM 
glucose and 25mM KCl (except where indicated).  
A number of variables have been shown to affect the ability of CGNs to survive 
and form functioning networks in culture; with cell plating density and the 
concentration of potassium in the culturing medium being of particular 
importance (Balázs et al., 1988, Young et al., 2000). Therefore, initial studies 
were carried out to establish the optimum level of each of these.  
Elimination of non-neuronal cell types is also a key step in most methodology for 
establishing primary neuronal cultures; the antimetabolite cytosine arabinoside 
is frequently used in the preparation of CGN cultures (Castilho et al., 1998, 
Chuang et al., 1992, Damschroder-Williams et al., 1995, Marini et al., 1998). 
This compound was applied 24 hours post-plating at a final concentration of 
10µM. Cytosine arabinoside is a nucleotide analogue, which is toxic to dividing 
cells due to its interference with DNA replication and repair. As CGNs are no 
longer replicating by 7-8 days into the neonatal period, the antimetabolic 
effects of cytosine arabinoside selectively kill only replicating non-neuronal 
cells. This treatment was selected for use in our culture system; therefore 
immunocytochemical studies were carried out to ensure that this treatment was 
effective and did not cause a discernable decrease in neurite network formation.  
During establishment of the protocols, two different cell viability assays, 
fluorescein diacetate and Alamar blue, were used to quantify the degree of cell 
death resulting from the various treatments. In order to have complete 
confidence in the accuracy of each, the assays were trialled against CGN 
cultures plated at varying densities, to identify a linear increase in assay reading 
corresponding to increasing cell density. Secondly, the results obtained with 
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each assay were compared when assessing cultures given identical treatments, 
to ascertain whether readings from each were directly comparable. Finally, the 
accuracy of the assay used for the majority of the project’s viability studies was 
compared with the morphological appearances of cells seen microscopically and 
with PI staining to identify dead cells (Tauskela et al., 2003).  
 
3.2 Aims and Objectives 
• Identify the optimum plating density for neonatal rat CGN cultures  
• Determine the culture medium potassium concentration for optimal 
neuronal survival and neurite network formation in neonatal rat CGNs 
• Confirm the elimination of non-neuronal cell types by addition of cytosine 
arabinoside to culture medium 
• Determine the ability of CGNs to form comparable neurite networks in 
either the presence or absence of cytosine arabinoside 
• Establish comparative model using neonatal cerebral cortical neurones 
• Ascertain the linear increase in assay reading relative to cell density with 
both FDA and Alamar blue viability assays 
• Compare the FDA and Alamar blue viability assays to ensure concordant 
results 
• Confirm the accuracy of FDA assay by comparing fluorescein staining of 
neurones with morphological appearances 
• Utilize PI to stain dead neurones, and correlate this with corresponding 
morphological appearances 
• Confirm reliability of FDA assay by application of both FDA and PI 
simultaneously 
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3.3 Cell density  
In order to ensure that an optimum cell density was used in our system, a range 
of plating densities were tested and the appearances of the resultant neuronal 
cultures recorded. The cell plating densities tested were selected based on 
review of previous studies using cultured neonatal Sprague-Dawley rat CGNs 
(Chuang et al., 1992, Wick et al., 2002).  
 
 
  
Figure 3.1 CGNs at 9 DIV, plated at a density of: A) 0.75 x106 cells/ml B) 1.00 x106 cells/ml C) 
1.20 x106 cells/ml. Bars = 100µm. There was limited variation between densities, although 
slightly less extensive networks were seen using a plating density of 0.75 x106 cells/ml.  
 
As can be seen from the representative images, more extensive networks were 
formed using cells at a density of 1.0 or 1.2x106 cells/ml, compared to cells at a 
density of 0.75x106 cells/ml (Fig 3.1). There was no apparent qualitative 
difference between cultures plated at 1.0 or 1.2x106 cells/ml. A plating density 
of 1.0x106 cells/ml was chosen in order to minimise the risk of increased 
sensitivity to medium changes associated with higher plating densities (Schramm 
et al., 1990, Ciotti et al., 1996, Young et al., 2000) and to maximise the 
material available for experiments each week.  
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3.4 Effects on culture morphology of potassium 
concentration in culture medium 
As alteration in potassium concentration has been shown to affect survival of 
cultured CGNs, neurones were plated in a range of potassium concentrations, 
and the appearance of the resultant cultures observed. A clear correlation was 
seen between CGNs cultured in higher potassium concentrations and with 
neuronal survival and neurite network formation. The most commonly used 
concentration was 25mM KCl, which produced cultures with neurones of 
consistent, normal morphology and with extensive neurite outgrowth (Fig 3.2D).  
  
 
  
 
  
Figure 3.2 Morphological appearances at 9 DIV of CGNs cultured in medium containing: A) 
5mM KCl, B) 10mM KCl, C) 15mM KCl, D) 20mM KCl, E) 25mM KCl, F) 30mM KCl. Bars = 
100µm. The greater survival of CGNs using higher concentrations of KCl can be seen, with 
optimal appearances reached at 25mM.  
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3.5 Immunocytochemical studies of culture purity and 
neurite network morphology 
In order to confirm that cytosine arabinoside treatment was effective but did 
not inhibit the formation of neurite interconnections between individual 
neurones, immunocytochemistry was performed to identify both neuronal and 
non-neuronal populations in the presence or absence of cytosine arabinoside 24 
hours after culture plating.  
  
 
  
Figure 3.3 Immunocytochemical staining of CGN cultures (fixed at 9 DIV) with and without 
10µM cytosine arabinoside added to medium at 1 DIV: A) and B) Cultures without cytosine 
arabinoside, immunostained against β–tubulinIII and glial fibrillary acid protein (GFAP) 
respectively, C) and D) Cultures with cytosine arabinoside, immunostained against β–
tubulinIII and GFAP respectively (A and B, C and D are paired images of the same areas). 
Bars = 100µm. The addition of cytosine arabinoside extensively reduced the presence of 
glial cells, with no evident effect on neuronal morphology.  
 
Cytosine arabinoside caused an obvious reduction in the number of glial cells 
present in the cultures (Figs 3.3B and 3.3D) but without any substantial loss of 
neurones (Figs 3.3A and 3.3C). Furthermore, cytosine arabinoside did not reduce 
the establishment of networks of neurite interconnections or cause any changes 
in morphology. Figs 3.4 and 3.5 show the clear differences in morphology 
between cells with β–tubulinIII stained and those with GFAP stained.  
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Figure 3.4 Immunocytochemical staining of CGN cultures (fixed at 9 DIV) immunostained 
against β–tubulinIII (cultures with 10µM cytosine arabinoside added to medium at 1 DIV) at 
different magnifications. Bars = 100µm (A), 50µm (B), 20µm (C). The extensive neurite 
connections between neurones can be seen clearly.  
 
 
 
  
Figure 3.5 Immunocytochemical staining of non-neuronal cells (fixed at 9 DIV) 
immunostained with GFAP (from cultures not treated with cytosine arabinoside). Bars = 
100µm (A), 50µm (B), 20µm (C). The contrast in appearance between these cells and those 
stained against β–tubulinIII can be easily identified.  
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3.6 Assay results vary with cell plating density (FDA and 
Alamar blue) 
To confirm that each of the viability assays used gave results consistent with the 
cell population density, results were compared from cultures plated at a range 
of densities (500x105 to 1.5x106 cells/ml). The FDA assay dye was applied for 10 
minutes and the Alamar blue assay dye for 4 and 6 hours, with all assays 
performed at 10 DIV (the time to be used during most subsequent experiments).  
Both assays (and indeed at both time points for Alamar blue) produced a linear 
reading increase proportional to the increase in cell plating density, confirming 
the suitability of both in quantifying viable cell numbers in this culture system 
(Figs 3.6, 3.7 and 3.8).  
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Figure 3.6 Cell density versus FDA reading (excitation at 485nm, emission at 538nm). Mean 
+/- standard error of mean (SEM), n=5. A linear increase in the quantity of fluorescein 
produced with increasing cell number is seen.  
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Figure 3.7 Cell density versus Alamar blue readings at 4 hours (colorimetric readings at 
540nm and 595nm). Mean +/- SEM, n=5. A linear increase in the quantity of Alamar blue 
reduction with increasing cell number is seen.  
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Figure 3.8 Cell density versus Alamar blue readings at 6 hours (colorimetric readings at 
540nm and 595nm). Mean +/- SEM, n=5. A linear increase in the quantity of Alamar blue 
reduction with increasing cell number is seen.  
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3.7 Assay comparison (FDA and Alamar blue) 
Having established that both viability assays give results consistent with a linear 
increase in cell population, it was of interest to establish whether the results 
attained with each were directly comparable. Viability readings were quantified 
as a percentage of those from sham controls, which were subjected to medium 
changes to replicate the mechanical stresses encountered by treated cultures 
during aspiration and replacement of medium, and hence compensate for this 
potential source of variation. This method was used as the standard for assessing 
viability in the remainder of the study (with occasional exceptions, identified as 
such in the relevant figures).  
In all studies, the two assays provided results which were comparable and 
analysis of variance (ANOVA) followed by Tukey’s post-hoc test for each set of 
three results (of each individual compound at each concentration) showed no 
significant differences in any case, with the p value determined to be ≥ 0.5 in 
each (Fig 3.9, 3.10 and 3.11).  
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Figure 3.9 Comparison of FDA and Alamar blue in assaying tryptophan toxicity (applied for 
1 hour at 9 DIV) in cultured CGNs. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test (in 
each set of three assay results) found no significant difference, indicating that the assays 
provide comparable data.  
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Figure 3.10 Comparison of FDA and Alamar blue in assaying kynurenine toxicity (applied for 
1 hour at 9 DIV) in cultured CGNs. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test (in 
each set of three assay results) found no significant difference, indicating that the assays 
provide comparable data.  
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Figure 3.11 Comparison of FDA and Alamar blue in assaying QA toxicity (applied for 1 hour 
at 9 DIV) in cultured CGNs. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test (in each set 
of three assay results) found no significant difference, indicating that the assays provide 
comparable data.  
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3.8 Fluorescein staining and cell morphology 
comparison 
With the readings from each assay consistent with cell number and with each 
other, further confirmation of assay accuracy was obtained by investigating 
whether the viability data provided by the assays were consistent with 
phenotypic appearances indicating viability. Fluorescein produced from FDA is 
visible under fluorescent light at a wavelength of 480nm, hence cells stained 
with FDA were examined under both white light and at 480nm (Fig 3.12).  
  
 
  
Figure 3.12 Staining of viable CGNs at 10 DIV with fluorescein: correlation with 
morphological appearances. A) Control CGNs, B) CGNs in A at wavelength 480nm, C) CGNs 
treated with 100µM 3-hydroxykynurenine for 5 hours at 9 DIV, D) CGNs in C; at wavelength 
480nm. Bars = 100µm. A normal healthy morphology corresponds with increased 
fluorescein production, whereas no fluorescein staining is seen in dead cells.  
 
There was a clear correlation between neurones with normal morphology and 
positive staining with fluorescein (Fig 3.12A and 3.12B), and between neurones 
with shrunken perikarya and destroyed neurites (features consistent with dead 
or dying neurones) and a lack of positive staining (Fig 3.12C and 3.12D). This 
demonstrated that the FDA assay provided an accurate assessment of neuronal 
viability in our culture system. Furthermore, as results obtained with both assays 
were consistent, Alamar blue also provided an accurate method of evaluating 
viability.  
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3.9 Fluorescein and PI co-staining 
A common method of assessing viability is simultaneous staining with FDA and PI, 
marking viable and dead cells respectively. Further investigation of the 
specificity of intracellular de-esterified fluorescein as a viability marker was 
performed in a small comparative study, with both compounds applied 
simultaneously for 10 minutes and images recorded using both white light and at 
wavelengths of 480nm for fluorescein or 530nm for PI. Propidium iodide was 
shown to be an effective cell death marker and fluorescein staining a specific 
marker of viable cells (Fig 3.13).  
    
 
    
 
    
 
Figure 3.13 Comparison at 12 DIV of untreated CGNs (A, B, C) and CGNS treated with 50µM 
glutamate for 24 hours at 11 DIV (D, E, F) showing morphological appearance (A, D) 
fluorescein staining at 480nm (B, E) and PI staining at 530nm (C, F). Bars = 100µM. The 
morphological images show clearly that cells stained with PI are indeed dead, and that 
staining with PI and fluorescein are mutually exclusive.  
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3.10 Discussion of optimising culture conditions 
3.10.1 Plating density 
A major influence on survival in CGN cultures is the density at which cells are 
plated: it is well known that if plated at too low a concentration, then cells have 
a much lower chance of survival (Trenkner, 1998). This effect has been 
quantified in rat neonatal CGNs plated at densities of 1.1x105, 2.2x105, 4.4x105, 
8.8x105, 17.6x105 and 35.2x105 cells/ml, with cell survival compared at 5 DIV 
(Young et al., 2000). Of these densities, optimal survival proved to be at 8.8x105 
cells/ml. Survival rates at densities either below 4.4x105 or above 17.6x105 
cells/ml were substantially reduced, although the addition of medium 
conditioned by CGNs at a density of 4.4x105 cells/ml was shown to increase 
survival of CGNs plated at 2.2x105 cells/ml (Young et al., 2000). The range of 
densities used in this study was much narrower, between 0.75x105 and 1.2x106 
cells/ml, nevertheless variation in the extent of the neurite network formed was 
appreciable in cultures plated at 0.75x105 cells/ml compared to those at higher 
densities.  
A significant factor to consider when selecting plating density is that higher 
densities may increase the vulnerability of CGNs to damage from changes in 
culture medium. Schramm and co-workers showed that Sprague-Dawley rat 
neonatal CGNs can be vulnerable to replenishment of culture medium with fresh 
serum after 14 DIV, with the medium change producing a neurotoxic effect. This 
effect was blocked by NMDA receptor antagonists 3-(2-carboxypiperazin-4-yl) 
propyl-1-phosphonate (CPP) or MK-801 (Schramm et al., 1990), suggesting that 
serum supplementation caused an excitotoxic insult. Furthermore, the toxic 
effect of glutamate is of greater potency when CGNs were plated at higher 
densities (Ciotti et al., 1996). Taken together, these results strongly indicate 
that CGNs plated at higher densities have greater vulnerability to an excitotoxic 
effect induced by glutamate or replenishment with fresh serum.  
The increased susceptibility of higher-density CGN cultures to such an insult is 
unsurprising, as any excitotoxic stimulus (for example, glutamate in serum) 
causes an increase in neuronal firing, which in CGN cultures could lead to 
intracellular glutamate release. Therefore, increased extracellular glutamate 
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(above that causing neuronal firing) would be proportional to the CGN plating 
density, with toxicity rising proportionally above a certain threshold.  
However, a more complicated process is implicated, since addition of medium 
conditioned by high-density CGN cultures after 8 DIV increased sensitivity of low-
density CGN cultures to glutamate. This suggests that potentiation occurred due 
to a component within medium conditioned by high-density CGN cultures (Ciotti 
et al., 1996). The effect of high-density plating on inducing a potential toxic 
quality to culture medium was also demonstrated by culturing CGNs at a lower 
density in a lower volume and was possibly mediated by increased expression of 
NMDAR1 receptor protein (Dus et al., 1997).  
Clearly these effects potentially complicate any studies concerning neuronal 
viability when culture medium changes are required, and particularly 
compromise those studies involving glutamate or any other excitotoxic stimuli. 
For these reasons, an excessively high plating density would be just as 
detrimental to culture survival over the course of the experimental protocol as 
an unduly low one. The study by Schramm et al. (1990) demonstrated 
vulnerability to serum replenishment used CGNs plated at 1.6x106 cells/ml, a 
density considerably higher than in our experiments, with the exception of the 
cell density study. Additionally, the finding that reducing medium volume 
impacts significantly on the development of cultured CGNs underlines the 
necessity of excluding the outer rows of wells on the culture plate from 
experimental protocols due to the higher degree of evaporation (see Materials 
and Methods section).  
These findings indicate that glutamate receptor stimulation levels, particularly 
of the NMDA subtype, are delicately balanced in CGNs, with the potential for 
induction of considerable damage by either excessive or insufficient receptor 
stimulation. Furthermore, this highlights that insufficient consideration of the 
precise plating density when using cultured CGNs risks significant undesirable 
effects, due to variations in plating density potentially adversely altering the 
levels of NMDA receptor stimulation.  
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3.10.2 Potassium concentration 
Stimulation of NMDA receptors and its effect on CGN survival is also of relevance 
when considering the interaction between potassium concentration and neuronal 
survival, which is known to vary substantially depending on potassium (K+) 
concentration. Neurones maintained in 25mM KCl, a depolarising concentration, 
showed greater cell survival and had more extensive neurite interconnections 
than those maintained in 5mM KCl. When neurones in 25mM KCl were switched 
to medium containing 5mM KCl, extensive apoptotic death occurred within 72 
hours. Similarly, when CGNs were cultured in medium containing 5mM KCl from 
initiation of plating onwards, they suffered widespread apoptosis by 5 DIV (Gallo 
et al., 1987, Kharlamov et al., 1995).  
The precise action of how the higher K+ concentration produces greater cell 
survival is uncertain, although it is possible that the depolarisation it causes 
reduces or prevents excitotoxic damage or that it aids neuronal maturation. This 
second explanation is unlikely given that the replacement of 25mM KCl with 5mM 
KCl resulted in neuronal survival falling to levels similar to those in cultures that 
had been maintained in 5mM KCl since plating, i.e. growth in 25mM KCl did not 
confer irreversible protection. However, it is possible that such an explanation is 
correct, but that the duration of the neuronal maturation process is notably 
longer than the time interval usually used in culturing CGNs, i.e. full maturation 
may take longer than 14 DIV.  
The depolarisation hypothesis was also examined using the depolarising agent 
veratridine, which was not protective, although notably this agent worked by 
opening sodium channels (Daniels and Brown, 2002). The protective effect of 
elevated K+ is also not prevented by sodium channel blockade using either 
tetrodotoxin or xylocaine (Gallo et al., 1987). Additionally, the extent of 
apoptosis induced by reduction of the extracellular K+ concentration from 25mM 
to 5mM KCl was markedly reduced by co-applying the Na+, K+-ATPase inhibitor 
ouabain, an effect not blocked by application of MK-801 and the AMPA receptor 
antagonist CNQX (Isaev et al., 2000). Isaev and co-workers also showed that 
ouabain protected CGNs subjected to oxidative stress by Fe2+ and ascorbic acid. 
If this is the mechanism of the protective action of ouabain against low K+-
mediated toxicity, this would also be consistent with the explanation of low K+ 
toxicity as due to calcium influx, as protection against oxidative damage reduces 
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the vulnerability of mitochondria to damage from excessive intracellular 
calcium.  
Investigations of effects of potassium concentration beyond simply monitoring 
cell survival have studied expression of NMDA receptor subunit proteins in CGNs, 
revealing that expression of mRNA coding for subunits NR1 and NR2A increased 
over 2-9 DIV, with greater increases in CGNs cultured in 25mM KCl relative to 
those in 10mM KCl (Resink et al., 1995). Conversely, expression of mRNA for 
subunit NR2C increased over 2-9 DIV, with a greater increase with 10mM KCl 
than 25mM KCl (Resink et al., 1995). This increase in NR1 expression due to high 
K+ gives an interesting parallel with the 1997 finding of Dus et al. that culture of 
CGNs in a low volume of medium (comparable to high-density plating) also 
increased expression of NR1.  
Previous studies with either higher (24.5mM) or lower (5.4mM) potassium have 
demonstrated clear differences in neuronal morphology. Cultured mouse CGNs 
maintained in both concentrations of K+ (fixed at 8 DIV) were seen to form 
clusters of cells, which were more extensive in neurones cultured in 5.4mM KCl. 
Clusters consisted of neuronal soma predominantly at the outer edges, with 
extensive neuropil in the centre. However in cultures maintained in 5.4mM KCl, 
extensive neuropil degeneration was evident, particularly dendritic constituents, 
with pre-synaptic components relatively spared although synaptic vesicles were 
less developed (Peng et al., 1991).  
Plating and maintaining neonatal rat CGNs in 5mM KCl has also been shown to 
significantly reduce the expression of the dominant glucose transporter type 
GLUT3 to approximately a third of the levels seen with CGNs in 25mM KCl, 
although KCl concentrations above 25mM did not cause further increases in 
GLUT3 expression (Maher et al., 1994). Expression of GLUT1 was also reduced, 
albeit less extensively than that of GLUT3, which is perhaps unsurprising as the 
expression of GLUT3 is 8-10 fold greater than GLUT1 in neonatal rat CGNs (Maher 
et al., 1994).  
Culturing CGNs in 5mM K+ also caused significant reductions in PKC activity (Lin 
et al., 1997). Activity increased in both 5mM KCl and 25mM KCl between 2-4 DIV, 
with PKC levels in CGNs in 25mM KCl continuing to rise until 8 DIV then 
remaining stable. However levels in CGNs cultured in 5mM KCl declined after 4 
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DIV, falling to below a third of the levels of 25mM CGNs by 8 DIV (Lin et al., 
1997). The range of roles of PKC, including involvement in neuroprotection, 
provides further evidence that CGNs in medium with a 5mM potassium 
concentration represent a neuronal type abnormally vulnerable to excitotoxic or 
oxidative damage.  
The maintenance of CGNs in lower K+ concentrations leads to significant levels of 
apoptotic cell death, associated alterations in expression of NMDA and GLUT3 
receptors, PKC activity and an abnormal phenotype. This highlights the necessity 
of a depolarising concentration of K+ in the medium and was borne out in the 
pilot qualitative study using a range of K+ concentrations, in which optimal 
morphology was with a K+ concentration of 25mM.  
Both cell plating density and K+ concentration and their consequent effects on 
NMDA receptor stimulation may mimic aspects of inter-neuronal signalling which 
occur during migration of CGNs into the external granular layer in vivo, 
specifically stimulation by mossy fibre neurones (Balázs et al., 1988, Morán and 
Patel, 1989). It is known that failure to successfully migrate, with consequent 
lack of neuronal stimulation and depolarisation, is associated with DNA 
fragmentation and apoptosis during normal postnatal cerebellar development 
(Balázs et al., 1988, Wood et al., 1993). Consequently a plating density and K+ 
concentration at the optimal levels will mimic the degree of NMDA receptor 
stimulation necessary for CGN survival, but without reaching excessive levels 
that risk excitotoxicity-mediated damage and cell death.  
Application of NMDA to CGNs increased activity of the glutamate-synthesising 
enzyme glutaminase, an effect blocked by cycloheximide or actinomycin D and 
not replicated in cultured cerebellar astroglial cells (Morán and Patel, 1989). 
The loss of CGNs in a non-depolarising K+ concentration can be prevented by the 
use of NMDA, an effect blocked by receptor antagonists. Furthermore, the use of 
these antagonists in vivo caused an increase in apoptotic death of CGNs (Balázs 
et al., 1988, Monti et al., 2002, Alvarez et al., 2006).  
Maturation of CGNs (both in vivo and in vitro) is associated with phosphorylation 
of the cAMP response-element binding protein (CREB), which is significantly 
reduced by blockade of the NMDA receptor in vivo or by the use of a non-
depolarising potassium concentration in vitro, this latter effect prevented by the 
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application of NMDA (Monti et al., 2002). It is of interest to note that CREB 
phosphorylation is also involved in differentiation of CGNs during development 
and that the extracellular matrix protein vitronectin (which acts to induce 
differentiation) induces CREB phosphorylation (Pons et al., 2001). Furthermore, 
CGNs overexpressing CREB have a significantly higher rate of differentiation 
(Pons et al., 2001).  
In any exclusively neuronal culture system, an integral stage is the removal of 
non-neuronal cells, most commonly by pharmacological elimination, using an 
agent selectively toxic to mitotic cells. Cytosine arabinoside is frequently used 
in the preparation of CGN cultures, at doses ranging from 5µM to 50µM, with 
10µM most commonly used for cultures prepared from 8-day old Sprague-Dawley 
rat neonates (Marini et al., 1998, Trenkner, 1998, Wick et al., 2002).  
Cytosine arabinoside is a nucleotide analogue which eliminates proliferating 
cells, reducing DNA synthesis by inhibiting DNA polymerases, and which becomes 
incorporated into newly-formed DNA (Grant, 1998). The dose applied has to be 
at a non-toxic concentration for neurones as it has been reported to generate 
ROS, interfere with membrane lipid synthesis and can cause apoptosis in 
cultured neurones: this effect is dose-dependant and mediated by (although not 
dependant on) activation of Bax (Grant, 1998, Besirli et al., 2003). It has been 
demonstrated however that 10µM cytosine arabinoside does not cause significant 
neuronal death when applied to neonatal rat CGN cultures (Courtney and Coffey, 
1999).  
Cerebellar granular neurones maintained in 5mM KCl are significantly more 
vulnerable to the toxic effects of cytosine arabinoside than cells grown in 25mM 
KCl. In experiments using rat and mouse CGNs, a clear increase in toxic effect 
was demonstrated as the concentration of cytosine arabinoside increased, with 
greater toxicity seen against neurones in 5mM KCl cultures than those in 25mM 
KCl cultures (Daniels and Brown, 2002). With 10µM cytosine arabinoside, the 
difference in survival rates was only ~10%, but at a concentration of 100µM, the 
disparity was ~20% and ~80% (Daniels and Brown, 2002). However, this group 
noted only a slight effect of K+ withdrawal on CGN viability (using a normal 10µM 
concentration of cytosine arabinoside, in either rat or mouse CGNs). This is in 
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contrast to the extensive loss seen in our studies, so direct comparison with our 
system is uncertain.  
The study of the effectiveness of cytosine arabinoside in our culture system was 
qualitative in nature and relied on immunocytochemical investigations using an 
antibody raised against β-tubulinIII, a protein specific to neuronal cells including 
neonatal rat CGNs (Ankarcrona et al., 1996, Cumming et al., 1984), and an 
antibody raised against GFAP to stain for the presence of glial cells. Both 
antibodies were effective in labelling their respective target cell populations, 
and the presence of 10µM cytosine arabinoside 24 hours after plating effectively 
inhibited non-neuronal cells. Only a few cells stained positive for GFAP in 
cytosine arabinoside treated cultures. There were no evident differences in 
neuronal populations and neurite networks produced when cultures in the 
presence or absence of 10µM cytosine arabinoside were compared.  
3.11 Discussion of viability assay reliability 
A range of assays to quantify levels of cell viability or death have been used with 
cultured CGNs: Trypan blue, PI, FDA, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), lactate dehydrogenase (LDH) and Alamar 
blue (Altman et al., 1993, Budd and Nicholls, 1996, Marini and Paul, 1993, Morán 
et al., 1999, Ward et al., 2005, White et al., 1996 respectively). The limitations 
of Trypan blue in assessing mature neuronal viability have been reported 
previously (Altman et al., 1993), making either Alamar blue or FDA the most 
practical assay for use. These were compared initially to determine the most 
effective in our system. Alamar blue is a relatively recent non-toxic assay dye, 
initially used for quantification of cell proliferation rather than survival (Ahmed 
et al., 1994). Fluorescein diacetate is well established, having been in use for 
more than forty years (Rotman and Papermaster, 1966).  
The range of cell concentrations used to quantify the assays was limited by 
similar factors to those affecting the choice of cell plating density. The lowest 
concentration used was 500x105 cells/ml, below which the risk of cell death due 
to apoptosis was too great. The highest density used was 1.5x106 cells/ml, which 
was potentially vulnerable to damage from fresh serum in the medium used in 
the Alamar blue assay (Schramm et al., 1990). However, the Alamar blue 
readings for this cell density and their positions relative to the final R2 lines are 
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comparable to those achieved with FDA, which did not use any serum. This 
suggests that replenishment of the higher density cultures with fresh serum-
containing medium was unlikely to have substantially impacted on cell survival 
in this experiment. However, the period over which any such insult could have 
taken place was limited to the 4 or 6 hours during which the Alamar blue was 
active, so it is possible that a density-related neurotoxic effect would have 
become more apparent over a longer period of time.  
The lack of time for a potential neurotoxic effect to act is also a relevant factor 
when considering the effect of serum withdrawal, which is a feature of the 
fluorescein diacetate assay method. However, neurotoxicity resulting from the 
withdrawal of serum from the culture environment takes several hours to 
become apparent (Atabay et al., 1996), whereas the FDA assay reading is taken 
after only 10 minutes. Therefore, although serum withdrawal could be a 
significant source of error if the assay duration was equivalent to that for Alamar 
blue, the withdrawal period used with this assay renders it immaterial.  
When comparing results in a human hepatoma cell line, HepG2, following 
treatment with a range of 117 cytotoxic drugs, it was found that, excepting two 
drugs studied, Alamar blue appeared slightly more sensitive than MTT (Hamid et 
al., 2004). Our study compared the results from Alamar blue and FDA assays in 
identically-treated CGN cultures exposed to tryptophan, kynurenine or QA at 
10µM-1mM concentrations and clearly indicated that results using either assay 
were comparable. It is noteworthy that the statistical analysis used to exclude 
any significant difference was highly conservative, with the minimum number of 
comparisons used for ANOVA (three). Also, in each case there were very large p-
values, indicating that the absence of any observed difference was extremely 
unlikely to be a type 2 error (false negative). Furthermore, this was observed in 
experiments using different compounds and a range of concentrations for each, 
and the analysis (a total of nine sets of three readings, each with a total of 5 
repetitions) gave no significant difference. Nor is there any indication that one 
assay produced results that were consistently higher or lower than the other, 
even to a statistically insignificant degree.  
Comparison of fluorescein staining with morphological characterisation gave 
clear evidence that the application of FDA for 10 minutes represented an 
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accurate assessment of neuronal viability in our system, with good correlation 
between fluorescein staining of cells and the presence of a viable phenotype. 
Fluorescein production is only possible in cells with functioning intracellular 
esterases to cleave the two acetate groups from the molecule (thus producing 
fluorescein: Rotman and Papermaster, 1966) and an intact cell membrane to 
retain the produced fluorescein. Therefore, positive staining is not possible in 
dead neurones, as was indeed evident.  
Co-staining with PI, a DNA intercalating agent known to stain the nuclei of dead 
cells, also confirmed the efficacy of the FDA assay. Propidium iodide was 
excluded from the nuclei of viable cells by the intact cell membranes and hence 
provided an effective contrast with the viability marker of de-esterified 
intracellular fluorescein. This comparative study demonstrated that dead cells 
identified by positive staining with PI were not stained with fluorescein as 
further confirmation of the specificity of FDA as a marker of viable cells.  
Co-application of FDA and PI, giving results for both viable and non-viable cells 
used, is an alternative method of viability analysis (Manev et al., 1989, 
Scorziello et al., 2001). With the effectiveness of FDA alone already clearly 
established, the double confirmation method was not necessary. An additional 
reason for not using this method was that (as is seen in the representative 
images), light at 480-485nm used to produce excitation of fluorescein also 
caused some response from PI, an effect that could potentially interfere with 
results taken via an automatic plate reader. The alternative method, to use 
representative images quantified by counting individual cells, was rejected due 
to increased potential for error, risk of observer bias and excessive time 
consumption for no appreciable gain.  
The main drawback of FDA is that the fluorescein produced by viable cells 
gradually leaks out of the cellular cytoplasm into the medium, leading to 
potential increasing inaccuracy as this accumulates. In this study, the brief 
period of application of assay solution meant that this was minimal; however in 
studies necessitating a greater period of assay solution exposure, an analogue of 
fluorescein diacetate with a less membrane-permeable active product would be 
preferable. A wide range of such compounds is available, such as 5-
carboxyfluorescein diacetate (Smith et al., 2003), which could be of use in 
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studies investigating precisely when the loss of viability seen by the FDA assay at 
24 hours occurs.  
Having established the suitability of each of these methods for use as a viability 
assay, the choice between the two was primarily based on logistical factors. 
There is a higher potential for error if any inaccuracies in timing occur with the 
use of the FDA assay, as even a brief delay will cause significant alteration to 
the final result, and consideration of this factor is essential with use of this 
assay. However, the use of FDA was more efficient in terms of time (a ten 
minute incubation prior to assay period, compared to a four or six hour 
incubation for Alamar blue), and in cost effectiveness. Hence, although some 
early studies used Alamar blue, the vast majority of the subsequent viability 
studies in this study were carried out with FDA.  
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4 Excitotoxicity and Oxidative Stress 
4.1 Introduction 
The experiments in this chapter were concerned with the investigation of 
excitotoxic and oxidative damage to CGNs mediated by a variety of stressors, 
with a particular focus on the actions mediated by tryptophan and compounds of 
the kynurenine pathway, as this is known to produce neurotoxic compounds 
capable of generating excitotoxic or oxidative damage in neurones. The 
interaction of these toxic effects with increased levels of glucose was also 
considered. In addition, the effects of glutamate, NMDA, 3-nitropropionic acid 
(3-NPA) and OGD on CGN viability were examined.  
These insults provided a range of stressors that have been identified as acting 
via excitotoxic NMDA receptor activation or generation of oxidative stress. The 
use of glutamate, increased glucose concentrations and tryptophan metabolites 
allowed examination of toxic effects due to endogenous agents of excitotoxicity 
or oxidative damage, with glutamate application and OGD also modelling aspects 
of damage to neurones during an ischaemic injury (for review see Lee et al., 
2000).  
The investigation of the range of tryptophan metabolites subsequently focused 
on the neurotoxic effects of three compounds: 3-hydroxykynurenine (3-HK), 3-
hydroxyanthranilic acid (3-HAA) and 5-hydroxyanthranilic acid (5-HAA). The 
mechanisms involved, concerning both the means of generating neurotoxic 
damage and the intracellular mechanisms leading to cell death, were explored. 
As published CGN culturing protocols use a variety of concentrations of glucose 
in medium, and increased concentrations of glucose can affect the toxicity of 
glutamate and 3-NPA (Fink et al., 1996, Delgado-Esteban et al., 2000), we set 
out to investigate whether the neurotoxic effects of tryptophan metabolites 
would be altered by a difference in glucose concentration.  
Following the discovery of an altered ratio of anthranilic acid to 3-HAA 
concentrations found in stroke patients compared with those of healthy subjects 
(Darlington et al., 2007), the effect of altering the concentration of anthranilic 
acid on the toxicity to CGNs of 3-HAA was also examined.  
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4.2 Aims and Objectives 
• Demonstration of a dose-responsive neurotoxic effect of glutamate to 
CGNs 
• Demonstration of reduced survival and increased vulnerability to 
glutamate in CGNs maintained in a non-depolarising potassium 
concentration 
• Demonstration of a dose-responsive neurotoxic effect of 3-NPA on CGN 
viability 
• Establishment of an effective system for delivering consistent OGD to 
cultured CGNs 
• Investigation of mechanisms for OGD toxicity 
• Investigation of the effects on CGN viability of increased glucose 
concentration 
• Investigation of the effects on CGN viability of treatment with tryptophan 
and several metabolites, over a range of doses and exposure times, 
examined in both low and high glucose environments 
• Effect of different medium glucose concentration on metabolism of 
tryptophan and selected metabolites in cultured CGNs 
• Investigation of mechanisms involved in neurotoxic effects of selected 
tryptophan metabolites known to generate oxidative damage 
• Investigation of effects on CGN viability of altered ratios of anthranilic 
acid and 3-HAA 
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4.3 Glutamate, N-methyl-D-aspartate and 3-nitropropionic 
acid toxicity 
4.3.1 Glutamate toxicity 
The application of glutamate, over a concentration range of 1µM to 10mM for 24 
hours, at 9 DIV caused a dose-dependant reduction in neuronal viability up to a 
concentration of 5mM, beyond which no further damage due to glutamate-
mediated toxicity was observed (Figure 4.1). It was notable that a relatively 
sharp drop in viability compared with the sham control was noted when applying 
the normally non-toxic concentration of 1µM glutamate, suggesting that the 
‘sham control’ procedure may not have accounted for all of the damage inflicted 
by the treatment procedure. A possibility is that the presence of any 
supplementary glutamate in the medium causes a larger rise due to release of 
endogenous neuronal glutamate. It was also noted that even very high 
concentrations of glutamate did not completely eliminate viable cells: it is 
possible that a percentage of this is due to remaining glial cells, or neurones 
other than CGNs.  
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Figure 4.1 Effect of glutamate added in medium for 24 hours at 9 DIV on CGN viability 
(assessed by fluorescein diacetate assay), producing increased toxicity with increasing 
glutamate concentration. Mean +/- SEM, n=6; ANOVA plus Tukey’s test, ** p<0.01, *** 
p<0.001.  
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4.3.2 Glutamate toxicity in low potassium medium 
The survival of CGNs following glutamate treatment was reduced by switching 
the K+ concentration to 5.5mM KCl 48 hours before treatment (Figure 4.2). The 
reduction in K+ itself caused notable toxicity (cell viability was reduced to 45.5% 
of control values in 25mM KCl).  
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Figure 4.2 Effect of glutamate added in medium for 24 hours on viability of CGNs cultured in 
medium with 25mM KCl, then switched to 5.5mM KCl 48 hours before glutamate treatment 
(assessed by Alamar blue assay).  Mean +/- SEM, n=5; ANOVA plus Tukey’s test, * p<0.05, ** 
p<001 (relative to 0µM glutamate in 5.5mM KCl medium group). A striking decrease in 
viability occurred due to the switch to 5.5mM KCl, with maximum damage achieved using 
100µM glutamate, as compared to 1mM in cultures maintained in 25mM KCl.  
 
Although this demonstrated that this characteristic of CGN cultures was present 
in our system, further work using 5.5mM KCl medium was not continued since 
these cultures were clearly abnormal, with increased cell death due to K+ 
withdrawal. Any damage by excitotoxic or oxidative insults therefore would have 
taken place against this background, making quantification of treatment damage 
difficult. Additionally, the significance of results from a culture system known to 
produce CGN networks with abnormal characteristics (Peng et al., 1991, Resink 
et al., 1995) would be uncertain.  
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4.3.3 3-Nitropropionic acid toxicity 
The known excitotoxin and mitochondrial poison 3-NPA applied at concentrations 
of 1µM to 10mM for 24 hours at 9 DIV caused damage in a dose-dependant 
manner up to a concentration of 5mM, with no further damage observed beyond 
this point (Figure 4.3). This compound was studied to determine the effect on 
CGN viability of an excitotoxic insult complicated by metabolic compromise. As 
with glutamate, a percentage of cells survived this treatment, although the 
combined toxic effects of 3-NPA were evidently lethal to a larger number of 
cells.  
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Figure 4.3 Effect of 3-NPA added in medium for 24 hours at 9 DIV on CGN viability (assessed 
by fluorescein diacetate assay), producing increased toxicity with increasing 3-NPA 
concentration. Mean +/- SEM, n=5; ANOVA plus Tukey’s test, ** p<0.01, *** p<0.001.  
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4.3.4 Toxicity of glutamate or 3-NPA unaffected by glucose 
concentration 
Despite the findings by others that glutamate-induced neurotoxicity is 
dependent on glucose levels (Delgado-Esteban et al., 2000), and that increased 
glucose protects against the neurotoxic effect of 3-NPA (Fink et al., 1996), there 
was no difference in effect seen when these compounds were applied in medium 
containing either 5.5 or 25mM glucose.  
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Figure 4.4 Toxicity of 100µM glutamate or 100µM 3-NPA unaffected by presence of either 5.5 
or 25mM D-glucose (assessed by fluorescein diacetate assay). Mean +/- SEM, n=5; Student’s 
T-test comparing paired columns identified no significant difference in the toxicity of either 
compound due to alteration of the glucose concentration.   
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4.3.5 Toxicity of glutamate, NMDA or 3-NPA unaffected by 
cycloheximide 
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Figure 4.5 Toxicity of 100µM glutamate, 300µM N-methyl-D-aspartate or 100µM 3-NPA is 
unaffected by co-application of 0.05µg/ml cycloheximide (assessed by fluorescein diacetate 
assay). Mean +/- SEM, n=4; ANOVA followed by Tukey’s test identified no significant 
protection by cycloheximide against the toxicity of any treatment.  
 
Figure 4.5 showed that protein synthesis is not required to produce the 
neurotoxic effect mediated by 100µM glutamate, 300µM NMDA or 100µM 3-NPA 
(applied in medium for 24 hours at 9 DIV). This finding was confirmed by 
examination of neuronal morphology (Figure 4.6). It should be noted however, 
that this does not exclude the involvement of apoptotic mechanisms in these 
insults, only that the compounds’ toxic effects are not dependent on protein 
synthesis: therefore increased production of death signalling proteins such as 
TNFα or Fas are not implicated.  
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Figure 4.6 Effects of (A, B) 100µM glutamate, (C, D) 300µM NMDA and (E, F) 100µM 3-NPA 
applied for 24 hours at 9 DIV on morphology at 10 DIV. Effects shown with (B, D, F) and 
without (A, C, E) co-applied 0.05µg/ml cycloheximide. Also shown are controls (G) and 
cultures treated with 0.05µg/ml cycloheximide only (H). Bars = 50µm. Extensive neuronal 
death was induced by all three insults, with no protection given by cycloheximide.  
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4.4 Toxicity of oxygen-glucose deprivation 
4.4.1 OGD toxicity – MK-801, kynurenic acid and nifedipine 
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Figure 4.7 Effect of antagonists on toxicity of 5 hours OGD on CGNs at 9 DIV. Mean +/- SEM, 
n=4; Student’s T-test, ** p<0.01 comparing OGD alone with sham control; ANOVA followed 
by Tukey’s test identified no significant protection from any treatment, indicating that the 
toxic effect of OGD was not dependent on NMDA receptor stimulation or influx of calcium 
via voltage-gated calcium channels.  
 
Oxygen-glucose deprivation for 5 hours at 9 DIV proved a potent method of 
inducing neuronal damage (Figure 4.7). The effects were not attenuated by the 
presence of the NMDA receptor antagonist MK-801, the glutamate receptor 
antagonist kynurenic acid or by the calcium channel blocker nifedipine (all 
applied throughout the period of OGD).  
The role of protein synthesis in the neurotoxicity of OGD was also examined to 
determine if production of death signalling proteins was involved in the neuronal 
death mechanisms induced (Figure 4.8). Co-application of cycloheximide during 
or after OGD (or for both periods) was carried out to ascertain whether any such 
response was mediated during the OGD insult itself or during the period 
immediately after (with OGD as a model of ischaemia, this period would be 
comparable to the reperfusion stage). The use of cycloheximide in either or 
indeed both of these periods did not reduce the toxic effect seen either by 
viability assay (Figure 4.8) or with morphological observations (Figure 4.9).  
108 
4.4.2 OGD toxicity – effect of cycloheximide 
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Figure 4.8 Effect of 0.05µg/ml cycloheximide application on toxicity of 5 hours OGD on 
CGNs at 9 DIV. Mean +/- SEM, n=4; Student’s T-test, *** p<0.001 comparing OGD alone with 
sham control; ANOVA followed by Tukey’s test identified no significant protection from 
cycloheximide treatment, whether applied during or after OGD.  
 
 
  
 
  
Figure 4.9 Effect of 5 hours oxygen-glucose deprivation at 9 DIV on CGN morphology at 10 
DIV: A) OGD only, B) OGD with 0.05µg/ml cycloheximide, C) OGD with 1µM MK-801, D) OGD 
with 100µM kynurenic acid. Bars = 50µm. As can be seen, none of these treatments were 
able to reduce the toxicity of OGD for this duration.  
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4.5 Effect of increased glucose concentration 
 
4.5.1 Effect of raised glucose in culture medium on viability 
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Figure 4.10 Effect of culturing in medium supplemented to 25mM D-glucose on viability of 
CGNs at 10 DIV. Mean +/- SEM, n=5; Student’s one-sample t-test performed, with no 
significant difference seen in CGN viability with either concentration of glucose.  
 
Figure 4.10 demonstrates that CGN cultures were maintained well in medium 
containing either 5.5 or 25mM glucose. Although previous studies have 
maintained CGNs in a range of glucose concentrations, and an increased glucose 
concentration in vitro or hyperglycaemia in vivo has been associated with 
several changes (Delgado-Esteban et al., 2000, Sima, 2003, Vincent et al., 
2005), there was no significant neurotoxic effect in our system after 10 DIV. 
However, this does not exclude the possibility of the CGNs being exposed to a 
sub-lethal increase in oxidative stress.  
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Figure 4.11 Morphological appearances of CGNs in medium containing (A, C) 5.5mM and (B, 
D) 25mM glucose at 12 DIV (A, B) and 31 DIV (C, D). Bars = 50µm. Neurones have a healthy 
appearance in both concentrations of glucose and at both 12 and 31 DIV, indicating a 
healthy phenotype can be maintained for long after the duration of our experimental 
protocols.  
 
In addition to providing confirmation of the viability assay findings, observations 
of CGN morphology in medium containing 5.5 and 25mM glucose showed that 
over the period of 8-14 DIV, under either of these conditions, neuronal 
phenotype with extensive neurite networks were maintained (Figure 4.11 A-C), 
and could be sustained for over four weeks (Figure 4.11D). It is therefore clear 
that experiments performed within 14 DIV are well within the CGNs’ normal 
period of survival.  
111 
4.6 Toxicity of tryptophan and kynurenine pathway 
compounds 
Tryptophan and eight metabolites from various branches of the kynurenine 
pathway were included in the study. The compounds were selected as they 
together constitute the main products of the kynurenine pathway, and thus 
illustrate the major effects due to tryptophan metabolism via this route. The 
effects of the compounds on CGN viability were studied over a concentration 
range of 10µM to 1mM, and over time periods ranging from 1 to 9 hours. 
Additionally, each of the compounds was examined both in medium with a 
glucose concentration of 5.5mM and with 25mM, in order to demonstrate any 
differences in neurotoxic effect due to increased glucose concentration.  
A positive correlation between concentration and toxicity for three compounds 
(3-HK – Figure 4.14, 3-HAA – Figure 4.15 and 5-HAA – Figure 4.20) was evident, 
although no consistent relationship with concentration occurred with the 
remaining six compounds (tryptophan - Figure 4.12, kynurenine – Figure 4.13, QA 
– Figure 4.16, kynurenic acid – Figure 4.18, anthranilic acid – Figure 4.19 and 
picolinic acid – Figure 4.21). However, a tendency towards an increase in toxicity 
with longer exposure times, although not at every concentration, was evident in 
all nine compounds.  
In addition to assessment of cell viability levels using the FDA assay, neuronal 
morphological changes were recorded following treatment with each of the 
compounds for a comparable duration (Figure 4.17). These findings were 
consistent with the results achieved using the FDA assay.  
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4.6.1 Tryptophan toxicity 
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Figure 4.12a Toxicity of tryptophan in medium containing 5.5mM glucose to CGNs at 9 DIV. 
Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, * p<0.05, ** p<0.01, *** p<0.001. 
Tryptophan toxicity increased with exposure time, but was not affected by concentration.  
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Figure 4.12b Toxicity of tryptophan in medium containing 25mM glucose to CGNs at 9 DIV. 
Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, ** p<0.01, *** p<0.001. Tryptophan 
toxicity increased with exposure time, but was not affected by concentration.  
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4.6.2 Kynurenine toxicity 
0
20
40
60
80
100
120
1 hour 5 hours 9 hours
Exposure time
Vi
ab
ili
ty
 
(p
er
ce
nt
ag
e 
of
 s
ha
m
 c
on
tr
ol
)
10µM 100µM 1mM
**
**
****
*
* *
Figure 4.13a Toxicity of kynurenine in medium containing 5.5.mM glucose to CGNs at 9 DIV. 
Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, * p<0.05, ** p<0.01. Kynurenine toxicity 
increased with exposure time, but was not affected by concentration.  
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Figure 4.13b Toxicity of kynurenine in medium containing 25mM glucose to CGNs at 9 DIV. 
Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, ** p<0.01, *** p<0.001. Kynurenine 
toxicity increased with exposure time, but was not affected by concentration.  
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4.6.3 3-Hydroxykynurenine toxicity 
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Figure 4.14a Toxicity of 3-HK in medium containing 5.5mM glucose to CGNs at 9 DIV. Mean 
+/- SEM, n=5; ANOVA followed by Tukey’s test, * p<0.05, ** p<0.01, *** p<0.001. 3-
Hydroxykynurenine toxicity increased with exposure time (although this was not evident at 
10µM) and with concentration.  
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Figure 4.14b Toxicity of 3-HK in medium containing 25mM glucose to CGNs at 9 DIV. Mean 
+/- SEM, n=5; ANOVA followed by Tukey’s test, * p<0.05, ** p<0.01, *** p<0.001. 3-
Hydroxykynurenine toxicity increased with exposure time (although this was not evident at 
10µM) and with concentration.  
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4.6.4 3-Hydroxyanthranilic acid toxicity 
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Figure 4.15a Toxicity of 3-HAA in medium containing 5.5mM glucose to CGNs at 9 DIV. Mean 
+/- SEM, n=5; ANOVA followed by Tukey’s test, ** p<0.01, *** p<0.001. 3-Hydroxyanthranilic 
acid toxicity increased with exposure time (although this was not evident at 10µM) and with 
concentration.  
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Figure 4.15b Toxicity of 3-HAA in medium containing 25mM glucose to CGNs at 9 DIV. Mean 
+/- SEM, n=5; ANOVA followed by Tukey’s test, * p<0.05, ** p<0.01, *** p<0.001. 3-
Hydroxyanthranilic acid toxicity increased with exposure time and with concentration.  
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4.6.5 Quinolinic acid toxicity 
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Figure 4.16a Toxicity of QA in medium containing 5.5mM glucose to CGNs at 9 DIV. Mean +/- 
SEM, n=5; ANOVA followed by Tukey’s test, * p<0.05, ** p<0.01, *** p<0.001. Quinolinic acid 
toxicity increased with exposure time, but was not affected by concentration.  
 
 
0
20
40
60
80
100
120
1 hour 5 hours 9 hours
Exposure time
Vi
ab
ili
ty
 
(p
er
ce
nt
ag
e 
of
 s
ha
m
 c
on
tr
ol
)
10µM 100µM 1mM
***
***
**
**
Figure 4.16b Toxicity of QA in medium containing 25mM glucose to CGNs at 9 DIV. Mean +/- 
SEM, n=5; ANOVA followed by Tukey’s test, ** p<0.01, *** p<0.001. Quinolinic acid toxicity 
increased with exposure time, but was not affected by concentration.  
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Figure 4.17a Cerebellar granule neurone morphology at 10 DIV after treatments at 9 DIV: A) 
Control, B) 1mM tryptophan for 1 hour, C) 1mM kynurenine for 1 hour, D) 100µM 3-HK for 1 
hour, E) 100µM 3-HAA for 1 hour, F) 1mM QA for 1 hour. Bars = 50µm. Although panels B, C 
and F are somewhat obscured by debris, a higher level of surviving CGNs compared with 
panels D and E can be seen, with all treatments decreasing the number of viable cells in 
comparison with the control (A).  
 
As shown in Figure 4.17a, the neurotoxic effect identified by the FDA viability 
assay was also evident in the morphological appearances of treated CGNs, with 
moderate damage due to tryptophan, kynurenine and quinolinic acid, and more 
extensive damage apparent following treatment with 3-HK and 3-HAA.  
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Figure 4.17b Cerebellar granule neurone morphology at 10 DIV after treatments at 9 DIV: G) 
100µM kynurenic acid for 1 hour, H) 100µM anthranilic acid for 1 hour, I) 100µM 5-HAA for 1 
hour, J) 100µM picolinic acid for 1 hour. Bars = 50µm. Kynurenic acid for 1 hour was not 
toxic and the toxicity of 5-HAA was more extensive than that of anthranilic acid or picolinic 
acid.  
 
The notably less neurotoxic effect of kynurenic acid treatment for 1 hour is 
confirmed by morphological observations (Figure 4.17b, G), with appearances of 
treated neurones found to be comparable to controls (Figure 4.17a, A). All other 
treatments (anthranilic acid, picolinic acid, 5-HAA) induced obvious neuronal 
damage, with the effect of 5-HAA most pronounced, which is a finding that is 
again consistent with FDA assay results.  
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4.6.6 Kynurenic acid toxicity 
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Figure 4.18a Toxicity of kynurenic acid in medium containing 5.5mM glucose to CGNs at 9 
DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, * p<0.05. Kynurenic acid toxicity 
was initially limited, but increased with exposure time, but was not affected by 
concentration.  
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Figure 4.18b Toxicity of kynurenic acid in medium containing 25mM glucose to CGNs at 9 
DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, ** p<0.01, *** p<0.001. Kynurenic 
acid toxicity was initially limited, but increased with exposure time, but was not affected by 
concentration.  
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4.6.7 Anthranilic acid toxicity 
0
20
40
60
80
100
120
1 hour 5 hours 9 hours
Exposure time
Vi
ab
ili
ty
 
(p
er
ce
nt
ag
e 
of
 s
ha
m
 c
on
tr
ol
)
10µM 100µM 1mM
*** ***
***
*
***
*
**
Figure 4.19a Toxicity of anthranilic acid in medium containing 5.5mM glucose to CGNs at 9 
DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, * p<0.05, ** p<0.01, *** p<0.001. 
Anthranilic acid toxicity increased with exposure time to 9 hours, but was not affected by 
concentration.  
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Figure 4.19b Toxicity of anthranilic acid in medium containing 25mM glucose to CGNs at 9 
DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, ** p<0.01, *** p<0.001. Anthranilic 
acid toxicity increased with exposure time, but was not affected by concentration.  
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4.6.8 5-Hydroxyanthranilic acid toxicity 
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Figure 4.20a Toxicity of 5-HAA in medium containing 5.5mM glucose to CGNs at 9 DIV. Mean 
+/- SEM, n=5; ANOVA followed by Tukey’s test, ** p<0.01, *** p<0.001. 5-Hydroxyanthranilic 
acid toxicity increased with exposure time and with concentration.  
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Figure 4.20b Toxicity of 5-HAA in medium containing 25mM glucose to CGNs at 9 DIV. Mean 
+/- SEM, n=5; ANOVA followed by Tukey’s test, ** p<0.01, *** p<0.001. 5-Hydroxyanthranilic 
acid toxicity increased with exposure time and with concentration.  
 
 
122 
4.6.9 Picolinic acid toxicity 
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Figure 4.21a Toxicity of picolinic acid in medium containing 5.5mM glucose to CGNs at 9 
DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, * p<0.05, ** p<0.01, *** p<0.001. 
Picolinic acid toxicity increased with exposure time, but was not affected by concentration. 
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Figure 4.21b Toxicity of picolinic acid in medium containing 25mM glucose to CGNs at 9 
DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, ** p<0.01, *** p<0.001. Picolinic 
acid toxicity increased with exposure time, but was not affected by concentration. 
  
123 
Comparison of the neurotoxic effect of the tryptophan metabolites in medium 
containing 5.5 and 25mM glucose showed that a significant potentiation in 
neurotoxic effect occurred in cultures in higher glucose, when applied for 5 
hours (Figure 4.22). This was evident for most of the compounds studied (the 
exceptions being 3-HK, 3-HAA and 5-HAA), raising the question of the underlying 
mechanism. Possible explanations included: that potentiation was due to 
increased catabolism or an osmotic effect of the additional glucose in the 
treatment medium; increased vulnerability due to pre-existing sub-lethal 
oxidative stress (caused by additional glucose in the plating medium); 
metabolism of the additional glucose altered metabolism of the compounds 
themselves. Therefore, the difference in toxicity identified in the two groups 
was compared directly, and each possible explanation explored.  
The first question considered was whether the increased vulnerability was due to 
plating and maintenance in a higher glucose concentration or to an effect that 
occurred during the treatment period.  
Switching over the glucose concentrations used for culturing and treatment 
caused a reduction in toxicity, but for several compounds there was still a 
significant potentiation (Figure 4.23). This suggested that much of the 
potentiation resulted from the treatments being applied in 25mM glucose-
containing medium, raising the further question of whether this was due to an 
osmotic effect or to metabolism of the additional glucose during the 5 hour 
treatment period.  
To investigate this question, a metabolically inert compound (providing the 
osmotic actions of glucose but not its metabolic properties), 3-O-methyl-D-
glucose, was added to an equivalent concentration of 25mM. This showed that 
the degree of toxicity seen in the groups supplemented with either D-glucose or 
3-O-methyl-D-glucose was comparable, and therefore that metabolism of the D-
glucose was not the cause of the potentiated toxicity (Figure 4.24).  
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4.6.10 Comparison of effects in 5.5 and 25mM glucose 
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Figure 4.22a Toxicity of tryptophan, kynurenine and QA to cultured CGNs is potentiated by 
increased medium glucose when applied for 5 hours at 9 DIV. Mean +/- SEM, n=5; Student’s 
t-test comparing groups, * p<0.05, ** p<0.01. Increased toxicity due to all compounds is 
apparent when they are applied in 25mM glucose.  
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Figure 4.22b Toxicity of kynurenic acid, anthranilic acid and picolinic acid to cultured CGNs 
is potentiated by increased medium glucose when applied for 5 hours at 9 DIV. Mean +/- 
SEM, n=5; Student’s t-test comparing groups, * p<0.05. Increased toxicity due to all 
compounds (although not all concentrations)  is apparent when they are applied in 25mM 
glucose.  
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4.6.11 Switchover of 5.5 and 25mM glucose 
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Figure 4.23a Toxicity of tryptophan, kynurenine and QA applied for 5 hours at 9 DIV to 
cultured CGNs with glucose in treatment medium increased or decreased in relation to 
glucose concentration in culturing medium. Mean +/- SEM, n=5; Student’s t-test comparing 
paired groups, * p<0.05. The toxic effect was more pronounced in CGNs maintained in 25mM 
glucose, although this was not significant in the case of quinolinic acid treatment.  
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Figure 4.23b Toxicity of anthranilic acid and picolinic acid applied for 5 hours at 9 DIV to 
cultured CGNs with glucose in treatment medium increased or decreased in relation to 
glucose concentration in culturing medium. Mean +/- SEM, n=5; Student’s t-test comparing 
paired groups showed no significant difference. No significant variation between the two 
alteraytions in glucose concentration were seen regarding their effects on the toxic effects 
of kynurenine pathway compounds.  
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4.6.12 Toxicity with D-glucose or 3-O-methyl-D-glucose 
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Figure 4.24a Toxicity of tryptophan and kynurenine in 5.5mM glucose medium 
supplemented with either 19.5mM D-glucose or 19.5mM 3-O-methylglucose. Mean +/- SEM, 
n=5; Student’s t-test comparing paired groups showed no significant difference. No 
difference was seen when treatments were applied in medium supplemented with D-glucose 
or 3-O-methylglucose, indicating that the potentiating effect of adding treatments in 25mM 
glucose-containing medium was not due to an effect caused by increased glucose 
metabolism.   
0
20
40
60
80
100
120
10µM anthranilic acid 100µM anthranilic
acid
10µM quinolinic acid 100µM quinolinic
acid
Treatment
Vi
ab
ili
ty
 
(p
er
ce
nt
ag
e 
of
 s
ha
m
 c
on
tr
ol
)
D-glucose
3-O-methylglucose
Figure 4.24b Toxicity of anthranilic acid and QA in 5.5mM glucose medium supplemented 
with either 19.5mM D-glucose or 19.5mM 3-O-methylglucose. Mean +/- SEM, n=5; Student’s 
t-test comparing paired groups showed no significant difference. No difference was seen 
when treatments were applied in medium supplemented with D-glucose or 3-O-
methylglucose, indicating that the potentiating effect of adding treatments in 25mM 
glucose-containing medium was not due to an effect caused by increased glucose 
metabolism.   
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4.6.13 HPLC of tryptophan metabolite products 
Sample  
(5.5mM glucose) 
Tryptophan 
(µM) 
Kynurenine 
(µM) 
Kynurenic 
acid (nM) 
Anthranilic 
acid (nM) 
Control  57.83 0.49 48.46 139.17 
Tryptophan 1 
hour 44.94 0.50 40.35 110.01 
Tryptophan 5 
hours 44.75 0.52 38.25 119.42 
Tryptophan 9 
hours 49.48 0.54 42.03 121.92 
Kynurenine 1 
hour 54.06 -21.66 42.11 116.85 
Kynurenine 5 
hours 54.03 -21.68 46.26 119.97 
Kynurenine 9 
hours 55.65 -18.61 48.90 129.79 
Anthranilic acid 
1 hour 53.65 0.52 39.38 109.44 
Anthranilic acid 
5 hours 54.25 0.55 40.79 117.45 
Anthranilic acid 
9 hours 52.80 0.53 37.21 108.36 
Table 4.1 High-performance liquid chromatography analysis of tryptophan, kynurenine, 
kynurenic acid and anthranilic acid levels in medium containing 5.5mM D-glucose from CGN 
cultures treated with 100µM tryptophan, 100µM kynurenine or 100µM anthranilic acid for the 
indicated periods at 9 DIV. Mean value from two separate experiments.  
 
Sample  
(25mM glucose) 
Tryptophan 
(µM) 
Kynurenine 
(µM) 
Kynurenic 
acid (nM) 
Anthranilic 
acid (nM) 
Control  65.22 0.52 54.57 197.63 
Tryptophan 1 
hour 45.82 0.53 50.05 128.28 
Tryptophan 5 
hours 55.11 0.57 49.85 131.26 
Tryptophan 9 
hours 46.85 0.55 47.94 126.85 
Kynurenine 1 
hour 53.26 -17.51 51.59 125.30 
Kynurenine 5 
hours 52.14 -19.44 52.69 129.83 
Kynurenine 9 
hours 54.96 -12.65 59.54 170.34 
Anthranilic acid 
1 hour 54.04 0.69 48.37 137.52 
Anthranilic acid 
5 hours 52.73 0.79 52.96 100.69 
Anthranilic acid 
9 hours 53.36 0.73 46.82 135.08 
Table 4.2 High-performance liquid chromatography analysis of tryptophan, kynurenine, 
kynurenic acid and anthranilic acid levels in medium containing 25mM D-glucose from CGN 
cultures treated with 100µM tryptophan, 100µM kynurenine or 100µM anthranilic acid for the 
indicated periods at 9 DIV. Mean value from two separate experiments.  
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Sample  
(5.5mM glucose) 
3-HK  
(µM) 
3-HAA  
(nM) 
5-HAA  
(nM) 
Control  0 5.494829 1.370648 
Kynurenine 5 
hours 0 0.8691 0 
Anthranilic acid 5 
hours 0 0 0 
 
3-HK 5 hours  22.60704 2.381419 2.736635 
 
3-HK 9 hours  22.008.62 3.927136 0.67824 
 
3-HAA 5 hours  0 43200.53 5.990729 
 
3-HAA 9 hours  0 40843.5 12.12206 
Table 4.3 High-performance liquid chromatography analysis of 3-HK, 3-HAA and 5-HAA 
levels in medium containing 5.5mM D-glucose from CGN cultures treated with 100µM 
kynurenine, 100µM anthranilic acid, 50µM 3-HK or 50µM 3-HAA for the indicated periods at 9 
DIV. Mean value from two separate experiments, with no compound metabolism evident.  
 
Sample  
(25mM glucose) 
3-HK (µM) 3-HAA (nM) 5-HAA (nM) 
Control  0 2.552336 0 
Kynurenine 5 
hours 0 1.833821 0 
Anthranilic acid 5 
hours 0 1.86033 0 
 
3-HK 5 hours  30.13986 3.141345 0 
 
3-HK 9 hours  28.87514 3.912287 0 
 
3-HAA 5 hours  0 44509.97 4.388807 
 
3-HAA 9 hours  0 40461.74 9.828422 
Table 4.4 High-performance liquid chromatography analysis of 3-HK, 3-HAA and 5-HAA 
levels in medium containing 25mM D-glucose from CGN cultures treated with 100µM 
kynurenine, 100µM anthranilic acid, 50µM 3-HK or 50µM 3-HAA for the indicated periods at 9 
DIV. Mean value from two separate experiments, with no compound metabolism evident.  
 
Additionally, examining the metabolism of compounds in medium from neurones 
cultured in both 5.5mM and 25mM D-glucose did not show any differences 
between the two groups (Tables 4.1 to 4.4). Therefore, the most likely cause of 
potentiation was the osmotic effect of the additional glucose in the treatment 
medium. However, the reduced potentiation seen when cultures were plated in 
medium containing 5.5mM glucose prior to treatment in medium with 25mM 
glucose suggested there was a heightened vulnerability in CGNs plated and 
maintained in 25mM glucose to this neurotoxic effect. It should also be noted 
that several of the compounds studied may have degraded during analysis.  
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4.7 Investigation of mechanisms of toxicity of selected 
kynurenine pathway compounds 
As 3-HK, 3-HAA and 5-HAA are capable of significant neurotoxicity, the 
mechanisms behind these effects were investigated. The effects of exogenously 
applied antioxidant enzymes during application of each of these three 
compounds were studied since 3-HK has been previously shown to generate H2O2 
and superoxide, using metal ions for electron exchange (Goldstein et al., 2000). 
Therefore, the effect on toxicity of the co-application of catalase (to remove 
H2O2) and of SOD (to remove superoxide) was studied.  
Neuronal survival was greatly enhanced when catalase was added, providing 
protection against toxicity and may be compared with the extensive death in 
cultures with SOD present in treatments with 3-HK (Figure 4.25, 4.28), 3-HAA 
(Figures 4.26, 4.28) and 5-HAA (Figures 4.27, 4.28). It is therefore apparent that 
the generation of H2O2 is of critical importance in the generation of neurotoxic 
damage by these three compounds.  
4.7.1 3-Hydroxykynurenine toxicity – effects of antioxidant 
enzymes 
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Figure 4.25 Effect of co-application of 200U/ml SOD or 200U/ml catalase with 100µM 3HK for 
5 hours at 9 DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, *** p<0.001. A very 
significant protective effect was seen due to catalase, although SOD was neither protective 
nor significantly potentiating.  
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4.7.2 3-Hydroxyanthranilic acid toxicity – effects of antioxidant 
enzymes 
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Figure 4.26 Effect of co-application of 200U/ml SOD or 200U/ml catalase with 100µM 3-HAA 
for 5 hours at 9 DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, *** p<0.001. A very 
significant protective effect was seen due to catalase, although SOD was neither protective 
nor significantly potentiating.  
 
4.7.3 5-Hydroxyanthranilic acid toxicity – effects of antioxidant 
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Figure 4.27 Effect of co-application of 200U/ml SOD or 200U/ml catalase with 100µM 5-HAA 
for 5 hours at 9 DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, *** p<0.001. A very 
significant protective effect was seen due to catalase, although SOD was neither protective 
nor significantly potentiating.  
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Figure 4.28 Effects of 100µM 3-HK (A, B), 100µM 3-HAA (C, D) or 100µM 5-HAA (E, F) applied 
for 5 hours at 9 DIV on CGN morphology at 10 DIV. Effects shown with 200U/ml catalase (A, 
C, E) or 200U/ml SOD (B, D, F) co-applied. Bars = 100µm.  The protective effect of catalase 
co-application against the neurotoxicity of all three compounds is clearly seen, whereas the 
co-application of SOD did not reduce damage.  
 
As shown in Figure 4.28, co-application of catalase caused an extensive 
reduction in the neurotoxic effects of 3-HK, 3-HAA and 5-HAA, whereas SOD co-
application did not provide any protection against the effects of any of these 
compounds.  
 
132 
4.7.4 3-Hydroxykynurenine toxicity – effect of desferrioxamine 
In order to establish the effect of removal of iron (which may act as an electron 
donor during ROS generation by the compounds studied), the iron chelating 
agent desferrioxamine was co-applied with treatments. Desferrioxamine was 
unable to afford protection against the toxicity of any of the compounds over 
the range of concentrations tested, 1-100µM (Figures 4.29, 4.30, 4.31). 
Replication of this experiment with the compounds and desferrioxamine applied 
for 5 hours was also unable to demonstrate protection due to desferrioxamine.  
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Figure 4.29 Effect of 1-100µM desferrioxamine on toxicity of 10µM 3-HK applied for 48 hours 
from 9 DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test identified no significant 
protection at any concentration of desferrioxamine used.  
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4.7.5 3-Hydroxyanthranilic acid toxicity – effect of 
desferrioxamine 
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Figure 4.30 Effect of 1-100µM desferrioxamine on toxicity of 10µM 3-HAA applied for 48 
hours from 9 DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test identified no 
significant protection at any concentration of desferrioxamine used.  
 
4.7.6 5-Hydroxyanthranilic acid toxicity – effect of 
desferrioxamine 
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Figure 4.31 Effect of 1-100µM desferrioxamine on toxicity of 10µM 5-HAA applied for 48 
hours from 9 DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test identified no 
significant protection at any concentration of desferrioxamine used.  
  
134 
4.7.7 Effects of cycloheximide on 3-HK, 3-HAA and 5-HAA toxicity 
Cycloheximide at 0.05µg/ml also failed to provide protection against the effects 
of 3-HK, 3-HAA and 5-HAA (Figures 4.32, 4.33). It was therefore concluded that 
protein synthesis was not necessary for the mechanism of neuronal death caused 
by treatment with these compounds, suggesting that an inflammatory response 
leading to increased production of TNFα and subsequent activation of death 
receptor-mediated pathways was not involved in the mediation of neuronal 
death that was mediated by treatment with any of these compounds.  
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Figure 4.32 Effect of 0.05µg/ml cycloheximide on toxicity of 3-HK, 3-HAA and 5-HAA for 5 
hours at 9 DIV. Mean +/- SEM, n=4; ANOVA followed by Tukey’s test identified no significant 
protection by cycloheximide co-application against the neurotoxicity of any of the 
compounds tested.  
 
 
 
 
135 
 
 
  
 
  
 
  
Figure 4.33 Effects of (A, B) 100µM 3-HK, (C, D) 100µM 3-HAA and (E, F) 100µM 5-HAA 
applied for 5 hours at 9 DIV on CGN morphology at 10 DIV. Effects shown with (B, D, F) and 
without (A, C, E) co-applied 0.05µg/ml cycloheximide. Bars = 50µm. Co-application of 
cycloheximide caused no reduction in damage due to treatment with any of the compounds 
tested.  
 
The co-application of cycloheximide at 0.05µg/ml was not protective against the 
neurotoxic effects of 3-HK, 3-HAA or 5-HAA, with morphological images clearly 
showing no alteration in the extent of CGN death induced by treating with these 
compounds in either the presence or absence of cycloheximide (Figure 4.33).  
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4.7.8 3-Hydroxykynurenine – p38 phosphorylation 
Western blots revealed that 100µM 3-hydroxykynurenine caused phosphorylation 
of the p38 signalling protein (Figure 4.34), with activity raised over the period 
0.5 to 9 hours, although reduced to normal levels by 24 hours. The numbers of 
samples (n=2) however were insufficient for statistical analysis of densitometric 
data (Figure 4.35).  
Figure 4.34 Representative blots of p38 and phosphorylated p38 (pp38) in samples from 
cultures treated with 100µM 3-HK for different time periods: C = control, 0.5 = 0.5 hours, 1 = 
1 hour, 2 = 2 hours, 5 = 5 hours, 9 = 9 hours, 24 = 24 hours. An increase in p38 
phosphorylation at 0.5 and 1 hours is evident in this sample blot.  
 
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
C 0.5 1 2 5 9 24
In
te
ns
ity
 
(a
rb
itr
ar
y 
un
its
)
Figure 4.35 Quantification of phosphorylation of p38 in samples from cultures treated with 
100µM 3-HK for different time periods: C = control, 0.5 = 0.5 hours, 1 = 1 hour, 2 = 2 hours, 5 
= 5 hours, 9 = 9 hours, 24 = 24 hours. Mean value of samples taken from two separate 
experiments.  An increase in p38 phosphorylation at 0.5 to 5 hours is evident.  
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4.7.9 3-Hydroxykynurenine – caspase-3 activation 
No increase in caspase-3 activation was seen in Western blots of samples treated 
with 100µM 3-HK (Figures 4.36, 4.37). This finding suggests that p38 activation in 
these neurones leads to activation of an alternative route to cell death, possibly 
activation of caspase-6 or -7.  
Figure 4.36 Representative blots of activated and non-activated caspase-3 in samples from 
cultures treated with 100µM 3-HK for different time periods: C = control, 0.5 = 0.5 hours, 1 = 
1 hour, 2 = 2 hours, 5 = 5 hours, 9 = 9 hours, 24 = 24 hours, S = 1µM staurosporine for 6 
hours at 9 DIV (positive control). No increase in caspase-3 activation is seen in this blot due 
to 3-HK treatment, although a staurosporine-induced increase is apparent.  
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Figure 4.37 Quantification of caspase-3 activation in samples from cultures treated with 
100µM 3-HK for different time periods: C = control, 0.5 = 0.5 hours, 1 = 1 hour, 2 = 2 hours, 5 
= 5 hours, 9 = 9 hours, 24 = 24 hours, S = 1µM staurosporine for 6 hours at 9 DIV (positive 
control). Mean value of samples taken from two separate experiments. No increase in 
caspase-3 activation is seen due to 3-HK treatment, although a staurosporine-induced 
increase is apparent.  
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4.7.10 5-Hydroxyanthranilic acid – p38 phosphorylation 
There was evidence that treatment with 100µM 5-HAA caused phosphorylation of 
the p38 signalling protein in CGNs, with a rise in activity over the period of 0.5 
to 9 hours after exposure to 5-HAA (Figure 4.38), although the numbers were 
insufficient for statistical analysis of densitometric data (Figure 4.39).  
Figure 4.38 Representative blots of p38 and phosphorylated p38 (pp38) in samples from 
cultures treated with 100µM 5-HAA for different time periods: C = control, 0.5 = 0.5 hours, 1 
= 1 hour, 2 = 2 hours, 5 = 5 hours, 9 = 9 hours, 24 = 24 hours. An increase in p38 
phosphorylation at 0.5 to 9 hours is evident in this sample blot.  
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Figure 4.39 Quantification of phosphorylation of p38 in samples from cultures treated with 
100µM 5-HAA for different time periods: C = control, 0.5 = 0.5 hours, 1 = 1 hour, 2 = 2 hours, 
5 = 5 hours, 9 = 9 hours, 24 = 24 hours. Mean value of samples taken from two separate 
experiments. An increase in p38 phosphorylation at 0.5 and 1 hours is evident.  
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4.7.11 5-Hydroxyanthranilic acid – caspase-3 activation  
Treatment with 100µM 5-HAA did not lead to an increase in caspase-3 activation 
(Figures 4.40, 4.41), a finding again indicating that p38 activation in CGNs in our 
system leads to an alternative route to cell death.  
Figure 4.40 Representative blots of activated and non-activated caspase-3 in samples from 
cultures treated with 100µM 5-HAA for different time periods: C = control, 0.5 = 0.5 hours, 1 
= 1 hour, 2 = 2 hours, 5 = 5 hours, 9 = 9 hours, 24 = 24 hours, S = 1µM staurosporine for 6 
hours at 9 DIV (positive control). No increase in caspase-3 activation is seen in this blot due 
to 5-HAA treatment, although a staurosporine-induced increase is apparent.  
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
C 0.5 1 2 5 9 24 S
In
te
ns
ity
 
(a
rb
itr
ar
y 
un
its
)
 
Figure 4.41 Quantification of caspase-3 activation in samples from cultures treated with 
100µM 5-HAA for different time periods: C = control, 0.5 = 0.5 hours, 1 = 1 hour, 2 = 2 hours, 
5 = 5 hours, 9 = 9 hours, 24 = 24 hours, S = 1µM staurosporine for 6 hours at 9 DIV (positive 
control). Mean value of samples taken from two separate experiments. No increase in 
caspase-3 activation is seen due to 5-HAA treatment, although a staurosporine-induced 
increase is apparent.  
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4.7.12 3-Hydroxykynurenine – p38 phosphorylation (ICC) 
The activation of p38 in CGNs exposed to 3-HK for 0.5 to 5 hours was also 
investigated immunocyctochemically by staining with antibodies raised to both 
p38 and phosphorylated p38 (Figure 4.42). This was successful to a limited 
extent, but it was not as effective as Western blotting and therefore was not 
continued beyond a pilot study.  
  
 
  
Figure 4.42 ICC staining of CGNs with antibody against p38 (A, C) and phosphorylated p38 
(B, D) in untreated cultures (A, B) and cultures treated with 100µM 3-HK for 1 hour (C, D). 
Bars = 100µm. Staining for p38 can be seen in both treated and untreated cultures, with 
positive staining for phosphorylated p38 visible in treated CGNs.  
 
Both treated and untreated cultures show positive staining for non-activated p38 
(Figure 4.42A and C). Untreated cultures were negative for phosphorylated p38 
(Figure 4.42B), whereas there was occasional positive staining in cultures 
treated with 3-HK (Figure 4.42D).  
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4.8 Effect of altering ratios of anthranilic acid and 3-
hydroxyanthranilic acid concentrations 
4.8.1 Anthranilic acid and 3-hydroxyanthranilic acid ratios 
As previously described, an association between an increased ratio of anthranilic 
acid to 3-HAA has been demonstrated in stroke patients (Darlington et al., 
2007); the effect of directly altering the ration of exogenous anthranilic acid to 
3-HAA was therefore studied. Increasing the ratio of anthranilic acid to 3-
hydroxyanthranilic acid did not provide a significant attenuation of 3-
hydroxyanthranilic acid toxicity (Figure 4.43). When the concentration of 
anthranilic acid was increased, a slight additive toxic effect was noted, a finding 
in keeping with earlier studies of the effect of anthranilic acid applied alone 
(Figure 4.19). A similar result was seen if the experiment was performed in 
medium containing 25mM glucose.  
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Figure 4.43 Effect of 100nM-10µM anthranilic acid on the toxicity of 100nM-10µM 3-HAA for 5 
hours at 9 DIV. Mean +/- SEM, n=4-7. No protective effect is seen on 3-HAA toxicity if 
anthranilic acid is co-applied, indicating that an increased anthranilic acid-3HAA ration is 
not protective against 3-HAA toxicity in CGNs. It therefore appears most unlikely that an 
increased ration of anthranilic acid to 3-HAA provides any protective function in neurones.  
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4.9 Discussion of glutamate, NMDA, 3-NPA and OGD 
results 
4.9.1 Glutamate neurotoxicity 
Excessive glutamate exposure has long been recognised as a source of neurotoxic 
damage via excitotoxicity, which mediates damage by causing over-stimulation 
of neurones with excitatory amino acids (Olney and de Gubareff, 1978). Hypoxia 
or ischaemia trigger release of intracellular glutamate, bringing the glutamate 
concentration to high micromolar or millimolar levels, with excessive glutamate 
(100µM) destroying neurones after only 5 minutes exposure (Choi and Rothman, 
1990). Taken together, these factors explain why glutamate-mediated 
excitotoxicity following ischaemia results in a much more rapid onset of cell 
death in the CNS compared to other regions. It also accounts for the regional 
differences in sensitivity to ischaemia seen within the brain, such as the 
hippocampal CA1 region and dorsolateral striatum (Sims and Zaidan, 1995).  
Glutamate treatment in cultured mouse CGNs increased levels of cleaved 
collapsin response mediator protein 3 (CRMP-3), prevented by calpain inhibitors 
or small interfering RNA strands that down-regulated CRMP-3 production (Hou et 
al., 2006). It was also determined that CRMP-3 was normally predominantly 
cytoplasmic, whereas in glutamate-treated neurones, CRMP was mainly nuclear 
(Hou et al., 2006).  
Damage due to glutamate increases proportional to concentration due to the 
greater excitotoxic effect and calcium influx magnitude, with resultant loss of 
mitochondrial calcium regulation and damage to plasma membrane calcium 
pumps. Therefore the dose-response effect of glutamate was examined, which 
produced a series of results over a range of 1µM to 10mM glutamate, 
demonstrating an increasing degree of neurotoxicity up to a maximum reached 
at 5mM (with approximately 70% cell death).  
Cultures maintained in 25mM KCl-containing medium and then switched to 5mM 
KCl medium at 7 DIV for 48 hours prior to glutamate application were examined 
to assess whether lowering the KCl concentration to a non-depolarising level 
increased vulnerability of CGNs to glutamate. Higher levels of cell death were 
seen over a range of glutamate concentrations (50µM to 1mM), although the high 
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degree of background cell death (CGNs switched to 5mM KCl but untreated with 
glutamate suffered over 50% death relative to controls maintained in 25mM KCl 
throughout) overshadowed the additional damage due to glutamate. 
Nevertheless, the apparent maximum level in our system for glutamate-induced 
damage (70% cell death) was reached by 100µM glutamate, with no further 
increase up to 1mM glutamate: a lower maximally toxic dose than was seen in 
CGNs in 25mM KCl.  
Co-application of 0.05µg/ml cycloheximide did not affect the neurotoxicity of 
100µM glutamate applied for 24 hours, consistent with the findings of Dessi et 
al. in 1993, who demonstrated that glutamate neurotoxicity in CGNs was not 
blocked by co-application of 100µg/ml cycloheximide, or associated with DNA 
fragmentation. The cycloheximide dose initially selected (0.1µg/ml) had been 
shown to prevent caspase-3 activation in rat neonatal CGNs (Morán et al., 1999), 
but this dose damaged CGNs in our system; hence the lower concentration of 
0.05µg/ml was preferred. The reason for this toxicity was uncertain: it is 
unlikely that the exposure time of 24 hours was relevant, as this had been used 
previously (Morán et al., 1999).  
Glutamate toxicity evidently involves activation of more than one cell death 
mechanism (Fatokun et al., 2008a).  Exposure of rat cortical neurones to 100µM 
glutamate for 5 minutes caused neurotoxicity due to necrosis (48% versus 15% in 
controls) and apoptosis (14% versus 8% in controls), caused an increase in cyclic 
GMP (a marker of endogenous NO formation) and could be blocked by the NMDA 
receptor antagonist APV at 100µM or by the NOS inhibitor N-nitro-L-arginine 
methyl ester (NAME). The neurotoxic effects induced by glutamate were 
paralleled by reductions in ATP levels 24 hours post-glutamate and it was also 
shown that glutamate affected mitochondrial respiratory chain complex 
enzymes. Although no alterations were seen to the activity of either NADH-CoQ 
reductase or cytochrome c oxidase, a significant reduction in succinate-
cytochrome c reductase was seen, with levels of NADH also reduced (Delgado-
Esteban et al., 2000).  
Five to 60 minutes glutamate treatment resulted in upregulation of p38 
expression in neonatal rat CGNs, with toxicity inhibited by the specific p38 
inhibitor SB203580. The increased p38 expression was shown to be calcium-
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dependent, as it was blocked by pre-treating with 5mM EGTA (ethylene glycol 
tetra-acetic acid) and replicated by the calcium ionophore A23187. Pre-
treatment with verapamil or nifedipine was not protective however, suggesting 
L-type voltage-gated calcium channels are not involved in p38 induction by 
glutamate (Kawasaki et al., 1997). Blockade of NMDA receptors with AP5 caused 
a dose-dependant reduction in p38 activation, whilst NMDA itself was also shown 
to increase p38 expression (Kawasaki et al., 1997). Glutamate-induced 
excitotoxicity has also been linked to p38 activity in neonatal rat cerebral cortex 
in vivo (Rivera-Cervantes et al., 2004).  
As the greatest part of glutamate-mediated neurotoxicity is mediated by the 
NMDA receptor and damage via this receptor was of most interest, it was 
necessary to establish a dose of this compound that provided an equivalent 
degree of excitotoxicity to 50-100µM glutamate. An equal degree of 
neurotoxicity to 100µM glutamate for 24 hours was achieved using 300µM NMDA. 
As with glutamate, this insult was not prevented by addition of 0.05µg/ml 
cycloheximide, indicating little dependence on protein expression to induce 
neurotoxicity.  
4.9.2 3-NPA neurotoxicity 
The excitotoxin and mitochondrial poison 3-NPA has been used to explore 
neurotoxicity in CGNs in several studies (Hassel and Bråthe, 2000, Olsen et al., 
1999, Weller and Paul, 1993). 3-Nitropropionic acid was shown to exert 
neurotoxicity by NMDA receptor activation and calcium influx, as blockade with 
MK-801 caused significant reduction in both neuronal death and the associated 
calcium influx, although did not provide complete protection when the 
treatment period was increased from 3 to 24 hours (Olsen et al., 1999). 
Additionally, 3-NPA acts to inhibit succinate dehydrogenase (due to its close 
structural resemblance to succinic acid), causing a dose-related reduction in 
activity and an associated reduction in neurone (although not astrocyte) viability 
(Alexi et al., 1998, Olsen et al., 1999).  
The first step in our investigation of 3-NPA’s neurotoxic action on CGNs was to 
establish that the toxicity was concentration-dependent, as reported in previous 
work with cultured rat CGNs (Weller and Paul, 1993, Fink et al., 1996, Olsen et 
al., 1999). This was demonstrated over a range of 1µM to 10mM, with the 
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maximum effect (approximately 90% cell death) reached at 5mM. As with 
glutamate and NMDA, co-application of 0.05µg/ml cycloheximide with 3-NPA did 
not affect its ability to induce neurotoxic damage.  
Neurones from different regions of embryonic rat brain were found by Fink and 
colleagues to differ in their sensitivity to 3-NPA, with cerebellar neurones less 
sensitive than hypothalamic or hippocampal neurones. The reason for this 
apparent lack of sensitivity was not however a lack of sufficiently matured NMDA 
receptors, as blockade with MK-801 (but not kynurenic acid) was effective in 
significantly reducing 3-NPA-mediated toxicity in striatal neurones in this study 
(Fink et al., 1996). 3-Nitropropionic acid toxicity was also reduced by the 
presence of 20mM glucose, a protective effect not mediated against glutamate 
toxicity (Fink et al., 1996). Our findings, with 3-NPA used as a toxic insult at 11 
DIV in medium with 5.5mM and 25mM glucose, showed a slight but non-
significant decrease in 3-NPA toxicity in the higher glucose concentration.  
It has been suggested that the interaction between the NMDA receptor-mediated 
and the mitochondrial poison actions of 3-NPA may combine to generate a 
‘lethal triplet’ of actions, which accentuates excitotoxicity, oxidative stress and 
metabolic compromise (Alexi et al., 1998). Certainly, the inhibition of succinate 
dehydrogenase will reduce ATP formation, reducing the sodium-calcium 
exchange pump’s ability to remove excess calcium and will increase ROS 
generation in the mitochondria. Both of these effects will hamper the neurone’s 
ability to cope with the effects of NMDA receptor activation and hence 3-NPA 
provides a model of a simultaneously excitotoxic and oxidative insult.  
4.9.3 OGD-induced neurotoxicity 
Oxygen-glucose deprivation has been used as a more representative model for 
ischaemia than hypoxia alone, although it does not fully characterise an 
ischaemic episode. Anoxia alone causes depolarisation of neuronal membranes 
due to increased conductance of potassium channels, with depolarisation 
enhanced during OGD by reduced ATP formation and consequent failure of the 
Na,K-ATPase pump (Martin et al., 1994). In addition to increasing extracellular 
glutamate levels, this causes rises in intracellular levels of sodium, chloride and 
calcium.  
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The use of OGD as a toxic insult in our cultures necessitated considerable 
method development, with an initial trial of hypoxia only, followed by the 
introduction of a glucose-free buffer which could be applied to CGNs without 
causing cell death due to buffer toxicity. A suitable buffer formula was obtained 
from Dr. Joseph Tauskela (Tauskela et al., 2003) and a gas mixture of 95% 
nitrogen/5% carbon dioxide replaced the normoxic environment. The gas mixture 
and buffer were assayed to confirm accuracy of composition and that the 
procedure was effective in reducing pO2 (by approximately 40%) in the OGD 
buffer, this latter finding comparable to previously published work (Scorziello et 
al., 2001). Following this, the optimum period of OGD to effect neurotoxic 
damage was determined, with most consistent results achieved with 5 hours’ 
exposure, a finding consistent with previous demonstrations of OGD toxicity in 
neonatal rat CGNs of ~25% death after 3 hours and ~60% death after 6 hours 
(Wick et al., 2002).  
The NMDA receptor antagonist MK-801, the NMDA and AMPA receptor antagonist 
kynurenic acid and the calcium channel blocker nifedipine failed to significantly 
protect against damage due to OGD for 5 hours, despite using different 
concentrations for each agent. Involvement of protein synthesis in the mediation 
of damage by OGD toxicity was also investigated by adding cycloheximide during 
OGD treatment, during the 24 hour period between exposure and assay (the 
equivalent of the reperfusion period following ischaemia) and for both of these 
periods. However, cycloheximide did not protect in any of these periods, 
indicating that increased production of cell death signalling proteins (such as 
Fas) is not involved. This does not exclude the involvement of apoptosis or the 
possibility that apoptotic mechanisms were activated and superseded by 
necrotic cell death. Certainly, in rat CGN cultures a shorter duration of OGD (90 
minutes) induced cell death via both pathways, with notable secondary necrosis 
(Kalda et al., 1998).  
Considerable evidence links NMDA receptor activation to OGD-related 
neurotoxicity: OGD damage to cultured hippocampal neurones depends on 
synaptic connections, with attenuation of damage by NMDA receptor antagonists 
and high-dose magnesium, although this protection may be limited to preventing 
damage from mild to moderate severity OGD (Choi and Rothman, 1990). 
Hypoxia–induced loss of evoked field potentials in rat dentate gyrus slices, 
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attenuated by removal of extracellular calcium has also been reported (Kass and 
Lipton, 1982). Application of OGD to rat cerebral cortical neurones was not 
significantly reduced by the AMPA receptor antagonist CNQX, but was reduced by 
MK-801, with co-application of MK-801 and CNQX causing a reduction in cell 
death equal to that produced by MK-801 alone. These reductions in cell death 
were paralleled by reduced calpain expression (Tauskela et al., 2001).  
N-methyl-D-aspartate and kainate receptor channels change in response to 
hypoxia. In foetal guinea pig neurones, NMDA receptors demonstrated enhanced 
MK-801 binding when subjected to hypoxia and kainate channel desensitisation. 
This led to prolonged sodium influx and contributed to increased calcium influx 
due to greater sodium-calcium exchange (Mishra and Delivoria-Papadopoulos, 
1999). Increased calcium influx was also mediated via NMDA receptors in 
response to NMDA or glutamate stimulation. This altered receptor function may 
result from cycles between phosphorylation and dephosphorylation (Mishra and 
Delivoria-Papadopoulos, 1999). Another aspect of glutamate involvement in 
OGD-related damage to CGNs concerned blockade of metabotropic glutamate 
receptors, which attenuated damage induced by OGD in neonatal rat CGNs 
(Kalda et al., 2000).  
Scorziello and co-workers (2001) undertook a comparison of effects of OGD on 
neonatal rat CGNs and embryonic rat cortical neurones. After 1 hour of OGD, 
CGNs were unaffected but by 2 hours showed significant mitochondrial damage 
(assayed by MTT production), reduced ATP formation and increased lipid 
peroxidation (assayed by malondialdehyde production) were evident (Scorziello 
et al., 2001). Additionally, lipid peroxidation and LDH release in CGNs were 
increased by 24 hours reoxygenation and commenced prior to reoxygenation. By 
comparison, both 1 and 2 hours’ OGD caused cell death in cortical neurones, 
with lipid peroxidation again made more severe by 24 hours of reoxygenation. 
However, cortical neurones did not show LDH release following either 1 or 2 
hours’ OGD, with or without subsequent reoxygenation, nor was ATP production 
reduced.  
Further evidence of mitochondrial damage in neurotoxicity induced in neonatal 
rat CGNs by OGD was demonstrated by the use of melatonin, which caused a 
dose-dependent reduction in cytochrome c release, caspase-3 activation and 
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maintenance of mitochondrial membrane potential (Han et al., 2006). Two hours 
of OGD with 24 hours reoxygenation in CGNs has also been shown to cause a 
calcium-dependent increase in nitric oxide synthase activity and consequent 
nitric oxide production (Scorziello et al., 2004). Nitric oxide synthase inhibitors 
or intracellular Ca2+ removal were partially protective against this OGD-induced 
cell death, although a nitric oxide donor abolished the effect (Scorziello et al., 
2004).  
4.10 Discussion of findings concerning kynurenine 
pathway compounds and glucose 
4.10.1 Increased glucose concentration 
Hyperglycaemia or raised exogenous glucose causes a variety of effects both in 
vivo and in vitro, with increased neurotoxic effects seen due to hyperglycaemia 
directly and also heightened vulnerability to oxidative damage (see section 
1.3.6).  
Hyperglycaemia in vivo enhances vulnerability to ischaemia, with ischaemia in 
hyperglycaemic animals demonstrated to cause significant increases in 
mitochondrial cytochrome c release into the cytosol at 0.5, 1 or 3 hours of 
reperfusion, positive caspase-3 staining after 1 and 3 hours and positive TUNEL 
staining after 3 hours (Li et al., 2001, Muranyi et al., 2003). There was also 
correlation between staining for cytochrome c release and increased TUNEL-
positive staining compared to normoglycaemic animals subjected to ischaemia 
(Li et al., 2001, Muranyi et al., 2003). Another study of ischaemia in rats with 
streptozotocin-induced diabetes mellitus found that a high-dose of insulin was 
effective in reducing infarct volume significantly in hyperglycaemic animals (Rizk 
et al., 2006). It should be noted however, that insulin can induce AMPA receptor 
encocytosis (Ahmadian et al., 2004) and GABA receptor recruitment (Wan et al., 
1997), so these effects may not be entirely due to alterations in glucose levels.  
Transient ischaemia (30 minutes of MCA occlusion) in rats with streptozotocin-
induced diabetes caused more extensive damage 3 and 6 hours after occlusion in 
diabetic than non-diabetic rats (Muranyi et al., 2003). Examination at 7 days 
post-occlusion showed that damage had continued to develop beyond 6 hours’ 
reperfusion in non-diabetic but not diabetic animals, although infarct volume in 
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diabetic animals was significantly larger (39% vs. 16%), therefore not only was 
ischaemic damage in diabetic animals more extensive, but onset was also more 
rapid (Muranyi et al., 2003).  
Comparable in vitro data exist: a study of the effects of increased glucose on 
embryonic rat dorsal root ganglion (DRG) neurones cultured in medium with 
25mM glucose in which ‘hyperglycaemia’ was induced by raising the 
concentration to 45mM) found that 45mM glucose caused a range of effects. 
These included: increased NADH oxidase activity, increased ROS generation, 
mitochondrial swelling and disruption of inner cristae, caspase-3 cleavage and 
TUNEL staining, with similar levels of neuronal death induced by increased 
glucose exposure for 6 or 24 hours (Vincent et al., 2005). The exposure to high 
glucose led to increased expression of SOD and more markedly of catalase 
(Vincent et al., 2005).  
Increased apoptosis was evident in neuroblastomal cells (SH-SY5Y), hippocampal 
neurones and primary DRG neurones due to hyperosmolar conditions caused by 
glucose or mannitol (Pittenger et al., 1997, Sima, 2003). Glucose has an effect 
beyond hyperosmolarity and in DRG neurones of diabetic rats a progressive 
increase in intracellular calcium is evident (Ristic et al., 1996). A possible 
mechanism for hyperglycaemic neurotoxicity is that increased glycation of 
axonal structural proteins (tubulin, neurofilament and actin) leads to axonal 
atrophy and degeneration. Additionally, increased glucose levels induce 
alterations in redox status, dysregulation of glutathione synthesis and glucose 
autoxidation, generating ROS (Sima, 2003).  
A study of cultured rat cortical neurones, returned to medium with 5.5mM 
glucose, 20mM D-glucose or 20-mM L-glucose following glutamate application 
revealed that glutamate-induced neurotoxic effects (necrosis and apoptosis) 
were significant in control cultures and those with added L-glucose but not in 
neurones replenished with medium containing 20mM D-glucose (Delgado-Esteban 
et al., 2000). The reduction in succinate-cytochrome c reductase and NADH 
levels by glutamate were abolished by D-glucose supplementation post-
glutamate. The protective effect of D-glucose was unlikely to be due to ability to 
scavenge peroxynitrite, as L-glucose should also have had this ability (Delgado-
Esteban et al., 2000).  
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Activation of NMDA receptors in neonatal rat CGNs by glutamate also caused a 
concentration-dependent increase in glucose uptake which increased from 2 DIV, 
reaching its maximum by 8 DIV and increases were also seen with kainate and 
AMPA receptor stimulation (Minervini et al., 1997).  
It is perhaps unsurprising that increasing the concentration of exogenous glucose 
in this study failed to cause any obvious damage due to increased oxidative 
activity. It has been shown previously in cultured mouse cortical neurones that 
that rate of glucose oxidation becomes saturated when the extracellular 
concentration of glucose reaches 1.4mM, with no further rise when this 
concentration was increased up to 16.7mM in the study (Gorus et al., 1984). 
Using radio-labelled 2-deoxyglucose in neonatal rat CGNs to study uptake rates, 
saturation was found to occur at 4mM (Minervini et al., 1997). 2-Deoxyglucose 
undergoes phosphorylation, the rate-limiting step of glucose utilisation, and 
therefore makes a good model for this, although it should be noted that its 
phosphorylation uses ATP rather than generates it (Whitesell et al., 1995).  
However, as with the in vivo studies, the absence of any obvious increase in cell 
death does not exclude the possibility of hyperglycaemia (or an in vitro 
equivalent) causing an increased underlying vulnerability to subsequent damage 
from a neurotoxic stimulus.  
4.10.2 Kynurenine pathway compounds 
The finding that tryptophan and a number of kynurenine pathway metabolites 
were more neurotoxic in CGNs maintained in a higher glucose environment 
raised the question of whether this was due to elevation in glucose during 
plating and maintenance, or during treatment. To answer this, further studies 
were carried out: the glucose concentration for cultures plated in 5.5mM glucose 
was raised to 25mM in treatment medium and vice versa for cultures plated in 
25mM glucose. An increased toxicity when the treatment medium contained 
25mM glucose, applied to CGNs plated in 5mM glucose was observed, although 
the disparity was less clear than when using CGNs plated in 25mM glucose, with 
significance lost for several of the comparisons. This suggests that the 
potentiated toxicity was mainly mediated by the increased glucose in the 
treatment medium, although it was still uncertain whether this was due to an 
osmotic effect or its effects on cellular metabolism.  
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To answer this, a compound capable of mimicking the osmotic actions of the 
supplementary D-glucose, but without metabolic effects was required. Mannitol 
has been previously used (Vincent et al., 2005), although this was not a suitable 
replacement in our study since it protects against oxidative stress by scavenging 
hydroxyl radical (Ohkuna et al., 1998). Alternatives included a variety of 
modified forms of D-glucose, such as L-glucose, 2-deoxyglucose and 3-O-methyl-
D-glucose, although there were clear indications as to which compound would 
provide the most suitable model for metabolically inert D-glucose.  
Application of D-glucose to cultured CGNs leads to rapid uptake via GLUT1 and 
GLUT3 receptors (Maher et al., 1994). This D-glucose uptake effect was not 
mimicked by L-glucose in a study using cerebellar slice cultures (Renkawek et 
al., 1978). A study of the hyperosmotic stimulation of neuromuscular junction 
membranes found that the action of D-glucose was mimicked by either 2-
deoxyglucose or 3-O-methyl-D-glucose, but not by L-glucose (Shimoni et al., 
1978). The use of 2-deoxyglucose was unsuitable however, as it undergoes 
phosphorylation (the first stage of D-glucose metabolism, although it is not 
metabolised further), the metabolic step that rate-limits the utilisation of D-
glucose (Heidenreich et al., 1989). Furthermore, 2-deoxyglucose has been shown 
to precondition hippocampal neurones against subsequent glutamate treatment 
(Lee et al., 1999). For both of these reasons, 2-deoxyglucose was considered not 
to be an appropriate osmotic substitute for D-glucose. 3-O-methyl-D-glucose was 
selected as it is a metabolically inert compound which accurately mimics 
patterns of D-glucose uptake and retention and hence the osmotic effects of D-
glucose (Maher et al., 1996, Whitesell et al., 1995), and has no known anti-
oxidative or neuroprotective properties.  
The comparison of the neurotoxicity of tryptophan and selected kynurenine 
pathway compounds in treatment medium supplemented with either 19.5mM D-
glucose or 19.5mM 3-O-methyl-D-glucose demonstrated no significant difference, 
indicating that neurotoxicity was not potentiated by metabolism or utilisation of 
the increased glucose in the treatment medium. Having thus demonstrated a 
non-metabolic effect, it was concluded that the potentiation was primarily 
mediated by osmotic effects of the additional D-glucose in treatment medium, 
although plating and maintenance of CGNs in 25mM glucose contributed slightly.  
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A further possible effect of the additional glucose was that metabolism of the 
kynurenine pathway compounds themselves was altered. High-performance 
liquid chromatography (HPLC) was therefore carried out to study the metabolism 
of the compounds. It should be noted at this point that analysis of QA and 
picolinic acid levels would have been highly desirable, but was not possible due 
to technical limitations regarding which compounds could be accurately assayed 
using our equipment. The addition of 3-HK and 3-HAA, the toxicity of which had 
not been potentiated by higher glucose, was used to study whether these 
compounds were substantially metabolised during a 5 hour exposure (which was 
the secondary reason for the study of the other compounds by HPLC). No 
difference in the metabolism of any of the compounds due to the presence of a 
higher concentration of glucose was observed, nor was there any sign of 
extensive metabolic breakdown of any of the compounds: although a substantial 
drop in the concentrations of 3-HK and 3-HAA were seen, these did not alter 
between 5 and 9 hours, suggesting that this was due to compound instability and 
breakdown on addition to the culture medium rather than an ongoing metabolic 
effect. This was consistent with the other experiments in the study and indeed 
gave reassurance that treatments of 5 hours duration were treatments with the 
compound applied. The study was therefore sufficient with two sets of samples, 
as it was unlikely that any further relevant information would be gained from 
further repeats. A possible explanation for the lack of identifiable metabolism 
during the time periods studied was the absence of glial cells from the culture 
preparation, so it is possible that these findings would be at variance with 
equivalent in vivo studies.  
Concerning the neurotoxic effects of tryptophan and its metabolites themselves, 
3-HK and 3-HAA have been shown to cause a dose-related reduction in cell 
survival in cultured neurones, but no effect was seen with AA, kynurenine, QA or 
xanthurenic acid over the same range of concentrations (1-100µM) and time 
period (48 hours) (Okuda et al., 1998). Our findings for tryptophan, kynurenine, 
QA, kynurenic acid, anthranilic acid and picolinic acid are considered initially.  
Tryptophan produced a neurotoxic effect that was time-dependent but not 
concentration-dependent and was potentiated by 25mM glucose when applied 
for 5 hours. High performance liquid chromatography analysis did not reveal any 
reduction in tryptophan over the course of 1-9 hours, indicating that the toxic 
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effects were due to tryptophan itself rather than its metabolites. An in vivo 
study of induced hypertryptophanaemia in adult Wistar rats produced plasma 
tryptophan levels ten times higher than normal and demonstrated that the 
hypertryptophanaemia increased tryptophan levels in cortical neural tissue one 
hour after subcutaneous tryptophan injection. This was associated with a 
reduction in pyruvate kinase activity of ~20%, a finding reproduced in vitro, but 
prevented by co-application of alanine (which alone did not affect pyruvate 
kinase activity)(Feksa et al., 2003). The question arises of whether the inhibitory 
effect was due to the tryptophan itself, or to a product of its metabolism, but 
there was no significant difference in pyruvate kinase inhibition between tissues 
samples taken 1 hour and 12 hours after tryptophan injection (Feksa et al., 
2003).  
Pyruvate can reduce neurotoxicity induced by H2O2, in addition to an inhibition 
of glycolysis, in mouse neuroblastoma (N-2A) cells: preincubating cultures with 
pyruvate at concentrations of 1-10mM for 1 hour prior to addition of H2O2 caused 
a significant reduction in H2O2–mediated damage (Mazzio and Soliman, 2003). 
The inhibition of pyruvate kinase by excess tryptophan may have contributed to 
the potentiation due to higher glucose concentrations. In the current study, the 
potentiation was largely due to the higher glucose concentration in treatment 
medium, but a greater degree of damage was seen when CGNs were plated and 
maintained in 25mM glucose: the excess tryptophan may therefore have 
augmented any background oxidative stress, which although not sufficient to 
cause cell death alone, was more damaging due to suppression of pyruvate 
kinase.  
Kynurenine caused a very similar neurotoxic effect to that seen with tryptophan, 
with a slight but not significant increase in toxicity over time. There was no 
significant increase with concentration or notable potentiation due to higher 
glucose levels when applied for 5 hours. In Huntington’s disease patients, 
increased levels of plasma kynurenine occur (Stoy et al., 2005) and cross the 
blood-brain barrier using the same neutral amino acid transporter as tryptophan 
(Fukui et al., 1991, Chiarugi et al., 1996). It is notable that although there was 
no significant metabolism of kynurenine in our study, other studies using 
injection of kynurenine into the striatum of adult rats in vivo, showed a 
significant reduction in radio-labelled kynurenine after 4 hours (Guidetti et al., 
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1995). A slight increase in kynurenic acid was also reported, suggesting the 
presence of kynurenine aminotransferase, which is known to be present in 
neonatal rat cerebral cortex (Rzeski et al., 2005).  
Establishing whether the neurotoxic effects of kynurenine in CGN cultures could 
be replicated in mixed neuronal and glial cultures would be an interesting future 
avenue of study, as kynurenine is known to significantly increase the expression 
of nerve growth factor (NGF) when applied to cultured mouse astroglial cells at 
micromolar concentrations (Dong-Ruyl et al., 1998). Also, given the previous 
findings relating to the metabolism of kynurenine in the striatum in vivo, it 
would be of interest to determine whether the relative lack of kynurenine 
metabolism seen in our system was due to absence of glial cells or to a regional 
variation.  
Quinolinic acid (QA) produced a time-dependent neurotoxic effect, but again 
without any concentration-response correlation. Quinolinic acid has long been 
recognised as a neurotoxin, with injection of QA at concentrations of 20nM or 
above into rat striatum in vivo producing an axon-sparing neurodegenerative 
lesion, the volume of which increased in proportion to the QA dose applied 
(Guidetti and Schwarcz, 1999).  
Intracerebral injection of 1µl of 34nM QA in vivo caused a transient increase in 
expression of c-Jun N-terminal kinase (JNK) and p38 in the core of the lesion, 
which were no longer evident at 24 hours, but which correlated with areas of 
subsequent cell death. TUNEL-positive cells were also identified, although there 
was no evidence of an increase in active caspase-3 expression (Ferrer et al., 
2001). Injection of QA also caused increased expression of mitogen-activated 
protein kinase (MAPK) in the penumbra of the resultant lesion, with increased 
MAPK expression associated with subsequent cell survival (Ferrer et al., 2001).  
Quinolinic acid neurotoxicity appears to be closely related to its known NMDA 
receptor agonist action and oxidative stress, with application to rat brain 
homogenates shown to cause a significant increase in lipid peroxidation, an 
effect lessened by co-application of kynurenic acid with QA, suggesting the 
effect was mediated by the NMDA receptor agonist action of QA (Rios and 
Santamaria, 1991).  
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A finding comparable to glutamate-induced mitochondrial damage was that QA 
neurotoxicity in rat hippocampus was significantly reduced by co-administration 
of the antioxidant melatonin and that QA-induced lipid peroxidation in rat brain 
homogenates was reduced in a dose-dependant manner by melatonin (Behan et 
al., 1999). A further link between QA and oxidative damage was evident 
following co-application of the free radical generator xanthine oxidase, which 
significantly potentiated QA neurotoxicity in rat hippocampus in vivo, but with 
only minor loss caused by either of the two compounds alone. Notably co-
application of kynurenic acid significantly reduced the toxicity of QA alone but 
not of QA and xanthine oxidase combined (Behan and Stone, 2002).  
The co-application of either APV,  MK-801, the NOS inhibitor nitroindazole or the 
poly(ADP-ribose) polymerase (PARP) inhibitor DPQ was effective in significantly 
reducing damage due to 10µM QA applied for 48 hours, but QA toxicity was not 
reduced by co-application of cyclosporine and the pan-caspase inhibitor Z-VAD-
fmk (Chiarugi et al., 2001). This reconfirms the links with NMDA receptor 
activation and oxidative stress, but further indicates that the cell death 
mechanism most likely to be involved in QA neurotoxicity is necrosis rather than 
apoptosis.  
Kynurenic acid caused less toxicity than was seen with the other compounds, 
with only prolonged exposure times causing damage, particularly in the presence 
of higher glucose concentrations, where osmotic effects will also contribute. The 
compound is more noted for possession of neuroprotective properties than 
neurotoxic ones, with the glutamate receptor antagonist properties of kynurenic 
acid have been used to protect against a variety of excitotoxic insults. Kynurenic 
acid protected adult rat dopaminergic subtantia nigra neurones against injection 
of 60nmoles of QA or 15nmoles of NMDA, with endogenous kynurenic acid 
generated by administering kynurenine with the kynureninase inhibitor 
nicotinylalanine, thus ensuring that an increased quantity of the administered 
kynurenine was converted into kynurenic acid (Miranda et al., 1997). Kynurenic 
acid was also shown to reduce infarct volume in neonatal rats subjected to left 
carotid artery occlusion, despite being applied after ischaemia was already of 
two hours’ duration (Andine et al., 1988).  
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Little has been published with regard to anthranilic acid as a potential 
neurotoxin, although one study has previously reported damaging effects on 
cultured insect neurones (Cerstiaens et al., 2003). This was not however 
reproduced in a study using cultured rat striatal neurones, where no toxicity 
occurred despite using concentrations up to 100µM and for 48 hours (Okuda et 
al., 1998). Although this is in contrast to our findings, there was no toxicity seen 
in the Okuda group’s 1998 study using the same concentration range and 
exposure time with kynurenine or QA either, suggesting that a substantial 
difference exists between these neurones and CGNs. Anthranilic acid caused 
neurotoxicity in a time-dependent but not concentration-related manner, with 
toxicity at 5 hours again potentiated by the use of higher glucose levels.  
Picolinic acid also demonstrated time-dependent neurotoxicity with a slight 
concentration-related effect at 1 hour. Picolinic acid has also been relatively 
little studied, although it has been linked with cerebral malaria in both clinical 
and animal studies (Medana et al., 2003, Clark et al., 2005). It is notable that 
while a significant effect on neuronal viability was not identified with picolinic 
acid alone, it did reduce QA neurotoxicity, although interestingly it does not 
affect excitation of neurones, in contrast to the protection given by kynurenic 
acid against QA (Jhamandas et al., 1990). A possible mechanism is via picolinic 
acid’s known action as a zinc chelator, as this has been shown to protect against 
excitotoxic and ischaemic damage with other compounds (Jhamandas et al., 
1998).  
This was also demonstrated in an in vivo study of the effect of QA on NADPH 
diaphorase-containing rat striatal neurones, where picolinic acid infusion 
protected the neurones against an otherwise neurotoxic dose of QA, while 
picolinic acid alone did not affect neuronal viability (Kalisch et al., 1994).  
The discovery of a significant switch over in the ratio of anthranilic acid to 3-
HAA in patients suffering from stroke, with an increased anthranilic acid to 3-
HAA, raised the question of what role this finding may play in the generation of 
the associated pathology (Darlington et al., 2007). To investigate this question, 
a series of combinations of anthranilic acid and 3-HAA were applied to CGNs for 
5 hours at 9 DIV, to examine whether this caused any significant alterations in 
neurotoxicity.  
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No protection was evident by an increased ratio of anthranilic acid to 3-HAA with 
a 3-HAA concentration range of 100nM to 10µM and with anthranilic acid 
concentrations ranging from 100nM to 100µM. There was a slight potentiation in 
toxicity, although this was predictable given the toxicity of anthranilic acid 
applications for 5 hours. This experiment was also performed in cultures plated 
and maintained in medium containing 25mM glucose, although results were the 
same as those found using 5.5mM glucose.  
4.10.3 Oxidative stress generation by kynurenine pathway 
compounds 
Treatment with 10µM-1mM 3-HK, 3-HAA or 5-HAA over 1 to 9 hours caused a 
time- and concentration-dependent neurotoxic effect. A previous study in 
cultured striatal neurones showed that an accumulation of intracellular 
peroxides and a significant reduction in viability resulted from application of 
1µM 3-HK 24 or 48 hours (Okuda et al., 1996). Co-application of catalase 
prevented peroxide accumulation and toxicity from 1-100µM 3-HK, but SOD had 
no protective effect; the iron chelating agent desferrioxamine reduced 3-HK 
toxicity in a concentration-dependent fashion. Allopurinol pre-treatment for 24 
hours was highly protective against 10µM 3-HK but was less effective against 
higher concentrations (Okuda et al., 1996).  
It has also been shown that 3-HK uptake was by large amino acid transporters in 
striatal neurones, as co-application of neutral amino acids or blockade of the 
sodium-dependant neutral amino acid uptake prevented 3-HK neurotoxicity. A 
dose-dependant reduction in tryptophan uptake occurred following 3-NK 
treatments, an effect not seen with 3-HAA, which is probably not taken up by 
the transporter (Okuda et al., 1998).  
3-Hydroxykynurenine in striatal neurones caused death with features of 
apoptosis, with cycloheximide or actinomycin-D almost entirely preventing 
neuronal death (Okuda et al., 1998). The neurotoxic effect involved generation 
of ROS. A range of antioxidants (ascorbic acid, 2,3,5,5-tetramethyl-pyridine-N-
oxide(TMPO), α-tocopherol, trolox) prevented neurotoxicity induced by 3-HK at 1 
and 10µM, although not 100µM and N-acetylcysteine was effective against all 
three concentrations: N-acetylcysteine is an effective scavenger of the hydroxyl 
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radical and to a lesser extent of hydrogen peroxide, but a poor scavenger of 
superoxide (Okuda et al., 1998).  
However, CGNs have been shown to be vulnerable to 3-HK, although less 
severely than striatal neurones, and with different characteristics to those 
identified by the Okuda group. As in striatal neurones and osteoblast cells 
(Fatokun et al., 2008b), co-application of catalase significantly reduced the 
neurotoxicity of 3-HK, whereas SOD co-application increased death; co-
application of SOD and catalase had the same effect as catalase alone. Although 
3-HK was shown to reduce tryptophan uptake through the neutral amino acid 
transporter, blockade of this transporter was not protective in CGNs, nor was 
there any protective effect seen with the pre-treatment of the cultures with 
xanthine oxidase inhibitors (Wei et al., 2000). Additionally, NMDA antagonists or 
the neurotrophic factors BDNF, neurotrophin-3 or neurotrophin-4 did not provide 
protection (Wei et al., 2000).  
3-Hydroxykynurenine, 3-HAA and 5-HAA were all capable of generating a 
concentration- and time-dependent neurotoxic effect, and therefore warranted 
investigation of the mechanisms involved. It has previously been shown that 3-
HK and 3-HAA are both capable of generating the ROS H2O2 and superoxide when 
added to phosphate buffer solution (Goldstein et al., 2000).  
Catalase caused a significant reduction in the neurotoxic effects of all three 
compounds, with a similar reduction in cell death for each. Superoxide 
dismutase failed to provide any protection, although neither was further cell 
death induced. Co-application of denatured superoxide and denatured catalase 
did not alter the toxicity of any of these compounds.  
Desferrioxamine has been used as a chelator of Fe2+ ions in a previous study of 
where addition of 1-100µM desferrioxamine provided significant dose-related 
protection to culture striatal neurones treated with 10µM 3-HK 48 hours (Okuda 
et al., 1996). Our initial trials using desferrioxamine (over the same 
concentration range) against 3-HK, 3-HAA and 5-HAA for 5 hours at 9 DIV did not 
produce a protective effect, hence the concentrations and exposure times of the 
previous study were replicated. Even under these circumstances however, there 
was no protection induced by desferrioxamine over a concentration range of 1-
100µM in our work.  
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It is perhaps not entirely surprising that desferrioxamine failed to protect 
against oxidative damage induced by 3-HK or 3-HAA, as it has been previously 
shown that the compounds can generate ROS alone. The chemical actions of 3-
HK and 3-HAA generate H2O2 and superoxide: either 3-HK or 3-HAA caused 
reduction of Cu2+ to Cu+, and of Fe3+ to Fe2+, in an environment with a 
physiological pH (Goldstein et al., 2000). These effects were not replicated by 
tryptophan, kynurenine, kynurenic acid, anthranilic acid, QA, nicotinic acid or 
xanthurenic acid, although xanthurenic acid caused reduction of Cu2+ to Cu+ only 
(Goldstein et al., 2000).  
A further aspect of the neurotoxicity induced by these three compounds of 
interest was whether or not the cell death they produced was dependent on 
protein synthesis. The levels of toxicity during treatments with the compounds 
for 5 hours at 9 DIV were not altered by addition of 0.05µg/ml cycloheximide, 
which would suggest that apoptotic mechanisms triggered by neuronal 
production of death proteins were not the major cause of cell death in CGNs. 
This was pursued folowing the findings of a previous study using striatal 
neurones, where chromatin condensation and protein synthesis were shown to 
be involved in cell death following 3-HK exposure (Okuda et al., 1996), although 
the responses of different neuronal types are not always consistent and indeed 
variations between striatal neurones and CGNs have been noted (Okuda et al., 
1998). Glutamate toxicity in CGNs has been shown not to be associated with DNA 
fragmentation (Dessi et al., 1993), although it was present in PC12 cells, again 
highlighting different responses to excitotoxicity between cell types.  
The finding that the neurotoxic effects of 3-HK, 3-HAA and 5-HAA are not 
primarily mediated through the action of superoxide is of interest when 
considering the possible cell death mechanisms involved. It has been 
demonstrated using neonatal rat CGNs that production of superoxide and 
molecular oxygen were associated with chromatin condensation and activation 
of caspases 3, 8 and 9, indicating apoptosis. In contrast, production of hydrogen 
peroxide caused no increase in any of these markers, while still producing 
comparable levels of cell death, suggesting a necrotic mechanism (Valencia and 
Morán, 2004).  
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Western blotting of protein extracted from CGNs subjected to 100µM 3-HK or 
100µM 5-HAA for 0.5 to 24 hours showed no increase in expression of activated 
caspase-3 in the present study. However, increases in phosphorylation of p38 
MAPK following both 3-HK and 5-HAA treatments were also observed. 
Phosphorylation of p38 MAPK has been reported in neurones exposed to 
glutamate or QA (Ferrer et al., 2001, Kawasaki et al., 1997), linking this 
signalling molecule and neuronal cell death induced by excitotoxic or oxidative 
stress stimuli. The current evidence of phosphorylation of this molecule by 3-HK 
and 5-HAA further strengthens this association.  
Application of 250µM 3-HK to human neuroblastoma SK-N-SH cells caused a 
significant increase in ERK1/2 phosphorylation between 0.5 and 2 hours’ 
exposure, returning to normal after 3 and 6 hours. Co-application of the ERK 
pathway inhibitor PD98059 caused a significant increase in cell death (Lee et al., 
2004). 3-Hydroxykynurenine caused a progressive loss of mitochondrial 
membrane potential over 3-12 hours, with release of cytochrome c from the 
mitochondrial matrix and associated activation of caspase-9 and activity of 
caspase-3: these effects were also exacerbated by PD98059 (Lee et al., 2004).  
In summary, it is clear that the metabolism of tryptophan causes the formation 
of a number of potentially significant neurotoxins, and that three of these (3-HK, 
3-HAA and 5-HAA) are capable of inducing extensive oxidative damage. The 
damage thus caused involves activation of cell death pathways, but does not 
depend on apoptotic processes to induce cell death.  
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5 Preconditioning 
5.1 Introduction 
Having established the suitability of our culture system for models of excitotoxic 
and oxidative neuronal damage, it was of interest to investigate the protection 
which could be provided against this damage by preconditioning. Initially, a 
relatively brief preconditioning period with a toxic insult applied 24 hours later 
was examined. Later work was concerned with investigating the protection 
provided by preconditioning neurones for a considerably longer period, with a 
toxic insult again applied 24 hours subsequent to preconditioning.  
 
 
Figure 5.1 Diagram representing protocol used for preconditioning with NMDA, 3-NPA and 
H2O2 at 8 DIV.  
 
The brief preconditioning regimen consisted of 6 hours treatment with NMDA 
(added to culture medium), after which medium was aspirated and replaced 
with fresh medium for 18 hours, then medium containing the toxic compound 
was applied for 24 hours. This model formed the basis for all studies using a 
brief period of preconditioning with NMDA, 3-NPA or H2O2.  
A small number of studies involved preconditioning at 12 DIV: in these 
experiments the same durations of treatment, recovery and toxin application 
were used, with the protocol commencing at 12 DIV instead of 8 DIV. In studies 
with shorter preconditioning treatments, the relevant preconditioning periods 
commenced at the same point as their equivalents in the 6 hour preconditioning 
studies.  
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The choice of 8 DIV and the 6 hour period of preconditioning were based on 
extensive review of the previously published NMDA preconditioning protocols and 
represented the times most likely to be successful with CGN cultures (Chuang et 
al., 1992, Damschroder-Williams et al., 1998, Lipsky et al., 2001). Some 
difficulties were encountered in extending the range of insults for which 
protection by NMDA preconditioning was effective, therefore the alternative of 
preconditioning at 12 DIV was investigated. Two alternative stimuli, 3-NPA and 
H2O2, were also tested, as these have been previously shown to precondition 
neurones against subsequent neurotoxic damage (Weih et al., 1999, Tang et al., 
2005a).  
The preconditioning protocol for 3-NPA preconditioning was essentially the same 
as with NMDA; however the toxicity of H2O2, even at very low doses, 
necessitated a much shorter period of preconditioning (5-15 minutes) (Fatokun 
et al., 2007).  
An alternative method, previously successful for cultures of both hippocampal 
and cerebral cortical neurones using the GABAA receptor antagonist bicuculline, 
supplemented by the potassium channel blocker 4-aminopyridine (4-AP), to 
provide protection by preconditioning neurones for a longer period (24-48 hours) 
(Papadia et al., 2005, Tauskela et al., 2008) was investigated.  
  
Figure 5.2 Diagram representing protocol used for preconditioning with 4-aminopyridine 
and bicuculline at 8-10 DIV.  
 
The initial experiments with this protocol in our system failed to protect when 
using bicuculline alone, although the protection induced by 4-AP (in either the 
presence or absence of bicuculline) was highly effective and was investigated 
further.  
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The methods used for 48 hour preconditioning experiments were similar to those 
in earlier preconditioning studies, with 4-AP (with or without bicuculline) added 
to medium and left to act over 48 hours. The medium was then aspirated and 
replaced by fresh medium for 24 hours before switching to medium containing 
the toxin, or to the OGD buffer.  
 
5.2 Aims and Objectives 
• Establishment of effective protocol for preconditioning with NMDA against 
glutamate based on findings from previous studies  
• Investigating efficacy of this protocol in protecting against alternative 
methods of neurotoxic damage 
• Replicate protection achieved with NMDA preconditioning in cerebral 
cortical neurone cultures 
• Study of effectiveness of 3-NPA in preconditioning against neurotoxic 
insults 
• Investigation of effectiveness of H2O2 in preconditioning against 
neurotoxic insults 
• Establishment of successful preconditioning protocol based on prolonged 
stimulation with bicuculline and 4-AP 
• Investigation of efficacy of this protocol in protecting against various 
methods of neurotoxic damage 
• Investigation of mechanisms of action involved in prolonged 
preconditioning model using both pharmacological and molecular 
techniques 
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5.3 Preconditioning with N-methyl-D-aspartate 
5.3.1 NMDA preconditioning protects against glutamate toxicity 
The use of NMDA to precondition at a moderately high concentration (100µM) for 
6 hours at 8 DIV provided a significant degree of protection against a range of 
concentrations of glutamate applied 24 hours subsequent to commencement of 
the preconditioning stimulus (Figure 5.3). Additionally, when the preconditioning 
stimulus alone was applied (i.e. without any subsequent toxic insult) there was 
no loss of viability detected; indeed the stimulus seemed to cause a mild 
(although not significant) trophic effect (Figure 5.3).  
 
0
20
40
60
80
100
120
140
0µM 1µM 10µM 50µM 100µM 500µM 1mM 5mM 10mM
Glutamate concentration
Vi
ab
ili
ty
 
(p
er
ce
nt
ag
e 
of
 s
ha
m
 c
on
tr
ol
)
Non-preconditioned
Preconditioned
* * *
Figure 5.3 Effect of preconditioning with 100µM NMDA for 6 hours at 8 DIV on toxicity of 
100µM glutamate for 24 hours at 9 DIV. Mean +/- SEM, n=5; Student’s t-test comparing 
preconditioned and non-preconditioned groups, * p<0.05. Effective preconditioning was 
induced by NMDA against the toxicity of 10-100µM glutamate.  
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5.3.2 NMDA preconditioning protects against 3-nitropropionic 
acid toxicity 
Further to previous findings demonstrating protection against glutamate, it was 
also established that preconditioning with NMDA for 6 hours at 8 DIV provided a 
significant degree of protection against subsequent application of a range of 
concentrations of 3-NPA (notably, significant protection against 3-NPA was 
effective over a wider range of concentrations of the toxin) (Figure 5.4). Again 
the preconditioning stimulus itself had no evident detrimental result, causing a 
slight (but again not significant) trophic effect (Figure 5.4).  
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Figure 5.4 Effect of preconditioning with 100µM NMDA for 6 hours at 8 DIV on toxicity of 
100µM 3-NPA for 24 hours at 9 DIV. Mean +/- SEM, n=5; Student’s t-test comparing 
preconditioned and non-preconditioned groups, * p<0.05, ** p<0.01. Effective 
preconditioning was induced by NMDA against the toxicity of 1-500µM 3-NPA.  
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The protective effect of NMDA at a moderately high dose (100µM) for 6 hours at 
8 DIV against both glutamate and 3-NPA was identified in viability assay 
readings, and confirmed by the morphological observations of preconditioned 
cultures, compared to positive controls (Figure 5.5). Furthermore, study of CGN 
morphology, again showed no evidence of notable damage due to the 
preconditioning stimulus.  
 
  
 
  
 
  
Figure 5.5 Phase contrast microscopic images of CGNs at 10 DIV: untreated control (A), 
effect of preconditioning with 100µM NMDA for 6 hours at 8 DIV without subsequent toxic 
treatment (B), following exposure to 100µM glutamate (C) or 100µM 3-NPA (E) for 24 hours 
at 9 DIV. Also shown: cultures preconditioned with 100µM NMDA prior to exposure to 100µM 
glutamate (D) or 100µM 3-NPA (F) for 24 hours at 9 DIV. Bars = 50µm. Preconditioning with 
NMDA did not cause any morphological changes, and was protective against the damage 
caused by treatment with either glutamate or 3-NPA.  
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5.3.3 NMDA preconditioning against hypoxia 
The ability of NMDA preconditioning to protect against other aspects of 
ischaemia was also investigated. Initial experiments involved hypoxia alone due 
to difficulty in developing a buffer which was non-toxic to CGNs (Figure 5.6a, b).  
0
20
40
60
80
100
120
140
50µM 100µM 200µM
NMDA concentration
Vi
ab
ili
ty
 
(p
er
ce
nt
ag
e 
of
 p
os
iti
ve
 c
on
tr
ol
)
 
Figure 5.6a Effect of preconditioning with 50-200µM NMDA for 6 hours at 8 DIV on toxicity of 
hypoxia for 1 hour at 9 DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test identified 
no significant protection by NDMA at any concentration.  
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Figure 5.6b Effect of preconditioning with 5-200µM NMDA for 6 hours at 12 DIV on toxicity of 
hypoxia for 2 hours at 13 DIV. Mean +/- SEM, n=4-6; ANOVA followed by Tukey’s test 
identified no significant protection by NMDA at any concentration.  
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5.3.4 NMDA preconditioning against OGD 
Once a suitable buffer had been identified, the representative model combining 
oxygen and glucose deprivation simultaneously was used. N-methyl-D-aspartate 
preconditioning from 10-200µM was not effective against toxicity due to hypoxia 
in cultures of any of the ages used, nor was any protection seen against oxygen-
glucose deprivation (Figure 5.7), which was consistent with the findings that 
NMDA did not protect against hypoxia at either 8 or 12 DIV (Figure 5.6a, 5.6b).  
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Figure 5.7 Effect of preconditioning with 10- 200µM NMDA for 6 hours at 8 DIV on toxicity of 
4 hours OGD at 9 DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test identified no 
significant protection by any concentration of NMDA against the toxicity of OGD for 4 hours.  
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5.4 Preconditioning with hydrogen peroxide and 3-
nitropropionic acid 
5.4.1 Hydrogen peroxide preconditioning against hypoxia 
An investigation of preconditioning against hypoxia at 12 DIV was also attempted 
using a low concentration of H2O2 as a potential preconditioning stimulus. As 
with the lower concentrations of NMDA used prior to hypoxia (Figure 5.6b), there 
was a slight, but non-significant increase in viability relative to positive controls; 
although even this was lost if either the concentration or preconditioning period 
were increased (Figure 5.8).  
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Figure 5.8 Effect of preconditioning with 2-10µM H2O2 for 5-15 minutes at 12 DIV on toxicity 
of 2 hours hypoxia at 13 DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test identified 
no significant protection by 2-10µM H2O2, all applied for 5-15 minutes, against hypoxia for 2 
hours.  
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5.4.2 3-Nitropropionic acid preconditioning against glutamate and 
NMDA 
Although 3-NPA had been successfully used to precondition by others (Weih et 
al., 1999), we were unable to provide protection against 100µM glutamate 
(Figure 5.9a) or 300µM NMDA (Figure 5.9b) despite using a range of 
concentrations of 3-NPA.  
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Figure 5.9 Effect of preconditioning with 3-NPA for 6 hours at 8 DIV on toxicity of a) 100µM 
glutamate or b)  300µM NMDA applied for 1 hour in HBSS buffer at 9 DIV. Mean +/- SEM, n=5; 
ANOVA followed by Tukey’s test identified no significant protection from 3-NPA 
preconditioning at any of the concentrations trialled, against subsequent treatment with 
either glutamate or NMDA.  
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5.5 48-hour preconditioning with 4-aminopyridine and 
bicuculline 
Although preconditioning using 100µM NMDA for 6 hours at 8 DIV had provided 
successful protection against glutamate and 3-NPA, this failed to protect against 
either hypoxia or OGD. Additionally, the uses of alternative preconditioning 
regimens using H2O2 or 3-NPA were less successful, with a considerable degree of 
variation in response from one experiment to the next.  
Following communication with Dr. Joseph Tauskela, who has developed a 
method of protection against neurotoxic insults by stimulating neurones with 
bicuculline and 4-AP for extended periods of time (24 to 48 hours) (Tauskela et 
al., 2008), a similar protocol was adopted, capable of effectively 
preconditioning CGNs against several neurotoxic insults.  
We initially established that the protocol was effective against subsequent 
glutamate application (Figures 5.10, 5.11, and then investigated whether the 
protection was dependent on neuronal electrical activity, NMDA receptor 
stimulation or calcium channel opening. Therefore the protocol was tried in the 
presence of the sodium channel blocker tetrodotoxin (TTX), the NMDA receptor 
antagonist MK-801 or the calcium channel blocker nifedipine (Figures 5.12, 5.13, 
5.14, 5.15, Table 5.2). In order to explore the effectiveness of this protective 
mechanism against a range of alternative toxic insults, several alternative 
methods of producing neurotoxicity were used, specifically: NMDA (Figures 5.16, 
5.17, 5.18, 5.19, 5.20, 5.21), 3-NPA (Figures 5.22, 5.23) and OGD (Figures 5.24, 
5.25).  
The possible molecular mechanisms underlying this protection were also studied, 
with CREB phosphorylation (Figure 5.30, 5.31), bcl-2 expression (Figure 5.32, 
5.33) and caspase-3 activation (Figure 5.34, 5.35) examined by Western blotting.  
It was found that preconditioning with 2500µM 4-AP for 48 hours gave complete 
protection against the toxicity of 50µM glutamate, 300µM NMDA or 50µM 3-NPA, 
although was unable to protect against the damage induced by 5 hours OGD. Co-
application of bicuculline did not improve the protection, and in fact was 
detrimental to it.  
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The use of TTX during preconditioning caused a reduction in 4-AP protection, 
with the protection afforded by preconditioning with 50µM 4-AP against 50µM 
glutamate eliminated entirely, and the protection given by 2500µM 4-AP reduced 
notably. This indicated that the generation of neuronal excitation is a key 
component of this mechanism of protection.  
Co-application of the NMDA receptor antagonist MK-801 during preconditioning 
did not reduce precontiioning, indicating that activation of these receptors is 
not required for the establishment of this protection. Although MK-801 
‘preconditioning’ itself did not provide significant protection against glutamate, 
there was significant protection given against NMDA treatment, although the 
protection given by 4-AP (at all concentrations) was still far greater. Another 
interesting effect of co-applying MK-801 was that the detrimental effect on 4-AP 
preconditioning induced by bicuculline co-treatment was eliminated, indicating 
that this damaging effect involved NMDA receptor stimulation.  
In order to establish whether calcium influx via voltage-gated calcium channels 
was involved in 4-AP protection, the L-type calcium channel antagonist 
nifedipine was co-applied also. Unfortunately, the use of nifedipine for 48 hours 
was highly toxic in itself, preventing any useful information being gained from 
this part of the study.  
The examination of CREB phosphorylation, bcl-2 expression and activation of 
caspase-3 by Western blotting found that although CREB phosphorylation 
appeared raised by 4-AP preconditioning relative to untreated controls, this 
effect was not statistically significant when analysed by quantification. There 
was no alteration in bcl-2 expression by either 4-AP of glutamate treatments, 
suggesting that this protein is not the mechanism by which 4-PA protection acted 
in this study. Activation of caspase-3 was not significantly altered by 4-AP 
treatment or glutamate application relative to negative controls.  
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5.5.1 48-hour preconditioning against glutamate 
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Figure 5.10 Effect of preconditioning with 10µM bicuculline (Bic) and 50-2500µM 4-AP for 48 
hours at 8-10 DIV on toxicity of 50µM glutamate applied for 24 hours at 11 DIV. Mean +/- 
SEM, n=5; ANOVA followed by Tukey’s test, ** p<0.01. Bicuculline and 2500µM 4-AP co-
treatment was protective against glutamate toxicity.  
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Figure 5.11 Effect of preconditioning with 50-2500µM 4-AP for 48 hours at 8-10 DIV on 
toxicity of 50µM glutamate applied for 24 hours at 11 DIV. Mean +/- SEM, n=5; ANOVA 
followed by Tukey’s test, * p<0.05, *** p<0.001. Preconditioning with 50 or 2500µM 4-AP was 
protective against glutamate toxicity.  
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5.5.2 48-hour preconditioning (with TTX) against glutamate 
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Figure 5.12 Effect of preconditioning with 10µM bicuculline and 50-2500µM 4-AP in the 
presence of 1µM TTX for 48 hours at 8-10 DIV on toxicity of 50µM glutamate applied for 24 
hours at 11 DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, * p<0.05. Co-
application of TTX reduced the protection provided by preconditioning with bicuculline and 
2500µM 4-AP, although this still provided significant protection.  
0
20
40
60
80
100
120
140
None TTX only 50µM 4-AP 500µM 4-AP 2500µM 4-AP
Preconditioning stimulus
Vi
ab
ili
ty
 
(p
er
ce
nt
ag
e 
of
 s
ha
m
 c
on
tr
ol
)
***
Figure 5.13 Effect of preconditioning with 50-2500µM 4-AP in the presence of 1µM TTX for 48 
hours at 8-10 DIV on toxicity of 50µM glutamate applied for 24 hours at 11 DIV. Mean +/- 
SEM, n=5; ANOVA followed by Tukey’s test, *** p<0.001. Co-application of TTX reduced the 
protection provided by preconditioning with 2500µM 4-AP, although this still provided 
significant protection; protection due to 50µM 4-AP was lost by TTX co-treatment.  
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5.5.3 48-hour preconditioning (with MK-801) against glutamate 
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Figure 5.14 Effect of preconditioning with 10µM bicuculline and 50-2500µM 4-AP in the 
presence of 1µM MK-801 for 48 hours at 8-10 DIV on toxicity of 50µM glutamate applied for 
24 hours at 11 DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, *** p<0.001. Co-
application of MK-801 with bicuculline/4-AP preconditioning caused a potentiation in the 
protective effect. 
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Figure 5.15 Effect of preconditioning with 50-2500µM 4AP in the presence of 1µM MK-801 for 
48 hours at 8-10 DIV on toxicity of 50µM glutamate applied for 24 hours at 11 DIV. Mean +/- 
SEM, n=5; ANOVA followed by Tukey’s test, *** p<0.001. Co-application of MK-801 with 4-AP 
preconditioning caused a potentiation in the protective effect.  
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5.5.4 48-hour preconditioning against NMDA 
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Figure 5.16 Effect of preconditioning with 10µM bicuculline and 50-2500µM 4-AP for 48 
hours at 8-10 DIV on toxicity of 300µM NMDA applied for 24 hours at 11 DIV. Mean +/- SEM, 
n=5; ANOVA followed by Tukey’s test, ** p<0.01. Bicuculline and 2500µM 4-AP co-treatment 
was protective against NMDA toxicity.  
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Figure 5.17 Effect of preconditioning with 50-2500µM 4-AP for 48 hours at 8-10 DIV on 
toxicity of 300µM NMDA applied for 24 hours at 11 DIV. Mean +/- SEM, n=5; ANOVA followed 
by Tukey’s test, *** p<0.001. Treatment with 2500µM 4-AP was protective against NMDA 
toxicity.  
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5.5.5 48-hour preconditioning (with TTX) against NMDA 
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Figure 5.18 Effect of preconditioning with 10µM bicuculline and 50-2500µM 4-AP in the 
presence of 1µM TTX for 48 hours at 8-10 DIV on toxicity of 300µM NMDA applied for 24 
hours at 11 DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, * p<0.05. Co-
application of TTX reduced the protection provided by preconditioning with bicuculline and 
2500µM 4-AP, although this still provided significant protection.  
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Figure 5.19 Effect of preconditioning with 50-2500µM 4-AP in the presence of 1µM TTX for 48 
hours at 8-10 DIV on toxicity of 300µM NMDA applied for 24 hours at 11 DIV. Mean +/- SEM, 
n=5; ANOVA followed by Tukey’s test, ** p<0.01. Co-application of TTX reduced the 
protection provided by preconditioning with 2500µM 4-AP, although this still provided 
significant protection.  
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5.5.6 48-hour preconditioning (with MK-801) against NMDA 
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Figure 5.20 Effect of preconditioning with 10µM bicuculline and 50-2500µM 4-AP in the 
presence of 1µM MK-801 for 48 hours at 8-10 DIV on toxicity of 300µM NMDA applied for 24 
hours at 11 DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test, *** p<0.001. Co-
application of MK-801 with bicuculline/4-AP preconditioning caused a potentiation in the 
protective effect.  
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Figure 5.21 Effect of preconditioning with 50-2500µM 4-AP in the presence of 1µM MK-801 
for 48 hours at 8-10 DIV on toxicity of 300µM NMDA applied for 24 hours at 11 DIV. Mean +/- 
SEM, n=5; ANOVA followed by Tukey’s test, *** p<0.001. Co-application of MK-801 with 4-AP 
preconditioning caused a potentiation in the protective effect.  
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5.5.7 48-hour preconditioning against 3-NPA 
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Figure 5.22 Effect of preconditioning with 10µM bicuculline and 50-2500µM 4-AP for 48 
hours at 8-10 DIV on toxicity of 50µM 3-NPA applied for 24 hours at 11 DIV. Mean +/- SEM, 
n=5; ANOVA followed by Tukey’s test identified no significant protection provided against 
the toxicity of 3-NPA.  
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Figure 5.23 Effect of preconditioning with 50-2500µM 4-AP for 48 hours at 8-10 DIV on 
toxicity of 50µM 3-NPA applied for 24 hours at 11 DIV. Mean +/- SEM, n=5; ANOVA followed 
by Tukey’s test, ** p<0.01. Preconditioning with 2500µM 4-AP provided very significant 
protection against the neurotoxic effect of 3-NPA.  
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5.5.8 48-hour preconditioning against OGD 
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Figure 5.24 Effect of preconditioning with 10µM bicuculline and 50-2500µM 4-AP for 48 
hours at 8-10 DIV on toxicity of 5 hours OGD at 11 DIV. Mean +/- SEM, n=5; ANOVA followed 
by Tukey’s test identified no significant protection by preconditioning with bicuculline and 
4-AP against the toxicity of OGD for 5 hours.  
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Figure 5.25 Effect of preconditioning with 50-2500µM 4-AP for 48 hours at 8-10 DIV on 
toxicity of 5 hours OGD at 11 DIV. Mean +/- SEM, n=5; ANOVA followed by Tukey’s test 
identified no significant protection by preconditioning with 4-AP against the toxicity of OGD 
for 5 hours.  
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5.5.9 48-hour preconditioning stimuli: control series 
To establish the effects of preconditioning stimuli on viability and of TTX, MK-
801 and nifedipine on glutamate or NMDA toxicity, a series of control 
experiments were performed. Preconditioning with 4-AP alone caused no 
significant neurotoxicity, whereas co-application of bicuculline was detrimental 
to protection from 2500µM 4-AP). Tetrodotoxin caused no significant effects on 
glutamate or NMDA toxicity but reduced viability; MK-801 did not affect viability 
or glutamate toxicity but significantly reduced NMDA neurotoxicity (Table 5.1). 
Preconditioning stimulus Toxic 
insult 
Viability  
(% of control) 
Significance (vs. neg. 
control unless stated) 
10µM Bic + 50µM 4-AP None 77.4 None 
10µM Bic + 500µM 4-AP None 75.1 None 
10µM Bic + 2500µM 4-AP None 83.5 None 
10µM Bic + 50µM 4-AP None 77.4 None (versus 4-AP) 
10µM Bic + 500µM 4-AP None 75.1 None (versus 4-AP) 
10µM Bic + 2500µM 4-AP None 83.5 ** (versus 4-AP) 
50µM 4-AP None 86.8 None 
500µM 4-AP None 89.4 None 
2500µM 4-AP None 102.9 None 
1µM Tetrodotoxin None 71.1 * 
1µM Tetrodotoxin Glutamate 60.4 None (vs. glutamate) 
1µM Tetrodotoxin NMDA 64.1 None (vs. NMDA) 
1µM MK-801 None 109.9 None 
1µM MK-801 Glutamate 69.5 None (vs. glutamate) 
1µM MK-801 NMDA 86.5 * (vs. NMDA) 
None Glutamate 60.6 *** 
None NMDA 61.6 ** 
None 3-NPA 57.6 *** 
Table 5.1 Effect of preconditioning stimuli on viability, and effect of TTX, MK-801 and 
nifedipine on viability and toxicity of 50µM glutamate and 300µM NMDA (average value of 5 
repetitions).  
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5.5.10 48-hour preconditioning: effect of nifedipine 
In order to identify the part played in 4-AP preconditioning by calcium uptake 
via voltage-gated calcium channels, the L-type calcium channel blocker 
nifedipine was applied during preconditioning. Unfortunately, nifedipine caused 
a significant reduction in viability, comparable to that induced by glutamate or 
NMDA and hence did not clarify the role of calcium currents via these channels 
in inducing protection (Table 5.2). 
 Preconditioning 
stimulus 
Toxic insult Viability  
(% of control) 
Significance (vs. neg. 
control unless stated) 
5µM Nifedipine None 59.1 ** 
5µM Nifedipine Glutamate 43.6 None (vs. glutamate) 
5µM Nifedipine NMDA 31.3 None (vs. NMDA) 
5µM Nifedipine  
+ 50µM 4-AP 
Glutamate 37.1 *** 
5µM Nifedipine  
+ 500µM 4-AP 
Glutamate 26.8 *** 
5µM Nifedipine + 
2500µM 4-AP 
Glutamate 36.7 *** 
5µM Nifedipine + 10µM 
Bic + 50µM 4-AP 
Glutamate 35.1 *** 
5µM Nifedipine + 10µM 
Bic + 500µM 4-AP 
Glutamate 33.6 *** 
5µM Nifedipine + 10µM 
Bic + 2500µM 4-AP 
Glutamate 29.5 *** 
5µM Nifedipine  
+ 50µM 4-AP 
NMDA 26.4 *** 
5µM Nifedipine  
+ 500µM 4-AP 
NMDA 18.8 *** 
5µM Nifedipine + 
2500µM 4-AP 
NMDA 30.3 *** 
5µM Nifedipine + 10µM 
Bic + 50µM 4-AP 
NMDA 28.3 *** 
5µM Nifedipine + 10µM 
Bic + 500µM 4-AP 
NMDA 33.1 *** 
5µM Nifedipine + 10µM 
Bic + 2500µM 4-AP 
NMDA 27.8 *** 
Table 5.2 Effect of preconditioning stimuli in presence of nifedipine on viability and toxicity 
of 50µM glutamate and 300µM NMDA (average value of 5 repetitions), showing that 
nifedipine treatment caused a very significant drop in viability when applied for 48 hours at 
a concentration of 5µM.  
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5.5.11 48-hour preconditioning: morphological appearances 
 
 
Preconditioning with 4-AP for 48 hours did not cause any adverse effects to CGN 
phenotypes, as both cell bodies and neurite networks appeared as control 
morphology (Figure 5.26). It was also clear that the co-application of either 
tetrodotoxin or MK-801 for 48 hours had no evident damaging effect on CGN 
morphology.  
 
 
 
 
 
  
 
  
Figure 5.26 Phase contrast microscopic images of CGNs at 10 DIV after 48-hour 
preconditioning stimulus: control (A), treated with 2500µM 4-AP for 48 hours (B), treated 
with 2500µM 4-AP and 1µM TTX for 48 hours (C) and treated with 2500µM 4-AP and 1µM MK-
801 for 48 hours (D). Bars = 50µm. It is shown that 4-AP preconditioning did not cause any 
morphological abnormalities, whether applied alone or with TTX or MK-801.  
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The protective effect of 2500µM 4-AP against the damage by 50µM glutamate 
treatment is seen in Figure 5.27. Glutamate caused an increase in both neuronal 
death and neurite loss, with these effects almost completely attenuated by 
preconditioning with 2500µM 4-AP. Additionally, this protection (at this higher 
dose) was also apparent in the presence of either 1µM TTX or 1µM MK-801 was 
also apparent (Figure 5.27).   
 
 
 
 
  
 
  
Figure 5.27 Morphology of CGN cultures at 12 DIV: control (A), following exposure to 50µM 
glutamate for 24 hours at 11 DIV (B), treated with 2500µM 4-AP for 48 hours prior to 
glutamate exposure (C), treated with 2500µM 4-AP and 1µM TTX for 48 hours prior to 
glutamate exposure (D) and treated with 2500µM 4-AP and 1µM MK-801 for 48 hours prior to 
glutamate exposure (E). Bars = 50µm. The damaging effect of treatment with glutamate was 
completely prevented by treatment with 2500µM 4-AP, an effect maintained in the presence 
of either TTX or MK-801.  
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Although the neurotoxic effect of 300µM NMDA was less than with glutamate, 
again cell death and neurite network destruction was apparent (Figure 5.28B). 
The protective effect of 2500µM 4-AP against NMDA toxicity was also evident, 
and also in the presence of 1µM TTX or 1µM MK-801 (Figure 5.28).  
 
 
 
 
 
 
 
  
 
  
Figure 5.28 Morphology of CGNs at 12 DIV: control (A), following exposure to 300µM NMDA 
for 24 hours at 11 DIV (B), treated with 2500µM 4-AP for 48 hours prior to NMDA exposure 
(C), treated with 2500µM 4-AP and 1µM TTX for 48 hours prior to NMDA exposure (D) and 
treated with 2500µM 4-AP and 1µM MK-801 for 48 hours prior to NMDA exposure (E). Bars = 
50µm. The damaging effect of treatment with NMDA was completely prevented by treatment 
with 2500µM 4-AP, an effect maintained in the presence of either TTX or MK-801.  
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100µM 3-NPA also produced clear morphological evidence of neuronal death and 
again 2500µM 4-AP has provided extensive protection against this insult, an 
effect that was not lost by co-application of either 1µM TTX or 1µM MK-801 
(Figure 5.29).  
 
 
 
 
 
 
 
  
 
  
Figure 5.29 Morphology of CGN cultures at 12 DIV: control (A), following exposure to 50µM 
3-NPA for 24 hours at 11 DIV (B), treated with 2500µM 4-AP for 48 hours prior to 3-NPA 
exposure (C), treated with 2500µM 4-AP and 1µM TTX for 48 hours prior to 3-NPA exposure 
(D) and treated with 2500µM 4-AP and 1µM MK-801 for 48 hours prior to 3-NPA exposure (E). 
Bars = 50µm. The damaging effect of treatment with 3-NPA was completely prevented by 
treatment with 2500µM 4-AP, an effect maintained in the presence of either TTX or MK-801.  
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5.5.12 48-hour preconditioning – CREB phosphorylation 
Stimulation of CGNs with 2500µM 4-AP increased CREB phosphorylation compared 
with untreated controls when samples were analysed (Figure 5.30). This 
contrasted to the reduced CREB phosphorylation in preconditioned CGNs relative 
to untreated controls when both were exposed to 50µM glutamate. 
Densitometric analysis did not show statistical significance, although this may 
have been due to the limited sample size (Figure 5.31).  
 
Figure 5.30 Representative blots of CREB and phosphorylated CREB in samples from 
cultures treated with 1 = control, 2 = 2500µM 4-AP for 48 hours at 8-10 DIV, 3 = 50µM 
glutamate at 11 DIV, 4 = 2500µM 4-AP for 48 hours at 8-10 DIV followed by 50µM glutamate 
at 11 DIV. Samples collected at 11 DIV (1 and 2) and 12 DIV (3 and 4) at points corresponding 
with beginning or end of toxic insult. Increased CREB phosphorylation due to 4-AP 
treatment is apparent in this sample blot.  
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Figure 5.31 Quantification of CREB phosphorylation in samples from cultures treated with: 1 
= control, 2 = 2500µM 4-AP for 48 hours at 8-10 DIV, 3 = 50µM glutamate at 11 DIV, 4 = 
2500µM 4-AP for 48 hours at 8-10 DIV followed by 50µM glutamate at 11 DIV. Samples 
collected at 11 DIV (1 and 2) and 12 DIV (3 and 4) ) at points corresponding with beginning 
or end of toxic insult. Mean +/- SEM, n=3. No statistically significant difference was seen.  
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5.5.13 48-hour preconditioning – bcl-2 expression  
Although bcl-2 has been associated with CREB activation and is known to act as 
an effective protector against either apoptotic or necrotic cell death, there was 
no evidence to suggest its involvement in the 4-AP-mediated preconditioning 
protection that was seen in our culture system (Figures 5.32, 5.33).  
 
 
Figure 5.32 Representative blots of bcl-2 in samples from cultures treated with 1 = control, 2 
= 2500µM 4-AP for 48 hours at 8-10 DIV, 3 = 50µM glutamate at 11 DIV, 4 = 2500µM 4-AP for 
48 hours at 8-10 DIV followed by 50µM glutamate at 11 DIV. Samples collected at 11 DIV (1 
and 2) and 12 DIV (3 and 4) at points corresponding with beginning or end of toxic insult. No 
variation in bcl-2 expression is seen following either 4-AP preconditioning of glutamate 
treatment in this sample blot.  
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Figure 5.33 Quantification of bcl-2 in samples from cultures treated with: 1 = control, 2 = 
2500µM 4-AP for 48 hours at 8-10 DIV, 3 = 50µM glutamate at 11 DIV, 4 = 2500µM 4-AP for 48 
hours at 8-10 DIV followed by 50µM glutamate at 11 DIV. Samples collected at 11 DIV (1 and 
2) and 12 DIV (3 and 4) at points corresponding with beginning or end of toxic insult. Mean 
+/- SEM, n=3. No alteration in bcl-2 expression due to either preconditioning or glutamate 
treatment is seen.  
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5.5.14 48-hour preconditioning – caspase-3 activation 
Although again not significant, preconditioning with 2500µM 4-AP appeared to 
mediate an interesting effect on the activation of caspase-3, with a reduction in 
activation seen when compared to both negative and positive (glutamate-
treated) controls (Figures 5.34, 5.35).  
 
Figure 5.34 Representative blots of activated caspase-3 in samples from cultures treated 
with 1 = control, 2 = 2500µM 4-AP for 48 hours at 8-10 DIV, 3 = 50µM glutamate at 11 DIV, 4 = 
2500µM 4-AP for 48 hours at 8-10 DIV followed by 50µM glutamate at 11 DIV, 5 = 1µM 
staurosporine for 6 hours at 9 DIV (positive control). Samples collected at 11 DIV (1 and 2), 
12 DIV (3 and 4) at points corresponding with beginning or end of toxic insult; and 9 DIV (5). 
No variation in caspase-3 activation is seen following either 4-AP preconditioning of 
glutamate treatment in this sample blot.  
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Figure 5.35 Quantification of activated caspase-3 in samples from cultures treated with: 1 = 
control, 2 = 2500µM 4-AP for 48 hours at 8-10 DIV, 3 = 50µM glutamate at 11 DIV, 4 = 2500µM 
4-AP for 48 hours at 8-10 DIV followed by 50µM glutamate at 11 DIV. Samples collected at 11 
DIV (1 and 2) and 12 DIV (3 and 4) at points corresponding with beginning or end of toxic 
insult. Mean +/- SEM, n=3. No significant variation in caspase-3 activation is seen following 
either 4-AP preconditioning of glutamate treatment.  
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5.6 Discussion of NMDA, hydrogen peroxide and 3-
nitropropionic acid preconditioning 
5.6.1 Preconditioning with NMDA 
Preconditioning with NMDA has previously been shown to confer protection 
against subsequent glutamate toxicity in neonatal rat CGNs (Marini and Paul, 
1993). This method was therefore employed in the current study to protect 
against the neurotoxic effects of glutamate, 3-NPA, hypoxia and OGD. Previously 
published data suggested that the NMDA concentration and exposure duration 
most likely to be effective in CGNs was 100µM NMDA for 6 hours at 8 DIV, with a 
toxic stimulus applied 24 hours after commencing the preconditioning stimulus 
(Chuang et al., 1992, Damschroder-Williams et al., 1998, Lipsky et al., 2001).  
This preconditioning regimen used here provided a significant degree of 
protection not only against a range of concentrations of glutamate (10µM to 
100µM) applied in medium for 24 hours, but also against 3-NPA over the 
concentration range 1µM to 500µM. For NMDA preconditioning, protein and RNA 
synthesis have been shown to be necessary since protection was blocked by the 
presence of either cycloheximide or actinomycin D (Marini and Paul, 1993).  
In our system however, this protocol was unable to provide significant protection 
against exposure to either hypoxia or OGD. Altering the preconditioning 
procedure by applying NMDA stimulation at 12 DIV 24 hours prior to 2 hours of 
hypoxia was also not effective in inducing protection, although a slight, non-
significant shift in the concentration at which NMDA was most trophic was seen.  
The period over which a sub-toxic concentration of NMDA protects against a 
toxic glutamate insult has been demonstrated as being over the range of 12-48 
hours, with protection not apparent outside this period (Damschroder-Williams 
et al., 1995). Additionally, NMDA treatments of cultured CGNs for 4 hours, 
followed by removal and replacement with control medium for 8 hours was not 
significantly less protective than treatment with NMDA for the full 12 hour 
period (Damschroder-Williams et al., 1995).  
The mechanism of NMDA preconditioning in CGNs was not via reduced calcium 
influx secondary to NMDA receptor down-regulation, as calcium influx caused by 
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NMDA receptor stimulation was not significantly lower in preconditioned 
neurones than in controls (Damschroder-Williams et al., 1995). Nor is it likely 
that preconditioning acts via alterations to NMDA receptor subunit composition, 
as in vivo ischaemic preconditioning in rats did not affect expression levels of 
subunits NR1, NR2A or NR2B in hippocampal CA1 or neocortex synaptosomes 
fractions (Shamloo and Wieloch, 1999).  
Levels of extracellular glutamate during toxic OGD are reduced by 
preconditioning with KCl or NMDA in cultured cortical neurones or by OGD-
preconditioning of brain slices (Johns et al., 2000, Tauskela et al., 2001, Grabb 
et al., 2002). Furthermore, ischaemia in rat hippocampus in vivo caused a 
significant rise in extracellular glutamate, which did not occur with ischaemic 
preconditioning, although a significant rise in extracellular GABA was noted 
(Dave et al., 2005). In both neurones and slices, GABA release in preconditioned 
neurones was enhanced during normally-lethal OGD and tolerance could be 
eliminated by blockade of GABA receptors during lethal OGD (Johns et al., 2000, 
Grabb et al., 2002).  
Effects of NMDA preconditioning on mitochondria are not limited to altered 
calcium levels, as mitochondrial decouplers blocked calcium influx into 
mitochondria, but did not prevent NMDA-induced reductions in mitochondrial 
movement in neuronal dendrites and morphological changes (Rintoul et al., 
2003).  
Ischaemic preconditioning in vivo, or OGD preconditioning in cortical cultures, 
caused expression of the mitochondrial uncoupler protein UCP-2, located on the 
mitochondrial inner membrane and induced membrane depolarisation, by 
reducing mitochondrial calcium uptake or by generation of ROS (Diano et al., 
2003, Mattiasson et al., 2003, Sullivan et al., 2003). Also, ischaemic 
preconditioning caused mitochondrial calcium levels to increase, in hippocampal 
CA1 neurones, while cytosolic levels decreased; the demonstrated ischaemic 
preconditioning-induced increase in bcl-2 could explain the ability of the 
mitochondria to hold greater amounts of calcium without damage (Shimazaki et 
al., 1994). Ischaemic preconditioning has been shown to reduce cytochrome c 
release following normally lethal cerebral ischaemia in rats, whilst isolated 
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mitochondria from preconditioned neurones were shown to release less 
cytochrome c after exposure to elevated calcium (Zhan et al., 2002).  
N-methyl-D-aspartate receptor stimulation causes release of brain-derived 
neurotrophic factor (BDNF), with a subsequent increase in neurotrophin receptor 
TrkB tyrosine phosphorylation due to BDNF binding with and activating TrkB 
(Marini et al., 1998). This neuroprotection was prevented by blockade of either 
the NMDA receptor or the TrkB receptor and replicated by treatment of the 
CGNs with BDNF before glutamate exposure, but not by nerve growth factor 
(NGF) or neurotrophin-3 (Marini et al., 1998).  
The involvement of the transcription factor nuclear factor kappa B (NF-κB) was 
also demonstrated (Lipsky et al., 2001). Nuclear factor kappa B is normally 
found in the cytosol, in an inactive complex with the inhibitory protein IκBα, 
which goes through phosphorylation and degradation upon activation and 
subsequent release of active NF-κB. N-methyl-D-aspartate preconditioning was 
completely lost if cells were pre-treated with NF-κB target DNA which acted as a 
‘decoy’ for the transcription factor, thus blocking any protein synthesis that 
would otherwise have been mediated by NF-κB (Blondeau et al., 2001, Lipsky et 
al., 2001, Ravati et al., 2001).  
When NF-κB translocates to the nucleus, it up-regulates genes involved in anti-
apoptotic pathways, including the production of Mn-SOD and inhibitors of 
apoptosis-related proteins (Hou and MacManus, 2002, Sapolsky et al., 2001). 
Glutamate-induced calcium rises are one of the signals which can lead to 
activation of NF-κB in neurones (Kaltschmidt et al., 1995). N-methyl-D-aspartate 
preconditioning is also effective at protecting against seizure activity and 
neuronal death in hippocampal neurones exposed to QA 24-48 hours later (Boeck 
et al., 2004).  
Stimulation of NMDA receptors with bicuculline and 4-AP increased neuronal 
survival when a period of neuronal electrical inactivity intervened between this 
stimulus and a toxic insult: this protection was blocked by the use of the CREB 
pathway inhibitor inducible cAMP early repressor (ICER), although protection 
against an insult applied immediately after stimulation was not CREB-dependent 
(Papadia et al., 2005).  
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The activation of CREB was associated with increased production of bcl-2 protein 
in cerebral cortical, hippocampal and hypothalamic neurones, in response to 
OGD-induced preconditioning, toxic exposure to glutamate and hypoxic 
preconditioning respectively (Mabuchi et al., 2001, Wu et al., 2004, Meller et 
al., 2005). These increases in bcl-2 were blocked by use of a CRE decoy 
oligonucleotide (Mabuchi et al., 2001, Meller et al., 2005) and associated with 
retardation of loss of mitochondrial membrane potential during severe anoxia or 
toxic H2O2 application (Wu et al., 2004, Tang et al., 2005b).  
5.6.2 Preconditioning with 3-NPA 
Preconditioning with 3-NPA has been shown in vitro, with rat cortical neurones 
preconditioned against subsequent OGD 24-48 hours later (Weih et al., 1999). 
The current study set out to investigate further the mechanisms involved in 
mediating this effect, such as whether the abilities of 3-NPA to activate NMDA 
receptors or inhibit succinate dehydrogenase were involved. N-methyl-D-
aspartate receptor stimulation in 3-NPA-mediated preconditioning is of 
particular interest, as blockade of the adenosine A1 receptor during 
preconditioning in gerbil hippocampal slices prevents protection, A1 receptor 
involvement in preconditioning having been previously noted (see section 1.4.1) 
(Aketa et al., 2000).  
A range of concentrations (1µM to 10mM) of 3-NPA for 6 hours was proved 
ineffective, failing to protect against either 100µM glutamate or 300µM NMDA, 
applied for 1 hour in Hank’s balanced salt solution (HBSS) buffer in this study. 
The concentrations range was comparable with that used by Weih et al. (1999), 
although was at the upper range of concentrations, since CGNs are known to be 
less sensitive than cerebral cortical neurones to neurotoxic stimuli of 
comparable severity (Okuda et al., 1998, Scorziello et al., 2001).  
Administration of 3-NPA to adult rats as a preconditioning stimulus 3 days prior 
to a cerebral infarct induced by MCA occlusion caused infarct volumes to be 
reduced relative to controls (Horiguchi et al., 2003). This protection was lost if 
either the mitochondrial KATP blocker 5-hydroxydecanoate (5-HD) or the non-
selective KATP channel blocker glibenclamide were co-applied with 3-NPA. 
Application of 3-NPA to cultured cerebral cortical neurones caused mitochondrial 
depolarisation, which could be prevented by the presence of 5-HD (Horiguchi et 
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al., 2003). 3-Nitropropionic acid preconditioning was also blocked by a free 
radical scavenger or protein synthesis inhibitor, which caused an increase in the 
bcl-2/bax ratio (Wiegand et al., 1999, Brambrink et al., 2000).  
There are similarities between the preconditioning induced by 3-NPA and that 
induced by NMDA, notably the involvement of ROS formation, mitochondrial 
depolarisation and protein synthesis. Differences also exist however, such as the 
failure of 3-NPA preconditioning in cerebral cortical neurones to induce 
translocation of the transcription factors NF-κB or hypoxia-inducible factor (HIF) 
(Weih et al., 1999).  
5.6.3 Preconditioning with H2O2  
Preconditioning against excitotoxic and oxidative insults was also investigated in 
the rat phaeochromocytoma cell line PC12 by using exogenous H2O2 (10µM for 90 
minutes) to protect against the toxicity of H2O2 itself or dopamine administered 
24 hours after preconditioning (Tang et al., 2005a, Tang et al., 2005c). 
Protection was shown to involve over-expression of bcl-2 and the prevention of 
increased ROS formation and mitochondrial membrane potential alterations, 
although protection was not dependent on KATP channel activation (Tang et al., 
2005a, Tang et al., 2005b, Tang et al., 2005c).  
As exogenous H2O2 can induce severe cell damage in CGN cultures, at even lower 
micromolar concentrations (Fatokun et al., 2007), the period of preconditioning 
was reduced substantially, to 5, 10 and 15 minute periods against 2 hours’ 
hypoxia in the current study. This however did not produce significant 
protection, and therefore was not continued.  
As protection induced by H2O2 preconditioning in other studies involved ROS 
production, it may have involved similar mechanisms to those in NMDA receptor 
preconditioning. However, although levels of viability seen in CGNs 
preconditioned by H2O2 were slightly raised, variability made this difference 
insignificant. This further underlines the problems of the previous method of 
preconditioning; where a relatively severe (albeit subtoxic) stimulus is used to 
induce protection.  
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This may be a limitation inherent in this model of preconditioning, as suggested 
by the finding that ischaemic preconditioning for 3 minutes (but not shorter 
durations) induced tolerance in rat brain in vivo, while even slightly longer 
durations caused cell death and that the preconditioning stimulus does indeed 
require toxic potential to be effective (Shamloo and Wieloch, 1999).  
5.7 Discussion of 4-aminopyridine and bicuculline 
preconditioning 
5.7.1 Preconditioning with 4-AP 
As the earlier studies using relatively high doses of NMDA to stimulate CGNs had 
been of limited success, development of a method of neuronal stimulation that 
was effective in generating protection, but did not induce even sub-lethal 
excitatory or oxidative stress, was investigated.  
A highly significant degree of protection resulted from application of 2500µM 4-
AP for 48 hours at 8-10 DIV against 50µM glutamate, 50µM 3-NPA or 300µM NMDA 
applied for 24 hours at 11 DIV, but was ineffective at protecting against 5 hours’ 
exposure to OGD at 11 DIV. Preconditioning with 50µM 4-AP was effective at 
protecting against 50µM glutamate. Co-application of bicuculline with either 
concentration of 4-AP reduced the protection against glutamate and NMDA, 
although a significant effect was still present. Protection against 3-NPA was 
eliminated by bicuculline co-application and again failed to protect against OGD.  
The neuronal population in our system differed from those used by the Tauskela 
group, with a higher concentration of purely glutamatergic neurones. For this 
reason, the effect of preconditioning with 50, 500 or 2500µM 4-AP alone was 
investigated alongside a combination of 10µM bicuculline with 50, 500 or 2500µM 
4-AP, the concentrations used based on previous studies (Mei et al., 2000, 
Lange-Asschenfeldt et al., 2005, Hu et al., 2006, Tauskela et al., 2008). 
Stimulation with 4-AP alone gave more extensive protection than was achieved 
using combined treatment with bicuculline and 4-AP. The use of 4-AP alone to 
induce preconditioning has been previously demonstrated against kainate (Ogita 
et al., 2005), but here we also demonstrated effective protection against 
glutamate, NMDA and 3-NPA. This is evidence that the protection induced by 4-
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AP is effective against a wide range of neurotoxic insults, including 
excitotoxicity complicated by oxidative stress and metabolic compromise.   
The finding that non-toxic excitatory stimulation with a low (5-10µM) 
concentration of NMDA for 12-24 hours was found to effectively precondition 
hippocampal neurones against subsequent glutamate or staurosporine exposure 
was of great interest (Soriano et al., 2006), suggesting a potential method for 
inducing preconditioning without any risk of neurotoxicity. The use of this 
method in rat hippocampal neurones caused CREB-dependent gene expression, 
increased BDNF mRNA expression and TrkB phosphorylation (Soriano et al., 
2006). This protected (depending on AP production) against glutamate, 
staurosporine or trophic deprivation in both acute and long-lasting forms and 
was still evident 48 hours after termination of the NMDA stimulus (Soriano et al., 
2006).  
Preconditioning with 5 or 10µM NMDA did not affect mitochondrial membrane 
potential, although higher concentrations caused a dose-related loss of 
mitochondrial membrane potential and an associated increase in toxicity. 
Additionally, NMDA preconditioning caused transient increases in mitochondrial 
calcium levels, whereas toxic levels of NMDA resulted in sustained mitochondrial 
calcium rises (Soriano et al., 2006). Tetrodotoxin prevented NMDA-induced AP 
firing, and significantly reduced the neuroprotection resulting from CREB-
dependent gene expression, BDNF mRNA expression and phosphorylation of TrkB, 
the BDNF receptor (Soriano et al., 2006).  
A similar method of stimulation using the GABAA receptor antagonist bicuculline 
also protected against trophin withdrawal, this protection potentiated by co-
application of bicuculline and the potassium channel blocker 4-AP (Papadia et 
al., 2005, Mei et al., 2000). A comparable protocol had been effective in 
providing protection against excitotoxicity in embryonic cerebral cortical 
neurones, using a combination of bicuculline and 4-AP (Tauskela et al., 2008) 
and was considered in our experiments in order to develop a more prolonged, 
but lower intensity, stimulus capable of protecting against excitotoxic and 
oxidative damage. The fact that 4-AP was a more effective preconditioning 
stimulus than bicuculline suggests there are significant differences between our 
CGN cultures and the hippocampal and cerebral cortical cultures of other 
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groups. It is possible that both receptor stimulation and membrane stimulation 
are capable of generating the pro-survival signalling induced by this method of 
preconditioning, but that the former is of less importance in CGNs while being of 
critical importance in other neuronal types.  
Jonas et al. (2001) showed that an extremely low concentration of glutamate 
protected cultures of cerebellar granule, spinal or cortical neurones against 
subsequent, otherwise lethal exposure to 25µM glutamate, with protection 
evident following exposure to 10-20M or 10-30M glutamate for 72 hours. However, 
although this indicated that prolonged, low-intensity stimulation provided 
protection against excitotoxic and oxidative neuronal damage, the degree of 
protection was limited, with viability increased by only approximately 10%. 
Furthermore, as there was no apparent concentration-response relationship, this 
model provides a less reliable method of inducing neuroprotection than could be 
achieved using the methods previously described.  
5.7.2 Mechanisms of 4-AP preconditioning 
The pharmacological and molecular mechanisms involved in 4-AP preconditioning 
were investigated. Tetrodotoxin, MK-801 and the L-type calcium channel blocker 
nifedipine were all co-applied with the preconditioning stimuli to determine the 
contribution of depolarisation, NMDA receptor activation and calcium channel 
opening respectively. The effects of the preconditioning procedure and exposure 
to a toxic glutamate insult on expression of bcl-2, phosphorylation of cAMP 
response-element binding protein (CREB) and activation of caspase-3 were also 
studied using Western blotting.  
Protection against glutamate and NMDA was reduced by co-application of 1µM 
TTX but was still significant at the most effective dose of 4-AP (2500µM), 
although protection attained by 50µM 4-AP against glutamate was abolished by 
TTX. That the highest used dose of 4-AP was able to protect despite the effect 
of TTX (albeit to a lesser extent) is not surprising, as 4-AP has been successfully 
used in vivo to counteract the effects of TTX poisoning in guinea pigs (Chan et 
al., 1997). This reduction in 4-AP protective effect indicates that generation of 
neuronal electrical activity is integral to this protection. The use of a higher 
concentration of TTX against 2500µM 4-AP would clarify the extent to which this 
protection is dependant upon depolarisation.  
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Co-application of MK-801 in the present study had little effect on the protection 
by 4-AP, showing that the mechanism involved was not dependent on NMDA 
receptor activation. The adverse effect of co-application of bicuculline on 4-AP-
induced protection was prevented by MK-801, indicating that the effect of 
bicuculline was dependent on NMDA receptor stimulation. Although co-
application of MK-801 alone caused a significant degree of protection against 
NMDA neurotoxicity, this was not equivalent to the protective effect seen with 
co-administration of MK-801 and 4-AP.  
Furthermore, ‘preconditioning’ with MK-801 alone failed to protect against 
glutamate treatment and the increased protective effect of MK-801 co-
application during 4-AP preconditioning was still present, which excluded the 
possibility that the protective effect of MK-801 co-application in cultures treated 
with toxic NMDA was due to inadequate washing out of MK-801 from the 
cultures. Given that such an effect was not seen against glutamate toxicity, it 
appears unlikely to have been due to inadequate washout, so may be an 
example of MK-801-induced preconditioning, which has previously been reported 
(Tremblay et al., 2000). The difference between the effect of MK-801 on NMDA 
and glutamate toxicity may be due to kainate receptor activation, as although 
MK-801-induced preconditioning was demonstrated against both NMDA and AMPA 
(Tremblay et al., 2000), the effect on kainate toxicity is unknown as yet.  
The independence of the 4-AP-induced protective effect from NMDA receptor 
stimulation clearly indicated a different mechanism from those involved in the 
relatively high-intensity preconditioning studies considered previously, 
suggesting that although the broad method (bicuculline or 4-AP-induced 
neuronal stimulation) may be similar, the precise component (receptor 
stimulation or membrane depolarisation) which induces protection varies in 
different neuronal types. A possibility is that involvement of AMPA receptors is a 
critical component, a possibility which could be addressed by further study.  
4-Aminopyridine has been shown previously as pharmacologically active, as 1-
5mM 4-AP blocked potassium flow and sodium influx triggered by depolarisation 
in a dose-dependant fashion in rat neonatal CGNs at 1-7 DIV. These effects 
occurred rapidly and were completely reversed by 4-AP washout (Mei et al., 
2000). 4-Aminopyridine did not alter the voltage level required for sodium 
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channel activation and was insensitive to alterations in frequency of the 
triggering electrical pulses (Mei et al., 2000). 4-Aminopyridine caused glutamate 
release and an increase in intracellular calcium in synaptosomes from rat 
cerebral cortical neurones (Zoccorato et al., 2001).  
The L-type calcium channel blocker nifedipine was used to test the involvement 
of non-NMDA receptor-mediated calcium currents on the induction of 4-AP 
preconditioning. Nifedipine alone however, caused significant neuronal death, 
greater than that induced by subsequent glutamate or NMDA, so that it was not 
possible to discern the effects on 4-AP preconditioning of L-type calcium channel 
blockade with this agent. The mechanism by which nifedipine caused increased 
neuronal death was unclear, although it is notable that exposure to 1µM 
nifedipine for 8 hours caused increased caspase-3 activation in rat CGNs (Morán 
et al., 1999). Cerebellar granule neurone death in vivo caused by L-2-
chloropropionic acid (acting via NMDA receptors) was increased by nifedipine 
and several other L-type calcium channel antagonists (Widdowson et al., 1997), 
and as previously noted, nifedipine also potentiated the neurotoxicity of kainate 
(Leski et al., 1999).  
Inhibition of L-type calcium channels by nifedipine may have disrupted the 
normal responses to calcium influx due to NMDA receptor activation, resulting in 
a critical impairment to cytosolic calcium homeostasis or an excessive reduction 
of intracellular calcium. Although MK-801 did not eliminate its protective effect, 
4-AP preconditioning evidently induced neuronal electrical activity, hence NMDA 
receptor stimulation was quite certain. As a result, the potential disruptive 
effect of nifedipine on calcium homeostasis during NMDA-induced calcium influx 
could still have occurred in our study. It has been previously noted that CGNs in 
high K+ can be vulnerable to nifedipine treatment of 48 hours’ duration, due to 
effects on levels of calcium influx via L-type calcium channels (Galli et al., 
1995). It is therefore clear that the sensitivity of CGNs to nifedipine prevents its 
use as a tool for investigating the role of calcium in 4-AP preconditioning.  
Nifedipine reduced intracellular calcium in CGNs as shown by Courtney et al. 
(1990) and although in our study this may have occurred during NMDA receptor 
activation-mediated increases, the prolonged period of L-type calcium channel 
inhibition could have resulted in an excessive reduction in intracellular calcium, 
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triggering neuronal death. Another aspect of this specific to CGNs is that as 
glutamate exocytosis is calcium dependent (Section 1.2.1). Although nifedipine 
does not reduce calcium influx due to depolarisations itself (Galli et al., 1995), 
the reduced intracellular calcium may inhibit glutamate release to such an 
extent that, as seen in CGNs maintained in 5mM KCl, depolarisation is 
suppressed to such an extent that apoptosis ensues. The lack of neuronal death 
induced by exposure to MK-801 for 48 hours indicates that lack of NMDA receptor 
activity was not the cause of death. However, it remains possible that the 
depolarisation itself was the critical factor in averting death, which would still 
have occurred due to AMPA and kainate receptor activity.  
The mechanism of protection involved in our study could be related to the 
depolarisation seen in neonatal rat cerebral cortical neurones and astrocytes 
where treatments with KCl or 4-AP caused an increase in synthesis of kynurenic 
acid of about 75% (Rzeski et al., 2005). Although this property would be likely to 
protect against OGD, the failure of 4-AP to protect against 5 hours’ OGD 
exposure in our study could be due to the severity of the insult itself.  
Injection of 5mg/kg 4-AP in mice in vivo induced c-Fos expression in both 
hippocampus and cerebral cortices, providing protection in hippocampal CA1 and 
CA3b regions against kainate injection between 2 and 7 days after 4-AP 
preconditioning, but were abolished by co-administration of MK-801 with 4-AP 
(Ogita et al., 2005). These findings are comparable with ours, particularly the 
effective protection noted over 2-7 days, which encompasses the time between 
preconditioning and toxic insult used in our experiments. The blockade of this 
protection by co-application of MK-801 in the study by Ogita and co-workers 
does however differ from our findings.  
In relation to c-Fos activation by 4-AP, increases in intracellular calcium (due to 
NMDA receptor stimulation, L-type calcium channel opening or release of 
intracellular calcium stores, all of which increase nuclear and cytoplasmic 
calcium) cause up-regulated expression of c-Fos (Hardingham et al., 1998).  
C-Fos contains two elements, a cAMP response element (CRE) and a serum 
response element, activated by increased nuclear and cytoplasmic calcium 
respectively. Transcription activated by calcium and mediated via the CRE and 
cAMP-response-element-binding protein (CREB) is dependent on an increase in 
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nuclear calcium, with the CREB activity also contingent upon its phosphorylation 
by Ser133, present in CGNs, and primary hippocampal neurones (Hardingham et 
al., 1998).  
Western blot analysis in the current study indicated that preconditioning with 
2500µM 4-AP increased CREB phosphorylation relative to negative controls in 
protein samples taken at 11 DIV, 24 hours following the preconditioning. This 
finding suggests that CREB phosphorylation may be involved in 4-AP 
preconditioning, with the possibility that samples taken during or at the 
conclusion of the preconditioning period would gain further information towards 
answering this question. This would be consistent with the finding in cerebral 
cortical neurones that CREB phosphorylation occurred during neuronal 
stimulation but not after (Tauskela et al., 2008).  
CREB has been associated with neuroprotection and is activated by calcium 
currents via NMDA receptors or L-type calcium channels (Mabuchi et al., 2001). 
Phosphorylation of CREB in the gerbil hippocampal CA1 region has been shown in 
response to ischaemic preconditioning, an effect suppressed by the use of CRE 
decoy oligonucleotide or an NMDA receptor antagonist. The CRE decoy 
oligonucleotide did not affect the damage produced by actual ischaemia, 
indicating that CREB is involved in ischaemic preconditioning, but not in 
ischaemia-related death (Hara et al., 2003).  
Raised levels of phosphorylated CREB were found in rat brains in vivo in the core 
of an ischaemic lesion but with higher levels in cells in the penumbra which 
subsequently survived. The penumbra-located increase was only seen in rats 
receiving previous ischaemic preconditioning (Nakajima et al., 2002). 
Phosphorylation of CREB occurred in both hippocampal and cortical neurones in 
response to both ischaemia in vivo and glutamate in vitro, with these responses 
again blocked by co-application of MK-801, but not CNQX or nifedipine (Mabuchi 
et al., 2001, Meller et al., 2005).  
Over-expression of bcl-2 has been shown to reduce lipid peroxidation in plasma 
and mitochondrial membranes, with associated increased levels of Cu,Zn-SOD, 
glutathione and glutathione peroxidase. These potentially have direct 
antioxidant actions which are complemented by increased nuclear translocation 
of glutathione, altering nuclear redox 
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Keller et al., 1998, Wei et al., 2000). Such an increase in antioxidant expression 
may enable bcl-2 to protect against oxidative damage and to increase 
mitochondrial DNA repair (Deng et al., 1999).  
Bcl-2 over-expression also protected against the toxicity of 3-HK, an effect not 
due to reduced 3-HK-induced ROS generation. This implied that the protective 
mechanism acted downstream of ROS-induced effects, such as preventing loss of 
mitochondrial membrane potential and resultant release of cytochrome c or by 
up-regulation of calcium-ATPase on the endoplasmic reticulum (Wei et al., 
2000). It has been demonstrated that bcl-2 reduced release of calcium from the 
endoplasmic reticulum, which may be an integral component of the 
neuroprotective action of this protein against neurotoxic stimuli (Lam et al., 
1994).  
In our study however, the expression of bcl-2 in CGNs was not affected by either 
4-AP preconditioning or by toxic exposure to glutamate, with bcl-2 levels in all 
samples comparable to untreated controls, indicating that bcl-2 up-regulation 
does not have a critical role in this protection.  
5.7.3 Preconditioning with bicuculline 
Bicuculline methobromide failed to induce preconditioning against either 
glutamate or 3-NPA in this study and actually reduced the protection given by 4-
AP. This was in direct contrast to the work of Papadia et al. (2005) using 
hippocampal neurones, but was consistent with Lange-Asschenfeldt and co-
workers (2005) who showed that bicuculline induced a dose-related reduction in 
the protection mediated by OGD-induced preconditioning in rat hippocampal 
slices. Therefore, blockade of GABAA receptors in CGNs for prolonged periods 
appears detrimental to CGN survival in our system, although this is not likely to 
be due to an excitatory effect, given that no damage was induced by 4-AP, even 
at notably high concentrations. It is possible that GABAA receptor activation 
increases pro-survival signalling, independent of neuronal excitation. Another 
possibility is that GABAA receptor activity plays a pro-survival role via regulation 
of neuronal stimulation; certainly it has been demonstrated that GABA receptor 
activity increases the survival of CGNs in higher K+ concentrations (Ikonomovic et 
al., 1997), and further evidence supporting this explanation is that the co-
application of MK-801 prevented cell death due to bicuculline in this study. It 
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may be this particular characteristic of CGNs which explains the difference 
between the detrimental effect seen in this study and the preconditioning effect 
seen in studies using hippocampal neurones.  
Stimulation of synaptic NMDA receptors by bicuculline in rat hippocampal 
neurones caused CREB phosphorylation which was not inhibited by nifedipine, 
but was blocked by MK-801 or APV. This stimulation was associated with 
upregulation of BDNF and TrkB receptor phosphorylation (Hardingham et al., 
2002a). The function of CREB was controlled via calmodulin kinase activation by 
calcium signals dependent on a nuclear calcium pool (Hardingham et al., 2001). 
Repeated neuronal stimulation by APs triggered by bicuculline caused rapid CREB 
phosphorylation, with the amplitude of resultant nuclear calcium transients 
varied according to the frequency of the APs (Hardingham et al., 2001).  
The use of bicuculline as a stimulus targeted specifically at synaptic NMDA 
receptor activity (minimising activation of extrasynaptic NMDA receptors) caused 
increased CREB phosphorylation. This was reversed by exogenous glutamate 
exposures, which acted on both extrasynaptic and synaptic receptors, and 
possibly stimulated AMPA and kainate receptors, thereby acting as an alternative 
source of the CREB ‘shut-off’ signal (Hardingham et al., 2002b).  
Stimulation of synaptic NMDA receptors by bicuculline in rat hippocampal 
neurones has been shown to cause significant increases in CREB phosphorylation, 
phosphatidylinositol 3-kinase (PI3K)-Akt pathway activation and resistance to 
apoptosis caused by trophin deprivation, staurosporine, C-2 ceramide, retinoic 
acid or okadaic acid (Papadia et al., 2005).  
5.7.4 4-AP preconditioning effective against non-apoptotic death 
Protection against apoptosis in neonatal rat CGNs induced by withdrawal of a 
depolarising potassium concentration or serum from culture medium, was 
conferred by 4-AP, with an associated dose-related reduction in inward 
potassium current, reversed by washout of 4-AP (Hu et al., 2006). Cytochrome c 
release and caspase-3 activation were also significantly reduced, with maximal 
protection provided by 5mM 4-AP, a concentration which did not lower the 
resting membrane potential, hence interference with potassium currents was 
presumed to be necessary for apoptosis to occur (Hu et al., 2006).  
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The lack of a significant increase in caspase-3 activation due to glutamate 
application was consistent with previous studies by others in cortical neurones 
(Hou and MacManus, 2002). Caspase-3 activation was reduced by preconditioning 
with 2500µM 4-AP, both in CGNs subsequently exposed to glutamate and in those 
left untreated; although this difference did not reach significance. The type of 
glutamate signalling is thought to regulate the death pathway induced: with 
sustained slow calcium influx leading to apoptosis and rapid severe influx leading 
to necrosis (Berliocchi et al., 2005). It is therefore proposed that glutamate 
treatment in our study caused a rapid influx of calcium leading to caspase-
independent cell death. Both 4-AP preconditioning and CREB activation have 
been previously identified as being protective against apoptosis, which indicates 
that the mechanism of protection induced by 4-AP preconditioning may be 
effective at providing neuroprotection against both apoptotic and necrotic forms 
of cell death.  
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6 Discussion 
Although the use of primary neuronal cultures provides a useful tool for studying 
the effect of treatments and conditions specifically on neurones, it should be 
noted that since the conditions in culture differ in several respects from those in 
vivo, the results achieved may differ as a result. One of the main differences 
(and one which was deliberately achieved) is the absence of glial and other non-
neuronal cells from the culture environment. This will alter the effect that is 
achieved with toxins, as the toxicity (for example) QA may in part be mediated 
by its effect on glial cells (Guillemin et al., 2005), and any neuroprotective 
effect mediated by glial cells against any of the toxic treatments will be 
similarly absent.  
Beyond the absence of the glial cells in the direct effects of toxic stimuli, the 
absence of glia will also affect excitotoxic stimuli in more subtle ways, such as 
the lack of glia sheathing synapses between CGNs, which will reduce the clear 
distinction between endogenous glutamate activating synaptic and extrasynaptic 
NMDA receptors. Another effect of producing monolayer cultures is to disrupt 
the normal neuronal architecture of the cerebellum, which may potentially alter 
the responses of CGNs to stimuli and toxins by interrupting the normal interplay 
between CGNs, mossy fibre neurones and Purkinje cells, although this effect is 
likely to be less significant than the absence of glia from cultures.  
Therefore, although the purity of neuronal cultures allows a great degree of 
clarity in determining the precise effect of various stimuli on neurones, further 
work to determine how these effects are manifested in vivo would be required 
to better determine their relevance to the development of pathologies or 
treatments. An alternative would be to use cultures of tissue slices, which would 
preserve the tissue architecture at least to an extent, and also preserve the 
presence and function of glial cells. This latter course would however still 
involve removing the tissue from its normal physiological environment and 
replacing that with culture medium. It has been suggested that the culture 
procedure itself causes cells to be exposed to excessive amounts of oxidative 
stress, due to increased ROS generation and reduced antioxidant defences 
(Halliwell, 2003).  
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A delicate balance exists in CGNs regarding the extent of excitatory activity and 
associated influx of calcium, with neuronal death being the consequence of 
these variables becoming either excessive or insufficient. The establishment of 
optimal culturing conditions concerning cell density and K+ concentration showed 
that even a moderate shift in levels of excitation (in either direction) caused 
striking effects on neuronal viability.  
The effect of these on calcium influx has been clearly established, with 
excessive increases or decreases in influx triggered by alterations in culturing 
conditions inducing cell death (Gallo et al., 1987, Peng et al., 1991, Morán et 
al., 1999). This occurs through various mechanisms, with necrotic or apoptotic 
cell death due to excessive calcium influx, in the case of receptor over-
stimulation, or apoptosis in the case of inadequate stimulation. It has also been 
shown that neurones subjected to mild stimulation undergo a homeostatic 
change, increasing their vulnerability to a sudden reduction in excitation 
(Moulder et al., 2003). Conversely, a mild increase in intracellular calcium 
allows neuronal survival in the absence of nerve growth factor (Franklin and 
Johnson Jr., 1994).  
The protective effect of higher K+ concentrations on CGNs is believed to be due 
to calcium flux and resultant alteration to intracellular calcium levels. Blockade 
of calcium channels was effective in both preventing the protective effect of 
raised K+ concentrations and in decreasing the toxic effect of K+ withdrawal, 
while inhibitors of calmodulin also blocked the protection from higher K+ levels 
(Gallo et al., 1987, Daniels and Brown, 2002). Conversely, dihydropyridine 
calcium agonists protected when combined with 15mM KCl but caused higher 
levels of death during K+ withdrawal (Gallo et al., 1987).  
These findings might seem somewhat contradictory, but the differences in the 
effects of blocking or amplifying calcium signalling can be explained. Uptake of 
radio-labelled calcium is more than two-fold greater in CGNs cultured in a lower 
(5.4mM) than in a higher (24.5mM) K+ concentration (Peng et al., 1991). This 
disparity in calcium current magnitude caused by different K+ concentrations 
could lead the effect of blocking calcium currents to be similarly disparate. If 
calcium currents were sufficient to generate beneficial effects (as could occur in 
CGNs in depolarising K+ concentrations), then blockade of these currents would 
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lead to inadequate stimulation and increase neuronal death. Certainly, it has 
been shown that hippocampal neurones maintained in depolarising K+ 
concentrations are vulnerable to a reduction in stimulation and resultant 
reduced calcium influx (Moulder et al., 2003). Conversely, such blockade of 
channels in the presence of excessive calcium currents (as may occur in CGNs in 
lower K+ concentrations) could be protective. Considering the key role of 
excessive calcium in NMDA receptor-mediated excitotoxic damage, this 
explanation is highly plausible.  
A related finding concerning CGNs cultured in 25mM KCl but transferred to 
serum-free medium containing 5mM KCl at 6 DIV is that this change caused a 
drop in intracellular calcium from ~300nM to ~50nM, leading to cell death via 
caspase-3 activation (Morán et al., 1999). A similar study compared neonatal rat 
CGNs transferred to 5mM KCl with CGNs maintained in 30mM KCl. It was found 
that incubation of neonatal rat CGNs in 5mM KCl for 4 hours caused increased 
caspase-3 and calpain activity, significant cell death and neurite retraction 
compared with cultures in 30mM KCl, with caspase-3 activation and cell death 
blocked by the p38 blocker SB-203580 (Nath et al., 2001). This is also consistent 
with the theory that higher K+ induces a lower sensitivity of calcium channels to 
stimulation, which makes a drop in stimulation potentially lethal. Conversely, 
maintenance from plating in lower K+ leads to hypersensitivity of calcium 
channels and a resultant predisposition to excessive calcium influx.  
The failure of NMDA antagonists to induce effective protection against stroke in 
clinical trials (Davis et al., 2000), despite the success of NMDA receptor blockade 
in animal models (Iijima et al., 1992, Mies et al., 1993) suggests that this 
equilibrium of receptor stimulation is finely balanced, and may imply significant 
differences between animal models and human subjects. There is however 
another explanation for this failure, namely the simple –but critically important- 
logistical factor that emergency clinical management of stroke very rarely begins 
immediately after the event. Therefore, by the time NMDA antagonists can be 
applied, the excitotoxic damage has occurred and NMDA blockade prevents 
sublethal (and potentially beneficial) stimulation (Ikonomidou and Turski, 2002).  
Further discrepancies in NMDA receptor activation have been noted in studies of 
neuronal excitation. The responses to stimulation of synaptic (predominantly 
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located on dendritic spines) and extrasynaptic (mostly located on the soma) 
NMDA receptors varied, with exclusively neurotrophic signals triggered by 
stimulation of the former, whereas excitation of the latter caused exclusively 
pro-death signalling (Hardingham et al., 2002b). It is unlikely that this was due 
to a property of the extrasynaptic NMDA receptors themselves, given that low 
concentrations of exogenous NMDA induced protection effectively, as exclusively 
synaptic receptor stimulation with bicuculline had done (Papadia et al., 2005, 
Soriano et al., 2006).  
Further evidence casting doubt on this theory is that NMDA receptor subunits 
NR2A and NR2B are found predominantly in synaptic and extrasynaptic receptors 
respectively, but both OGD and NMDA preconditioning have been successful in 
cultures with very low levels of NR2A, suggesting involvement of NR2B subunits 
or NR1 in this preconditioning (Tauskela and Morley, 2004). However, it has been 
demonstrated that NR2B-containing receptors may have either pro-survival or 
neurotoxic properties during different stages of development of the same neuron 
(Martel et al., 2008), indicating that the alternative pathways leading to 
protection or toxicity are not due to the subunit composition of receptors.  
A potential explanation for the discrepancy is the difference in sensitivity to 
calcium influx exhibited by mitochondria in each of these locations, with 
dendritic mitochondria showing a greater capacity for calcium uptake than somal 
mitochondria (Young et al., 2008). It is possible therefore that activation of both 
groups of NMDA receptors leads to similar fluxes in calcium, but that these 
translate into opposing signals depending on the differing abilities of 
mitochondria in various cellular locations to respond to them.  
Removal of extracellular calcium protects against glutamate-induced 
excitotoxicity in cortical, hippocampal and cerebellar neurones in vitro, as does 
NMDA, AMPA or kainate receptor antagonism (Manev et al., 1989, Choi and 
Rothman, 1990). By far the most important receptor for glutamate-mediated 
excitotoxicity in CGNs however, is the NMDA receptor, blockade of which is far 
more protective than kainate receptor blockade (Manev et al., 1989). The 
degree of cell death due to excitotoxicity in rat CGNs is proportional to neuronal 
calcium uptake and the NMDA dose applied; the intracellular calcium 
concentration at which 50% of CGNs died was calculated as being approximately 
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17mM, a striking contrast to the ~300nM normally present (Eimerl and Schramm, 
1994, Morán et al., 1999).  
Further, glutamate-induced CGN death can be reduced by NMDA receptor 
antagonists applied after a toxic glutamate insult or by removal of extracellular 
calcium up to 30 minutes after glutamate exposure. This indicates that 
glutamate-induced excitotoxicity continues to damage beyond the initial insult 
(Manev et al., 1989, Choi and Rothman, 1990). Activation of PKC attenuated 
NMDA-mediated calcium increases, perhaps by feedback inhibition of the NMDA 
receptor itself by PKC (Snell et al., 1994).  
Calcium imaging showed NMDA receptor activation led to calcium influx and 
mitochondrial calcium accumulation, with subsequent partial mitochondrial 
depolarisation preventing calcium uptake into the mitochondrial matrix, 
ameliorating increases both in cytoplasmic free calcium and in cell death (Budd 
and Nicholls 1996). This protective action of mitochondrial depolarisation 
affected the immediate calcium influx following NMDA receptor activation and 
also the calcium efflux into the cytoplasm, known as delayed calcium 
deregulation (DCD). This occurred approximately 40 minutes after the initial 
insult and was triggered by NMDA receptor activation, but was not reversed by 
NMDA receptor inhibition or prevention of mitochondrial permeability transition 
(MPT) pore opening (Castilho et al., 1998, Ward et al., 2005).  
Excitotoxicity due to glutamate caused increased mitochondrial superoxide 
production, correlated with higher cytoplasmic calcium levels. Also antioxidant 
treatment was effective in delaying DCD, indicating that ROS induce loss of 
mitochondrial calcium regulation (Castilho et al., 1999). Although MPT pore 
opening causes leakage of calcium and ROS from the mitochondria, release of 
cytochrome c from the mitochondria due to excess calcium influx can occur 
independently of MPT pore opening in rat brain mitochondria, in contrast to rat 
liver mitochondria (Andreyev and Fiskum, 1999, Chalmers and Nicholls, 2003).  
Nitric oxide is also active in this process, as stimulation of NMDA receptors 
resulted in calcium-dependent production of NO and superoxide (which can lead 
to formation of the potent oxidative agent peroxynitrite). Production of ROS by 
glutamate was abolished by MK-801, SOD, removal of extracellular calcium or 
application of the NO scavenger reduced haemoglobin (Gunasekar et al., 1995).  
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A possible key stage in cytoplasmic calcium deregulation is the destruction of 
the plasma membrane calcium pump by calcium-activated calpains (Bano et al., 
2005). Certainly this pump can be cleaved by caspases in mouse CGNs due to 
glutamate-induced excitotoxicity, a finding reproduced in rat neurones by 
ischaemia, and could be blocked by NMDA antagonists (Schwab et al., 2002). 
This provided a possible link between apoptosis and necrosis, as cleavage of 
plasma membrane calcium pumps caused an excess of intracellular calcium, 
which in turn caused subsequent necrotic cell death (an effect delayed in cells 
with a non-cleavable mutant form of calcium pump) despite the initial triggering 
of apoptotic cell death mechanisms (Schwab et al., 2002).  
It is also evident that alterations in neuronal metabolic activity, which naturally 
affect mitochondria, will impact on excitotoxic and oxidative insults. Although 
neither the toxicity of glutamate nor that of 3-NPA were potentiated by 
increasing the glucose concentration in the medium to 25mM, this glucose 
concentration rise did have a potentiating effect on the toxicities of treatment 
with tryptophan and several of its metabolites. This was largely due to the 
osmotic effect of the increased glucose concentration, but the degree of 
potentiation was not entirely explained by this, suggesting that an underlying 
oxidative stress effect increased vulnerability, but was insufficient to cause cell 
death itself. This is consistent with previous findings identifying an increased 
vulnerability to excitotoxic and oxidative damage due to ischaemia (Muranyi et 
al., 2003), and that a higher glucose concentration (45mM) in vitro can induce a 
number of indications of increased oxidative stress (Vincent et al., 2005).  
The potential sub-lethal effects of increased glucose concentration raise 
questions of what changes are induced, both in indications of cell damage and of 
increased activation of antioxidant defences. A proteomic study of neuronal 
tissue exposed to a range of different concentrations of glucose would be one 
possible route by which further information could be gained.  
The demonstration that three of the compounds on the kynurenine pathway of 
tryptophan metabolism (3-HK, 3-HAA and 5-HAA) were potently neurotoxic gave 
scope for further investigation of the mechanisms involved and associated cell 
death pathway activation. The toxicity of all three was unaffected by SOD, but 
significantly reduced by catalase, indicating that the production of superoxide is 
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not a critical step in the development of neurotoxicity (and therefore the 
production of peroxynitrite is unlikely to be implicated), but that either H2O2 or 
its product the free hydroxyl radical is the likely agent which induces damage.  
Superoxide was produced by both 3-HK and 3-HAA in PBS alone. Superoxide 
generation by 3-HAA, although not by 3-HK, was also significantly increased by 
Cu2+. Both 3-HK and 3-HAA were unable to generate H2O2 in PBS alone, but when 
Cu2+ was present, both compounds produced significant amounts of H2O2, with 
copper ions cycling between oxidised and reduced status for multiple cycles of 
H2O2 generation. This increase in H2O2 production was completely abolished by 
catalase at a concentration of 1000U/ml and reduction in molecular oxygen 
concentration also markedly inhibited H2O2 production (Goldstein et al., 2000).  
In another study of 3-HAA oxidation, auto-oxidation in aerobic reaction solution 
was reported and oxidation of 3-HAA was increased dramatically by addition of 
Cu,Zn-SOD to anaerobic solution or by re-admittance of air in anaerobic 
conditions. The most likely explanation for this was not the catalytic activity of 
SOD (as Mn-SOD was ineffective), but copper ions acting as redox reagents for 
the oxidation of 3-HAA (altering from Cu2+ to Cu+), followed by re-oxidation of 
Cu+ by O2- (Liochev and Fridovich, 2001).  
This process can be summarised as follows:  
3-HAA + O2  Anthranilyl radical + O2- 
2O2- + 2H+ —SODÆ H2O2 + O2 
H2O2 + Fe2+ Æ HO. + OH- + Fe3+ 
Fe3+ + 3-HAA Æ Fe2+ + Anthranilyl radical 
Consequently, 3-HAA (in the presence of oxygen) will increase levels of 
superoxide and with Fe3+ (or Cu2+) increase levels of Fe2+ (or Cu+). Both of these 
changes act on the middle equations to increase H2O2 levels if SOD is present and 
thus act to increase levels of hydroxyl radical formed from H2O2. Additionally, 
the removal of superoxide tips the equilibrium of the top equation towards 
generation of further anthranilyl radical and superoxide.  
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Certainly this explanation is consistent with the finding in cell-free buffer that 3-
HAA produced hydroxyl radical; this process was enhanced by SOD, a more 
alkaline pH or the presence of EDTA (ethylene diamine tetra-acetic acid), but 
was abolished by the presence of either desferrioxamine or catalase (Iwahasi et 
al., 1988). The amount of hydroxyl radical produced in a Fenton reaction 
solution containing hydrogen peroxide and Fe3+ ions was increased by addition of 
3-HAA (adding 3-HK caused a lesser increase in hydroxyl radicals than 3-HAA), 
and assay of Fe3+ ion reduction suggested that reduction of Fe3+ was caused by 3-
HAA under these conditions (Iwahashi et al., 1988). Furthermore, auto-oxidation 
of 3-HAA in sodium phosphate buffer can be increased by Cu,Zn-SOD, Mn-SOD or 
catalase, although not by inactivated Cu,Zn-SOD. As catalase did not inhibit this 
effect, the action of SOD on auto-oxidation was not reliant on formation of H2O2, 
suggesting that removal of superoxide played a significant part (Ishii et al., 
1990).  
Generation of ROS was achieved more readily when o-, m- and p-aminophenol 
were added instead of 3-HAA (Iwahashi et al., 1988). The presence of an 
aminophenol ring structure on the 5-HAA molecule suggests that this is the 
generator of ROS in both 3-HAA and 5-HAA, and consequently that 5-HAA 
constitutes a source of oxidative damage of comparable severity to the 
established neurotoxins 3-HK or 3-HAA. This also provides a possible explanation 
for the link between infarct volume and higher ratios of anthranilic acid to 3-
HAA, as 5-HAA is a metabolic product of anthranilic acid: higher levels of 
anthranilic acid may be a risk marker for higher levels of the actual neurotoxin 
5-HAA, rather than being the actual mediator of the damage.  
When reviewing the chemical equations covering the reactions involved in the 
activity of 3-HAA (and presumably of 5-HAA also), it was apparent that SOD 
alone should not be protective, as the molecular oxygen produced by the 
dismuting of H2O2 can be converted to superoxide radical by 3-HAA, which simply 
allows further generation of ROS by the compound to continue. Conversely, the 
action of catalase interrupts this process, removing both the source of hydroxyl 
radical and molecular oxygen required for 3-HAA to generate superoxide.  
As it is already known that 3-HK, 3-HAA and the aminophenol ring structure 
common to both 3-HAA and 5-HAA produce both superoxide and H2O2 (Goldstein 
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et al., 2000), it is clear that these unavoidable metabolic products constitute an 
ongoing source of oxidative stress during life. Furthermore, treatment with 3-HK 
and 5-HAA was also associated with increased p38 activation, directly 
implicating them in signalling for apoptosis, although there was no indication of 
increased caspase-3 activation.  
Oxidative stress is a significant source of pathology in neurones, as evidenced by 
the effects of amyloid-β in Alzheimer’s disease or the mimicry of Parkinson’s 
disease by the mitochondrial poison MPTP. This suggests that the ongoing 
generation of low-level oxidative damage due to the actions of kynurenine 
pathway compounds or excessive glucose could be an important cause of 
cumulative neuronal loss.  
The potentially neurotoxic actions caused by physiological levels of kynurenine 
pathway compounds are could also continue throughout life, and while subtoxic 
in healthy individuals, have the ability to induce gradual neurotoxic damage in 
the setting of abnormally vulnerable neurones. The abnormally functioning 
mitochondria of Huntington’s disease patients could cause neurones to be 
abnormally vulnerable, resulting in the generation of neuronal death by one or 
more of these compounds, with QA being a likely source.  
Hitherto, 5-HAA has received sparse attention as a potential generator of 
neurotoxic damage, having been noted for little more than being a potential 
generator of ROS in cataract formation (Truscott and Elderfield, 1995). The 
findings in this study clearly show that this compound should be considered as a 
potential source of neurotoxic damage alongside the other, more extensively 
studied tryptophan metabolites. As a result of this finding, there would appear 
to be little potential for a possible therapeutic intervention by reducing 
kynurenine mono-oxygenase activity (and thus reducing the amount of 3-HK 
formed), as the resultant relative increase in anthranilic acid would in turn lead 
to an increase in 5-HAA. Although anthranilic acid has less toxic potential than 3-
HK, the subsequent conversion to 5-HAA would eliminate even this limited 
benefit. As kynureninase is involved in conversion of both kynurenine to 
anthranilic acid and 3-HK to 3-HAA, increasing this enzyme’s activity would not 
be beneficial, and blockade of its activity is not an available therapy, as this 
would prevent formation of nicotinamide.  
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Figure 6.1 Adjusted diagram of kynurenine pathway, showing addition of findings of study: 
broken underlining denotes moderate neurotoxicity; solid underlining indicates a strong 
neurotoxic effect.  
A potential intervention would be to increase the activity of 3-
hydroxyanthranilic acid oxygenase, which metabolises 3-HAA, although this 
would increase levels of QA and picolinic acid. Therefore, the most inviting 
target for therapy in terms of manipulation of the pathway would be to increase 
the activity of the enzyme quinolinic acid phosphoribosyl transferase, which 
catalyses the first step of the conversion of QA to nicotinamide. This enzyme has 
been demonstrated to be present in the brain, having been identified in glial 
cells throughout the hippocampus (Köhler et al., 1988), an area especially 
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vulnerable to QA’s excitotoxic action. An alternative may lie in the action of the 
enzyme α–amino-β-carboxymuconate-ε-semialdehyde decarboxylase, which acts 
on the precursor to QA (and picolinic acid) α–amino-β-carboxymuconate-ε-
semialdehyde, coverting it to a benign compound which may then be coverted to 
acetyl-CoA (Fukuoka et al., 2002).  
Although kynurenine pathway compounds may be involved in the pathology of 
neurodegenerative disorders, the excitotoxicity and oxidative stress induced by 
ischaemia is better modelled by subjecting CGNs to OGD. The development of an 
effective system for generating OGD allowed this insult to be applied. As an 
important part of the toxicity of OGD when applied to CGN cultures is the 
increase in glutamate release which it induces (Tauskela et al., 2003), it is likely 
that a relatively minor alteration in response to OGD (in terms of altered 
endogenous glutamate release) could cause a notable disparity in the neurotoxic 
effect in CGNs.  
In order to achieve a consistent neurotoxic insult, CGN cultures were subjected 
to OGD for 5 hours, a period which both successful preconditioning protocols 
were unable to protect against, suggesting that this insult was extremely severe. 
However, it should be noted that despite the successful use of NMDA 
preconditioning to protect CGNs by ourselves and other groups, we are unaware 
of any studies where this has been used to effectively protect CGNs against OGD.  
That OGD of 5 hours duration was a severe insult was also demonstrated by the 
fact that blockade with MK-801 or kynurenic acid was ineffective in protecting 
against it, indicating that OGD was likely causing cell death by preventing ATP 
production, independent of receptor activation. The finding that protein 
synthesis blockade during and after OGD was not protective also indicates that 
OGD of this severity induced necrotic cell death, in a manner paralleling that 
seen in an infarct ‘core’ (Hou and MacManus, 2002).  
A future route of investigation to further clarify the effects of OGD on CGN 
neurones could be to vary the duration of the OGD period, studying the extent of 
neurotoxicity (and degree of variation in this) at each time point, and identifying 
the efficacy of NMDA receptor blockade in protecting against this insult as the 
duration of OGD increases. Furthermore, the effects of OGD on calcium influx 
and mitochondrial calcium control, particularly how these alter as OGD duration 
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increases could provide valuable information both on the neurotoxic actions of 
OGD and also the mechanisms active in different regions of an infarct.  
The use of a relatively high-intensity, but comparatively brief preconditioning 
stimulus with NMDA in this study was capable of providing protection against 
subsequent excitotoxicity and oxidative stress. It is possible that NMDA 
preconditioning involves calcium-induced cell death mechanisms, as calpain 
expression in rat cerebral cortical neurones was significantly reduced by NMDA 
preconditioning prior to either toxic NMDA or OGD exposure (Tauskela et al., 
2001). Additionally, preconditioning with NMDA caused a significant decrease in 
intracellular calcium signalling during otherwise lethal OGD treatments, 
although this did not occur with exposure to a lethal dose of NMDA (Tauskela et 
al., 2001), suggesting the involvement of different mechanisms in each of these 
insults. Similar findings have been reported with reduced cytosolic calcium 
levels after two days in hippocampal slices preconditioned with NMDA and gerbil 
brain preconditioned by ischaemia (Ohta et al., 1996, Shimazaki et al., 1998).  
The discrepancy in effect of NMDA preconditioning on intracellular calcium 
signals between cultures subjected to OGD and toxic NMDA (Tauskela et al., 
2003) suggests that changes to calcium signals were secondary to differences 
between stimulation with endogenous and exogenously-applied NMDA receptor 
agonists. This could be due either to OGD-induced endogenous glutamate release 
stimulating only synaptic NMDA receptors (excluding extrasynaptic NMDA 
receptors) or to stimulation of non-NMDA glutamate receptor subtypes by 
glutamate, with related effects on depolarisation and calcium influx. However, 
excitotoxicity induced by either exogenously applied glutamate or MPP+-induced 
release of endogenous synaptic glutamate caused cleavage of plasma membrane 
calcium pumps (Schwab et al., 2002). This suggests that differences in response 
may be due to factors other than the location of the NMDA receptors.  
Variation between the two insults was also seen by Tauskela and co-workers 
(2003) in that inhibition of calmodulin-dependant protein kinase II with KN-62 
caused a significant loss of protection by NMDA preconditioning against OGD, but 
not protection against toxic NMDA, although the KN-62 also significantly reduced 
the toxicity of exogenous NMDA in non-preconditioned neurones: an effect not 
seen against OGD (Tauskela et al., 2003).  
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Calcium flux through the NMDA receptor activates CaMKII, found in 
glutamatergic synapses and involved in synthesis and release of 
neurotransmitters, which provides a potential mechanism by which NMDA 
preconditioning could reduce extracellular glutamate during OGD (Fink and 
Meyer, 2002).  
Generation of oxidative stress was also induced by NMDA preconditioning, as co-
application of antioxidants during preconditioning significantly reduced the 
degree of protection afforded against subsequent OGD (Tauskela et al., 2003). 
Part of the protection involved was due to ROS generation in the mitochondria, 
as blockade of the mitochondrial anion channel with 4,4’-diisothiocyanostilbene-
2,2’-disulfonic acid (DIDS) caused a significant reduction in protection against 
subsequent NMDA or OGD exposure (Tauskela et al., 2003). However, this did not 
completely abolish protection due to NMDA preconditioning, indicating that it 
was not of critical importance, even if it was a component of protection.  
Mitochondrial calcium levels increase when cytosolic calcium levels increase 
(e.g. NMDA receptor activation, plasma membrane depolarisation), or due to 
physiological calcium signalling. It is therefore possible that preconditioning 
brings calcium levels to a level just below the threshold at which cell death 
would be induced, although as this seems not to be a mitochondrial calcium 
level and could instead be a cytosolic one.  
3-Nitropropionic acid as a toxic insult was also investigated alongside glutamate 
since the dual toxic properties of this compound (NMDA receptor activation and 
inhibition of succinate dehydrogenase) induce simultaneous excitotoxic and 
more directly oxidative insults to neurones. Both of these effects are further 
augmented by 3-NPA’s reduction of ATP production.  
As a result of this, preconditioning with NMDA against subsequent 3-NPA 
exposure was also tested, and effective protection was thus demonstrated 
against a range of neurotoxic mechanisms. Although this method of 
preconditioning was not associated with any reduction in neuronal viability, the 
degree of protection conferred varied in extent between experiments, 
apparently due to variations in sensitivity to excitatory stimulation from one set 
of neurones to the next. This finding is in keeping with other work using cerebral 
cortical neurones (Tauskela et al., personal communication) and suggests that 
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there is a very narrow range of stimulation intensities which will successfully 
induce preconditioning via this method.  
This is strengthened by clinical evidence in patients suffering cardiac ischaemia, 
where even ischaemic preconditioning stimuli sufficiently severe to cause pain 
may still be inadequate to induce protection against a subsequent infarction 
(Psychari et al., 2004). It is possible that this treatment is actually essentially 
mildly damaging, but the protective response invoked reduces vulnerability for a 
brief period afterwards (perhaps being somewhat comparable to the increase in 
antioxidant defences that occurs in response to hyperglycaemia). Generation of 
ROS by NMDA preconditioning in neurones was show to be an essential 
component of protection, as this was significantly reduced by antioxidant 
treatment during preconditioning is further evidence in support of this (Tauskela 
et al., 2003).  
These issues raise serious questions over whether this method of preconditioning 
would be effective in providing a sound basis for the development of clinical 
treatments to prevent or ameliorate damage caused by excitotoxic or oxidative 
damage due to ischaemia or any other pathology. The evidently very narrow 
therapeutic window raises concerns that the treatment risks being not only 
ineffective, but potentially a source of excitotoxic damage itself.  
As a result of these concerns, the successful induction of protection using a 
stimulus which showed no toxic potential, was consistently effective and 
provided a higher degree of protection against a range of insults was an 
important development of this study. Considering the correlation between 
increasing NMDA concentrations and toxicity-linked loss of mitochondrial 
membrane potential, and the strikingly different calcium level alterations seen 
with different doses (Soriano et al., 2006), the use of an excitatory stimulus 
more distant to the threshold of excitotoxic damage warrants further 
experiments.  
Exposure of CGNs to 50-2500µM 4-AP was an effective preconditioning stimulus 
that gave protection against excitotoxic treatments (glutamate and NMDA) and 
also against a combined excitotoxic and oxidative insult (3-NPA). Interestingly, 
and in contrast both to our previous findings with NMDA and to work using 
similar prolonged stimulations (Tauskela et al., 2008), there was no dependence 
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on NMDA receptor activation, suggesting a notably different mechanism to our 
previous work. It was advantageous to identify such a difference, given the 
shortcomings of the previous paradigm that have already been considered.  
Although NMDA receptor activation was not required for the development of this 
protection, neuronal electrical activity was a critical component, as blockade of 
sodium channels with TTX reduced or prevented protection. This suggests that 
the source of neuroprotection in this model of preconditioning may in fact be 
based on the actual depolarisation of neurones, irrespective of neurotransmitter 
or receptor activity. It is possible that this method of preconditioning with 4-AP 
causes a homeostatic change that leads to reduced vulnerability to over-
excitation, in a manner comparable to that seen by Moulder et al. (2003).  
The use of 4-AP to precondition the hippocampi of mice in vivo against kainate 
was shown to be dependent on NMDA receptor activation, although increased 
expression of c-Fos suggested that calcium influx via the NMDA receptor was 
most likely a key component of protection (Ogita et al., 2005). That CREB 
phosphorylation may be involved in 4-AP preconditioning in our study suggests a 
similar mode of action exists in both models. Our finding that 4-AP 
preconditioning may act independently of NMDA receptor activation may 
therefore indicate that this method of protection can protect both glutamatergic 
and non-glutamatergic neurones equally effectively.  
Further investigation of 4-AP preconditioning identified that the cell death 
induced by glutamate was independent of caspase-3 activation, suggesting that 
4-AP preconditioning was effective against necrotic insults. The importance of 
the finding that this protection was active against non-apoptotic neuronal cell 
death is that a very similar method of protection has been previously 
demonstrated to be effective against apoptotic cell death (Papadia et al., 2005). 
Therefore, this method of preconditioning could provide the basis for protection 
of neurones that is effective in both the core and penumbra of an infarct. An 
additional benefit would be giving protection to cells vulnerable to both 
mechanisms, i.e. those initially targeted for apoptosis, but which subsequently 
switch to necrotic cell death due to falling ATP.  
The potential involvement of calcium influx (with resultant CREB activation) in 
4-AP preconditioning was independent of NMDA receptors, so may have occurred 
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due to calcium influx via voltage-dependent calcium channels, an effect which 
has been shown to be neuroprotective (Mabuchi et al., 2001). The neurotoxic 
effect of nifedipine treatment prevented the role of these channels in 
preconditioning from being established in this study. This was similar to the 
deleterious effect of NMDA receptors post-stroke, where even neurones with 
increased calcium influx suffer from the complete blockade of calcium channel 
currents and resultant disruption of calcium homeostasis.  
There is significant scope for further investigation of how this method of 
preconditioning effects protection, such as whether the use of simultaneous 
blockade of AMPA and NMDA receptors would be effective in preventing 
protection. As influx of calcium due to AMPA receptor activation is an integral 
part of the activation of long-term potentiation, it is possible that this source of 
calcium influx is also critical to the development of this method of protection.  
More generally, determining the role played by calcium in this paradigm would 
be of great value, both in terms of understanding the effects of prolonged 4-AP 
stimulation on calcium currents during preconditioning, and ascertaining the role 
they play in relation to CREB activation. Identifying the effect of temporary L-
type calcium channels blockade on 4-AP-induced calcium currents during 
preconditioning would also provide useful information. Another aspect of this 
would be to discover what changes 4-AP preconditioning makes to the calcium 
influxes induced by subsequent glutamate or 3-NPA exposure, either to the 
initial influx of calcium from the extracellular environment or to the subsequent 
efflux of mitochondrial calcium. Alteration of mitochondrial regulation of 
calcium levels either during preconditioning or the toxic treatment gives a 
possible explanation for the protective mechanism of 4-AP preconditioning.  
Given the prolonged period over which 4-AP preconditioning has been applied in 
this study, an obvious question is what duration of stimulation is necessary to 
induce protection, and whether the duration of preconditioning correlates with 
the longevity of protection. Additionally, investigation of the effects on protein 
synthesis could provide key information to further identifying the mechanism of 
protection. A limited investigation of potential candidate proteins gave mixed 
results: activation of CREB may be involved, although an up-regulation of bcl-2 
was not implicated; likely alternative candidate proteins could include PKC and 
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ERK. An alternative course of investigation would be to perform proteomic 
studies of preconditioned tissue in order to identify potential mechanisms.  
Although further work is required to gain better understanding of the 
mechanisms involved, the identification of 4-AP preconditioning as effective in 
providing protection against excitotoxic and oxidative neurotoxicity indicates 
that this may provide the basis for successful protective treatments.  
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7 Potential future avenues of study 
There are a number of different areas which could be considered for further 
study based on this work:  
• Proteomic study of products of hyperglycaemia in neuronal cultures 
• Study of effect of OGD over range of durations on NMDA receptor 
activation and calcium influx in CGNs 
• Calcium imaging of 48-hour preconditioning 
• Exploration of onset and duration of 48-hour 4-AP protection 
• Study of effect of 48-hour preconditioning on ERK and PKC expression 
• Proteomic study of 48-hour preconditioning: effects on protein production 
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